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Most known genetic causes of severe childhood developmental disorders are rare,
deleterious, protein-coding changes that cause Mendelian disorders. Children with
these disorders typically show early-onset impairment in growth, learning and adap-
tive behaviours. Linkage and whole exome sequencing studies on these patients have
previously focused on identifying diagnostic rare variants that are solely responsible
for the patient’s phenotype. In this thesis, I investigate whether common, inherited
genetic variation also plays a modifying role in severe, presumably Mendelian
neurodevelopmental disorders. In addition, I study the effects of common variants
on the cognitive functioning of healthy individuals, who carry rare deleterious
variants in genes that are intolerant to such variants in the general population.
To test whether common variants contribute to neurodevelopmental disorders that
are expected to be almost entirely monogenic, I conduct a genome-wide association
study (GWAS) in nearly 7,000 patients from the Deciphering Developmental
Disorders (DDD) Study and ancestry-matched controls. I show that common
genetic variants explain almost 8% of variation in risk for these severe disorders.
I also find genetic overlap between our study and GWAS for other cognitive and
neuropsychiatric traits. This suggests that common variants individually have
a small effect on brain development and functioning, influencing both risk for
common diseases in the population and risk for severe disorders that affect only a
small number of individuals. This polygenic burden in the DDD is also not confined
to only patients who do not have diagnostic rare variants. Altogether, these results
may have important implications for understanding variable clinical presentation
of neurodevelopmental disorders and searching for secondary genetic modifiers.
Finally, I assess the interplay between common and rare variants on the cognitive
functioning of seemingly healthy individuals. Using data from the INTERVAL
Study, I test whether common variants are protective of the deleterious rare variants
in these individuals. Whilst these analyses are potentially currently underpowered,
with additional samples in the future, we may be able to shed more light on
expressivity and penetrance of deleterious variants in the general population.
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Chapter 1
Introduction
In human medical genetics there exists a dichotomy between rare diseases, thought
to be caused by rare variants with large deleterious effects, and common diseases
explained by common genetic variants that individually have a small effect on
the phenotype (Bamshad et al., 2011), combined with environmental factors.
With improved technology and understanding of genetic architecture of diseases,
more examples have emerged of common, more complex, phenotypes having a
contribution from both common variants and rare deleterious ones. However, in
the field of rare genetic diseases the contribution of common variants is less well
studied.
1.1 Genetics of Mendelian traits
1.1.1 Mendelian inheritance
Mendelian traits and diseases follow clear patterns of inheritance within family
pedigrees, and affect a single gene or locus. The term Mendelian trait comes from
Gregor Mendel, whose studies in the 1800s on inheritance of traits in peas led to
the formulation of Mendel’s laws. These are the law of segregation, where Mendel
hypothesized that alleles at a locus separate from each other randomly during
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gamete production, and the law of independent assortment which describes how a
pair of alleles separate independently of other pairs of alleles. The five Mendelian
inheritance patterns of inheritance are autosomal recessive, autosomal dominant,
X-linked recessive, X-linked dominant, and Y-linked patterns (Strachan and Read,
2011). Although most Mendelian diseases follow a clear pattern of inheritance,
some can be inherited in more than one way. For example, deafness associated
with gene CX26 can be caused by dominant and recessive variants in the gene
(Kemperman et al., 2002).
1.1.2 Genetic variants in Mendelian traits
We now know that Mendelian diseases are typically single gene diseases, in which
deleterious genotypes at one locus are enough to cause the disease phenotype. Some
genes are known to be associated with multiple Mendelian diseases (Zhu et al.,
2014; Singh et al., 2016), and sometimes the same severe phenotype can be caused
by variants in multiple different genes, e.g. there are over 120 genes in which
mutations have been found to cause deafness (Nance, 2003). It is thought that
there are many thousands of human disorders that are Mendelian (Antonarakis
and Beckmann, 2006), but a causal gene for all these has not yet been described
(Bamshad et al., 2011; Botstein and Risch, 2003). Mendelian diseases are typically
rare on the population level, and collectively affect a small number of individuals.
However, the burden on Mendelian diseases on health services is substantial, and
account for an estimated 10% of paediatric hospital admittances and 20% of infant
deaths in North America (Karczewski and Snyder, 2018).
In order for a variant to have a large deleterious effect enough to cause disease , it
typically has to reside within the protein-coding region of the genome (exons of
genes) (MacArthur and Tyler-Smith, 2010; Garcia-Alonso et al., 2014). Mendelian
disease variants therefore often cause loss-of-function effects, by truncating the
protein or disturbing its functional domains. This happens by the introduction of
an early stop codon either directly through nonsense mutations, disruption of the
reading frame (insertion or deletions), or the alteration the splice sites. Truncation
of the peptide sequence often results in depletion or altered function of the protein.
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In addition, damaging missense variants can effectively result in loss-of-function
effects or lead to a dominant-negative or gain of function effect. Genes associated
with Mendelian disorders are typically intolerant of loss-of-function mutations (Lek
et al., 2016), and deleterious variants in these genes are under negative selection
(Bustamante et al., 2005). Therefore Mendelian disease variants tend to be very
rare in the general population.
1.1.3 Penetrance and expressivity of Mendelian traits
Some Mendelian diseases do not always show the typical inheritance patterns.
Exceptions to these patterns may be introduced through incomplete (or reduced)
penetrance, particularly in the case of dominant traits (Strachan and Read, 2011).
Penetrance describes the probability that the phenotype is observed given the
individual has the associated genotype. When a proportion of individuals with
the disease genotype do not show signs of the disease, it is said to be incompletely
penetrant. An example of such a disease is phenylketonuria, which is caused
by loss-of-function mutations in the PAH gene encoding for an enzyme involved
in breakdown of phenylalanine. Without intervention, the disease causes severe
intellectual disability. However, if phenylalanine is restricted from birth, the child
will grow relatively healthy (Cooper et al., 2013), and thus the disease only manifests
depending on phenylalanine intake. Diseases such as Huntington’s disease are fully
penetrant; although there are differences in the age of onset between patients,
essentially everyone who has more than 40 repeats of the CAG-triplet repeats in
their HTT gene will develop disease (Myers, 2004). As an example of variable
penetrance, the overall 57% of women with BRCA1 variants develop breast cancer
by the age of 70, and 40% develop ovarian cancer (Chen and Parmigiani, 2007).
However, it is also known that there are differences in penetrance between different
variants within the same gene: for example, BRCA1 the mutation 185delAG in
exon 2 of the gene has a much lower penentrance which is also age-dependent than
does one of the more penetrant variants, the duplication of exon 13. The median
age of breast cancer affliction for 185delAG carriers was 55 years, whereas for exon
13 duplication carriers this was 41 years (Al-Mulla et al., 2009).
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Another characteristic of Mendelian phenotypes is the expressivity of the trait.
Variable expression of a disease refers to individuals with the same genotype showing
different symptoms or different severity of these, even within families (Strachan
and Read, 2011). In some diseases, expressivity has been shown to be explained at
least partly due to mutations in different functional regions of the gene (Zhu et al.,
2014). However, for some Mendelian diseases, so-called modifier genes have been
found to contribute to differential expressivity. Examples of this include cystic
fibrosis, where recessive variants in the gene CFTR cause cystic fibrosis, a disease
that obstructs the lungs and affects organs. Variants in several genes have been
reported to possibly alter the disease course and different organ system symptoms
associated with the disease (Cutting, 2010).
1.1.4 Linkage Studies for gene discovery
Early gene discovery studies focused on finding causal loci and genes for Mendelian
diseases and traits using genome-wide linkage (Botstein et al., 1980). These studies,
before the availability of human reference genomes, assessed the co-segregation of
the trait and known genetic markers, along family pedigrees (Ardlie et al., 2002).
Linkage is the physical relation between loci (Strachan and Read, 2011). When
two loci that are in physical proximity of each other, they tend to be transmitted
together and are thus termed ’linked’. Recombination during meiosis between the
loci is more likely if the loci are further apart, or less tightly linked (Strachan
and Read, 2011). Markers that were linked to the causal genetic locus would be
shared among affected family members, and not observed in unaffected family
members. Linkage studies assessing Mendelian diseases used statistical approaches
that assumed a specific disease model of inheritance, and in literature these studies
are called parametric linkage studies (Strachan and Read, 2011).
Because finding the causal loci for a disease using linkage studies did not require base
pair resolution of chromosomal sequences, many Mendelian disease loci and genes
were identified using linkage in the 90s when sequencing was still very expensive.
The markers initially used were microsatellites, small repeat sequences of DNA,
as these were highly polymorphic sites in the genome (Strachan and Read, 2011).
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Using a few hundred markers spread across the genome, the transmission of tagged
regions could be traced at a megabase resolution. Later on, studies switched more
to using single nucleotide polymorphisms (SNPs). An example of one of the early
successes was a study by Ha¨stbacka et al. (1992), where the authors traced the
causal dominant-acting variant for diastrophic dysplasia, a cartilage and bone
disorder, to ∼60kb region from the gene CSFR1 gene.
1.1.5 Sequencing for diagnosis and discovery
With an increasing number of genes and chromosomal loci associated with Mendelian
diseases, sequencing relatively small lists of candidate genes for a given disease
became more popular in clinical genetics for Mendelian disorder diagnosis in clinical
genetics (Zelst-Stams et al., 2014). In these studies a list of potential genes were
drawn based on what was thought could be the underlying biology behind the
disease. This best guess approach was also used for genetic discovery for disorders
that resembled those for which a causal gene had already been found (Bamshad
et al., 2011). However, sequencing technologies at the time were expensive (Petersen
et al., 2017), and often this approach did not in fact identify the causal genes.
Characteristics such as disease penetrance and expressivity, and the small sample
sizes of family studies also limited the power for gene discovery using these methods
(Bamshad et al., 2011).
With the emergence of next-generation sequencing technologies around a decade
ago, larger scale sequencing studies for Mendelian traits have since become possible
for both diagnosis and new gene discovery (Bamshad et al., 2011). Now, sequencing
of all protein-coding regions in the genome (the exome) has become the preferred
framework for targeted sequencing studies in Mendelian diseases (Petersen et al.,
2017). It is also likely that exome sequencing will be incorporated more into clinical
practice in the future even for early stages of clinical diagnostic investigations (Zelst-
Stams et al., 2014; Wright et al., 2018c). Whole exome sequencing (WES) uses
targeted capture of protein-coding regions, which amounts to ∼2% of the genome
(Sazonovs and Barrett, 2018). Since most variants contributing to Mendelian
diseases are located within the exome, this approach is justified for searching
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for genes associated with these rare diseases. Whole genome sequencing (WGS)
can also be used for Mendelian disease analyses, but the relative cost of WES is
still around a third of the cost of a WGS genome (Sazonovs and Barrett, 2018).
The downside of WES compared to WGS is that non-coding regions including
regulatory elements are not captured, the coverage is more variable, and it is harder
to accurately call structural variants.
Exome sequencing is particularly useful in finding diagnoses for patients with
Mendelian disease phenotypes but for whom the causal variant has not been iden-
tified through other means (Bamshad et al., 2011). WES has been particularly
useful for sequencing of trios, enabling the identification of de novo mutations in
genes that cause such severe phenotypes that these result in severe reduction in
reproductive capacity (meaning the patient is sterile, that carriers do not reach
reproductive age, or that they do not produce progeny due to the severity of the
clinical symptoms). WES of patients with previously undiagnosed neurodevelop-
mental or neurological Mendelian diseases has resulted in a genetic diagnosis of
up to ∼40% in some cohorts (Yang et al., 2013; Gilissen et al., 2014; Deciphering
Developmental Disorders Study, 2017). In addition, trio exome sequencing in
a large number of patients has proved useful for discovery of many new genes
associated with these Mendelian disorders (Deciphering Developmental Disorders
Study, 2017).
However, utilising WES and WGS comes with some drawbacks. Generating and
analysing sequence data is still computationally expensive, and requires particular
expertise (Sazonovs and Barrett, 2018). It may also be difficult to identify clinically
relevant variants given the large number of variants in the exome, particularly when
data is not available for parents. In some studies, candidate variants have been
fed back to clinicians, who have in turn assessed whether the variants identified
are likely to be diagnostic to the patient (Beaulieu et al., 2014), but this approach
requires careful study planning and involvement of clinical geneticists.
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1.2 Genetics of complex traits
1.2.1 Non-Mendelian inheritance
As early as the late 1800s, scientists already noted that not all human traits seemed
to be inherited according to Mendelian patterns, and instead were passed down in a
blended manner from parents to offspring (Visscher and Bruce Walsh, 2017). These
diseases or traits appeared to aggregate in families without following a distinct
recessive or dominant pattern. Additionally, non-categorical (continuous) traits
such as human height were also correlated between family members. Debate over
the inheritance of these complex or quantitative traits was eventually resolved by
Ronald Fisher, who in 1918 published his seminal work on the genetics of complex
traits (Fisher, 1918). This work included introducing the concept of variance,
and categorisation of genetic effects into additive and dominance effects (more in
section 1.2.3), without the need for prior knowledge of the genes underlying the
trait (Visscher and Bruce Walsh, 2017). Fisher proposed that some traits were
multifactorial, meaning many factors contribute to the trait, and that random
sampling of alleles in a population results in a continuous trait when multiple alleles
contributed to it. He also proposed that the individual contributions of each allele
becomes smaller when more alleles contribute to the trait (Fisher, 1918). These
ideas formed the basis of the study of complex traits and diseases.
Complex diseases are often relatively common in the population (Becker, 2004),
and therefore are regularly referred to as common diseases. Complex diseases
have a contribution from both environmental and genetic factors, but typically
the genetic component is a combination of multiple genetic variants, hundreds to
potentially tens of thousands (Lee et al., 2018). Some rare variants can cause the
same or a similar phenotype as the complex trait, but this constitutes a small
fraction (typically less than 10%) of the disease cases (Scheuner et al., 2004). It
is also thought that late-onset diseases are more likely to be polygenic instead of
Mendelian (Wright et al., 2003). Complex diseases also collectively affect a large
number of individuals, e.g. prevalence for type 2 diabetes is 8% (Morris et al.,
2012) and 15% for major depressive disorder (Major Depressive Disorder Working
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Group of the Psychiatric GWAS Consortium et al., 2013), which results in major
burden on health services.
1.2.2 Genetic studies in complex traits
Early attempts with linkage studies
Attempts to discover genes associated with complex diseases initially used many of
the same methods as studies for Mendelian diseases. This was because complex
diseases also cluster in families. However, without a known model of inheritance,
the statistical methods used had to be non-parametric (Strachan and Read, 2011).
Infrequent successes of linkage family-based linkage studies in mapping complex
disease loci, include the identification a susceptibility locus on chromosome 16
for inflammatory bowel disease (Hugot et al., 1996). The locus, which we now
know contains the gene NOD2, has since remained one of the strongest known
effect loci for Crohn’s disease, a subtype of inflammatory bowel disease. Eventually
though not many complex disease loci were mapped using linkage studies, because
the genetic variants contributing to complex diseases did not confer high enough
susceptibility in a population for it to be detected using family data, and at the
resolution that genetic markers at the time provided (Strachan and Read, 2011).
Improving the resolution for association
Over the years, it became apparent that mapping loci for complex traits was
difficult, likely due to the small effect sizes of the loci involved. The International
Hapmap Project was launched in 2002 to characterise the patterns of genetic
variation across different populations (International HapMap Consortium, 2003).
The HapMap project showed that the finer scale structure of human chromosome
haplotypes (blocks sequences that were inherited together) was more complex than
previously thought (Strachan and Read, 2011). The HapMap project facilitated
genetic association studies, by allowing researchers to better design DNA chips with
a limited number of markers that optimally tagged (i.e. were correlated with) most
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of the other common variation in the genome (mainly in European populations).
As it turned out, approximately 500,000 SNPs were sufficiently informative to tag
the remaining common variants (MAF>5%) in a European ancestry genome, due
to linkage disequilibrium (Consortium, 2007).
Linkage disequilibrium is a statistical association between two alleles that are
genetically linked, and therefore observed together on the same haplotype more
often than expected (Strachan and Read, 2011). A variant can tag the surrounding
variants within its haplotype block, as they are likely to be observed together given
the other surrounding markers. This also means the surrounding SNPs can be
statistically inferred (imputed) and subsequently tested for association (Marchini
and Howie, 2010). Linkage disequilibrium patterns also differ between populations
because of recombination events that happened in previous generations. Even
though for some diseases e.g. inflammatory bowel disease it has been shown that
many risk loci are shared between populations (Liu et al., 2015), the variants that
tag underlying causal variants in different population may not be the same. Because
of differences in LD structure, genetic association studies need to be carried out
within a fairly homogeneous population to avoid spurious associations (Anderson
et al., 2010) arising from the inclusion of individuals with differential haplotype
structure.
Genome-wide association studies
With the new information on haplotype structure, complex disease association
testing moved on to testing hundreds of thousands of SNPs at a time. Data for
these were generated using DNA chips, which were a relatively cheap (Sazonovs
and Barrett, 2018), enabling studies to recruit increasingly larger cohorts - and
consequently gained more statistical power for finding susceptibility loci with
smaller effects. Currently, genotyping one sample costs ∼$20 on the Illumina
Global Screening chip, and sample sizes for association analyses have moved from
few hundred to tens of thousands or up to a million (Lee et al., 2018). The reduced
cost per sample and the improved resolution at which disease associations could
be detected using chips caused the interest in genome-wide association studies
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(GWAS) to grow rapidly in the mid 2000’s. GWAS use statistical methods to
compare allele frequencies between cases and controls (e.g. logistic regression)
(Clarke et al., 2011) and to find variants that are associated with continuous traits
(e.g. linear regression). GWAS was the name given to these large association scans
that typically used chip data. At the time, it was understood that more power
could be gained for complex disease association analysis by genotyping unrelated
individuals to use as cases and controls (or for continuous traits) (Teng and Risch,
1999). It was also more straightforward to recruit these individuals rather than
genotype whole families where the trait clustered.
Modern GWAS typically test several million SNPs, of which the majority will
have been imputed in order to boost genome-wide coverage. This large number of
variants to test introduces the issue of false positives. Each test on a single variant
is treated as an independent test, and therefore setting a threshold of significance at
the typical P-value <0.05 would result in potentially millions of false associations.
To account for the number of tests performed in a genome-wide scan, multiple
testing correction (e.g. Bonferroni correction) is applied to GWAS data. Typically,
the P-value cut off for a GWAS in Europeans is set to < 5× 10−8 for 1M SNPs
(Risch and Merikangas, 1996; Pe’er et al., 2008). The problem with this however
is that many variants that probably do confer risk, do not pass this genome-wide
significance threshold, and studies have to recruit large numbers of samples to
gain sufficient power to detect the association. For example, autism spectrum
disorder (ASD) has for long been suspected to have a polygenic component to
disease aetiology, but researchers reported the first significant GWAS loci only after
reaching sample sizes of 18,000 cases and 28,000 controls (Grove et al., 2017).
It is important to note that association does not necessarily mean causation, and
the most highly associated variant is not necessarily the causal one. Finding the
causal variant requires fine-mapping of the region around the associated variants
(Schaid et al., 2018) and functional follow up using cell lines, animal models or
other methods. Most GWAS hits are in non-coding regions which makes it difficult
to figure out the causal variant and the biological pathways affected (Zhu et al.,
2017). One of the main aims of GWAS, as with family-based studies, is to find
potential drug targets for patients suffering from disease.
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One the biggest caveats of GWAS is that these only measure common variants. It
has been argued that rare variants may contribute substantially to many complex
traits (Lee et al., 2011), and there is now evidence for this for several traits
and diseases (Luo et al., 2016; Ganna et al., 2016). However, the challenge in
studying this hypothesis through GWAS is that rare variants are not well tagged by
surrounding common variants, so need to be ascertained directly through sequencing.
Power once again becomes an issue when investigating rare variant associations
(Sazonovs and Barrett, 2018). Some hope that by finding rare variant associations
at loci that likely lead to larger effects on the phenotype can point more quickly
towards causal genes. If we were able to find these, this could help with developing
drugs more quickly.
1.2.3 Heritability of complex traits
Broad sense heritability
Both Mendelian and complex diseases and traits are heritable, which means that
genetic variants contribute to phenotypic variance between individuals (Visscher et
al., 2008). The term broad-sense heritability (H2) is used to describe the proportion
of variation in the phenotype that is attributable to all genetic variation (Visscher
et al., 2008). Genetic effects contributing to the phenotypic variance can originate
from additive genetic effects (combined genetic effects are equal to the sum of
individual allele effects), dominance effects (where interactions between alleles
at the same locus affect the outcome), and epistatic effects (where interactions
between alleles at different loci affect each other) (Strachan and Read, 2011).
Fully penetrant Mendelian diseases are in principle fully heritable with a H2 of
1 (Visscher et al., 2008). Complex diseases will have a H2 less than 1, as part of
the variation in the phenotype typically comes from non-genetic effects for these
diseases. Importantly, heritability for a given trait can differ between populations
and timepoints. As an example of this, in European populations, a trait such
reading ability would have been far less heritable a few centuries ago than it is now.
This is because back then, one’s schooling depended mainly on socio-economic
status (although we note that socioeconomic status has now been shown to be at
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least partly heritable today (Trzaskowski et al., 2014), whereas with the modern
standardised schooling system the environment is less variable (Strachan and Read,
2011). Therefore the background (including genetic) characteristics enabling one
to learn to read, such as cognitive ability, will now contribute proportionally more
to the trait. The genetic architecture underlying heritability can also vary greatly.
In the case of fully penetrant Mendelian diseases, a single deleterious variant with
large effect size will explain all of the H2 (Visscher et al., 2008). But for complex
diseases, the number of genetic variants explaining H2 can be thousands to tens of
thousands (or more) spread across the genome, each with individually small effect
sizes (Lee et al., 2018).
It is important to quantify heritability in order to understand how much genetics
contributes to the trait. For complex diseases, H2 has traditionally been estimated
through family studies. These studies used data collected especially on twins. Twin
pairs typically share most of their environment, resulting in minimal bias from
different environments, and the average shared proportion of alleles is known. By
comparing the phenotypic concordance between monozygotic twins (who share all
their alleles) to the concordance between dizygotic twins (who share on average
half their genetic content) gives an estimate of the overall genetic contribution to
the trait (H2).
Narrow-sense heritability
The additive genetic component of broad sense heritability is termed narrow-
sense heritability or h2. It represents the total proportion of variance in the trait
that can be explained by summing the additive effects of all variants. Narrow-
sense heritability is of interest in population genetics, because it is relatively
straightforward to to measure within a population study design. The definition of
additive effects excludes factors such as interactions between variants, and it is often
thought to be a large contributor to the overall trait heritability on a population
level (Visscher et al., 2008). The additive model implies a linear relationship
between how much of their genome a pair of individuals share (i.e. how related
they are to each other) and how closely they resemble each for the trait in question.
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Narrow sense heritability could also be measured using family studies. The simple
twin studies advanced into more complicated family designs, in which the inclusion
of multiple relative types made it possible to tease apart additive from dominance
variance, and from the effects of shared environment and unique environment.
Dominance variance does not contribute much to heritability of complex traits
(Visscher et al., 2008).
SNP heritability
Family studies in complex disease had for decades shown that many diseases and
traits had substantial genetic contributions. Therefore when SNP genotyping
platforms became cheaper and more widely used in the early 2000s, it was expected
that the GWAS approach would finally find the additive genetic effects and pinpoint
causative variants to human traits and diseases. However, it was quickly realised
that the genome-wide significant SNPs discovered by GWAS failed to explain much
of the expected narrow sense heritability h2 that had been estimated through twin
and family studies (Lee et al., 2011). The heritability captured by GWAS is termed
SNP heritability or sometimes chip heritability and represents the additive genetic
effects tagged by common SNPs (Yang et al., 2010).
The remaining gap between family-study based estimates of H2 (∼h2) and the pro-
portion of variance explained by population studies was termed missing heritability
(Maher, 2008). At the time, possible sources of missing heritability were thought
to be the thousands of common variants with very small effect sizes hard to detect
using available study sample sizes, or in rarer variants with intermediate effects
that were not well tagged by the common SNPs (Eichler et al., 2010). Some have
also argued that twin and family studies have over-estimated the true narrow-sense
heritability due to flaws in their assumptions. The current predominant view is
that most of the missing heritability lies in thousands of common variants, which
we have increasingly better power to detect (Yang et al., 2010; Lee et al., 2018).
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Reporting heritability for dichotomous traits
An important consideration for reporting SNP heritability for categorical traits
such as disease status is to make the distinction between the discontinuous observed
and continuous liability scale heritability (Lee et al., 2011; Visscher et al., 2008).
For categorical traits, although the underlying polygenic liability may follow a
normal distribution in the population, the trait only has categorical outcomes (e.g.
no disease or disease). In this model, it is thought that the underlying polygenic
liability (together with other factors) pushes certain individuals past a threshold,
after which the individual’s phenotype will change categories (e.g. from no disease to
disease) (Lee et al., 2011). This becomes a problem for estimating SNP heritability
when a trait has low prevalence in the population. If the proportions of cases and
controls were to be kept the same as the population prevalence, a study would have
to recruit potentially hundreds of thousands of controls to gain enough cases to
study the trait with substantial power. Instead, genotyping or sequencing studies
tend to be over-represented for cases with respect to the population prevalence of
the trait (which itself can also differ between populations). This is because after
a certain point, the addition of more controls in effort to retain the population
proportions of cases and controls does not gain much power for the analysis, and
there is a considerable financial cost associated with such an endeavour. However,
it is possible to do a mathematical adjustment to scale the observed h2 estimate
for dichotomous traits in a GWAS, to account for the proportion of cases in the
study sample and the population prevalence of the trait (Lee et al., 2011).
1.3 Convergence of rare and common variant anal-
yses
Due to the seemingly stark differences in genetic architectures between Mendelian
and complex traits, for many decades there existed a dichotomy between rare
disease-rare variant and common disease-common variant theories. However, this
view has been gradually changing as we learn more about the genetic architectures
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of different traits and diseases. This has happened particularly in the case of
common complex traits, in which the role of rarer genetic variation has been
revealed through new sequencing technologies.
1.3.1 Low frequency variants in common disease
Years of attempts to find low-frequency, intermediate effect variants through GWAS
have so far not found many significant associations with complex diseases, with a
few exceptions. One study that set out to uncover these low frequency variants
was conducted on inflammatory bowel disease. The authors found one example
of an intermediate effect, low frequency variant that was significantly associated
with the disease. This variant in ADCY7 conferred risk for Crohn’s disease, and
had a minor allele frequency of 0.6% in Europeans (Luo et al., 2016). For some
traits, SNP heritability analyses partitioning SNP h2 by MAF bins have shown
evidence for intermediate frequency variants contributing to the trait. An example
of this, a recent study by Hill et al. (2018) showed that ∼20% more heritability of
intelligence can be explained by including variants with low MAF 0.1-1% (although
the error margins for this estimate are wide). However, generally it is now thought
that much of the missing heritability for complex traits is to be found in common
variants with smaller effect sizes (Lee et al., 2011). This view is becoming more
popular with larger and larger GWAS explaining more variation using variants
with tiny effect sizes.
1.3.2 Rare variants in common disease
Although, collectively rare variants likely do not contribute nearly as much to
complex trait heritability as do common variants, it is now evident that rare
variants play a role in complex diseases as well (Singh et al., 2016; Genovese et al.,
2016a; Luo et al., 2016; Fuchsberger et al., 2016). There is also now more evidence
that rare and common variants can affect the same genes or biological pathways
in complex diseases. For example, the Crohn’s disease susceptibility locus NOD2
has been implicated in both linkage studies, GWAS (Liu and Anderson, 2014) and
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more recently in rare variant burden analyses in sequence studies (Luo et al., 2016).
Schizophrenia GWAS have also found associations for calcium channel genes and
targets of the FMRP gene, and both groups of genes have been implicated in rare
variant burden analyses (Purcell et al., 2014). Even so, the effect sizes of rare and
intermediate variants in complex disease have not reached similar magnitudes as
Mendelian disease variants.
1.3.3 Common variants give rise to extreme phenotypes
It is often expected that rare variants cause more severe phenotypic outcomes than
common variants, if the trait is under negative selection. However, some recent work
has shown that for some complex diseases, both rare variants and common variants
can cause extreme phenotypes. One example of this is a study by Natarajan et al.
(2017), which showed that the overall polygenic load (polygenic scores, more in
Chapter 2) had a similarly large effect on LDL-C cholesterol levels as did rare
variants in known hypercholerolemia genes. In addition, from those individuals
who had clinically high LDL-C levels, only 2% had a rare variant where 23% had a
high polygenic score. Thee results demonstrate that common variation can play
an important role in severe traits. Similarly, a recent study by Khera et al. (2018)
found that particularly for coronary artery disease, but also for atrial fibrillation,
type 2 diabetes, inflammatory bowel disease, and breast cancer, individuals with
high polygenic scores had a similar risk of disease as those with monogenic forms of
the diseases. This study particularly has sparked global debate over the usefulness
of polygenic scores in predicting disease in the clinic.
1.3.4 Do common variants contribute to rare disease?
Evidence from chromosomal abnormality syndromes
There have not been many studies investigating whether common variants contribute
to rare, severe forms of disease. This is despite variable expressivity of Mendelian
disease phenotypes between patients being a known phenomenon. It would seem
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plausible that that expressivity could be affected by the genetic background,
nongenetic factors (e.g. skewed X-inactivation in Duchenne muscular dystrophy
(Abbadi et al., 1994)) or a combination of both. Interestingly, in literature on
chromosomal abnormalities, the idea of variable expressivity driven by inherited
common variants dates back to the 1970s (Moreno-De-Luca et al., 2015). In the
CNV disorder and aneuploidy field, it was suspected that background genetics of
the patient affected their performance outcome. This was because despite their
disease, the IQ of patients with chromosomal abnormalities (Olszewski et al., 2014)
(including trisomy-21 (47, XX/XY + 21) (Fraser and Sadovnick, 1976) and height
for patients with Turner’s (45, X0) and Klinefelter (47, XXY)(Brook et al., 1977))
correlated with parental phenotypes for cognitive performance and height. The
same was reported for IQ and height in Prader-Willi Syndrome in 2000 (Malich
et al., 2000). These studies implied that background genetic effects could be playing
a role in the phenotype outcome.
More recently, a study by Moreno-De-Luca et al. (2015) described that 16p11.2
deletion patients had a 1-2SD decrease in intelligence, social functioning, motor
functioning and body mass index compared to their parents and healthy siblings.
However, the correlation of patient-family phenotypes were similar to the correlation
between children and parents in the general population. The authors suggest it
would be possible to predict a range of social and cognitive performance metrics
for the affected child based on the parental phenotypes.
Common variants in monogenic disease
As mentioned, there are only a few examples of modifier effect from common
variation to monogenic diseases, with oligogenic modifiers of CFTR in cystic
fibrosis being one of the best known ones (Cutting, 2010). There are also now
some examples of common variants modifying the outcomes of monogenic, but not
fully penetrant diseases. Many of these examples are from the cancer and lipid
fields, where the effects of polygenic scores have been assessed for patients with
familial, severe effect mutations. As an example of this for breast and ovarian
cancers, Kuchenbaecker et al. (2017) investigated the effects of polygenic scores
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on the cancer risk in carriers of pathogenic BRCA1 and BRCA2 variants. Not
all carriers of deleterious BRCA1 and BRCA2 carriers develop breast or ovarian
cancers as these cancers are variably penetrant, but the lifetime risk for carriers
of these is extremely high. The authors of the study found that e.g. BRCA2
carriers with 10th percentile PRS (low polygenic risk) for ovarian cancer had a 13%
lower risk of ovarian cancer by 80 years of age, than did those with a polygenic
score at the 90th percentile (high polygenic risk). Another example of common
variants acting together with rare familial variants is a paper by Talmud et al.
(2013), where the authors compared polygenic scores for hypercholesterolemia in
patients with and without familial mutations to healthy controls. The authors
found that patients with familial mutations had lower polygenic scores for the trait
than patients without familial varaints, but still higher scores overall than healthy
controls.
Examples of common variants influencing the expressivity of monogenic diseases
are very few. Recently though, one of the first exciting examples of this came from
a study on Huntington’s disease. A study by Hensman Moss et al. (2017) described
a GWAS against a measure of Huntington’s disease progression. They discovered a
significantly associated locus which spanned three genes on chromosome 5. They
described how the gene MSH3 in this locus was a likely modifier of Huntington’s
disease progression, and found that the modifier effects were independent of the
age of onset of disease. The findings from this study are very interesting as they
represent one of the first known GWAS modifier associations for fully penetrant
monogenic disease. Another GWAS (Bezzina et al., 2013) identified three common
variant associations increasing risk of Brugada syndrome, a rare cardiac arrhythmia
disorder. The syndrome is thought to have dominant Mendelian inheritance, but it
has also been shown to have low penetrance in families with familial mutations,
and to affect family members who do not carry these mutations.
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1.4 Investigating common variants in rare, likely
monogenic disorders
In this thesis, I will focus on investigating common variant effects in the context of
rare neurodevelopmental disorders, which have been thought to be almost entirely
monogenic. As described above, this work represents one of the first studies looking
for common variant effects in presumably monogenic disease. In Chapters 2 and 3,
I will focus on analysing data from patients suffering from these disorders. Then in
Chapter 4, I describe further analyses looking at whether common variants modify
penetrance of rare, deleterious variants that are observed in the general population.

Chapter 2
Common variants contribute to
rare neurodevelopmental
disorders
2.1 Chapter overview
In this chapter, I address the question of whether inherited common genetic
variation plays a modifying role in severe neurodevelopmental disorders, that have
been thought to be almost entirely monogenic. I begin by identifying individuals
from the Deciphering Developmental Disorders Study (DDD) who had at least
one abnormality affecting the central nervous system morphology or physiology.
I then perform a discovery GWAS on neurodevelopmental disorder risk using
controls from the UK Household Longitudinal Study. Through SNP heritability
analysis of the GWAS results, I show that there is a significant contribution to
these disorders from common genetic variation. I then replicate this finding in
an independent set of proband-parent trios from the DDD Study, by showing
over-transmission of neurodevelopmental disorder risk from parents to patients.
For this analysis I utilise polygenic scores constructed from the discovery GWAS.
I will next introduce the DDD study and discuss background to polygenic scores.
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These scores are extensively used in complex trait genetics, and I implement them
in several analyses throughout this thesis.
2.2 Background
2.2.1 Severe neurodevelopmental disorders
Developmental disorders are a collection of disorders that manifest in early child-
hood, and severely impact the child’s normal growth and development. In the
UK, estimates of congenital abnormalities and/or developmental disorders ranges
from ∼2-5% (Deciphering Developmental Disorders Study, 2017). Usually when
no other environmental causes are identified, the disorder is thought to be genetic.
Developmental disorders often include abnormalities affecting the central nervous
system (neurodevelopmental disorders), resulting in cognitive and motor delay,
and impairment of social functioning (Sontheimer, 2015). Examples of neurodevel-
opmental disorders include global developmental delay, intellectual disability and
autism. However, developmental disorders can also affect other organ systems than
the nervous system, and can include morphological anomalies (dysmorphology).
The treatment and disease management opportunities largely depend on the specific
disorder. For example, metabolic disorders if diagnosed early may be managed
with dietary changes. Other forms of disease management include e.g. language
and behavioural therapy (Myers et al., 2007).
Often children with developmental disorders show severe symptoms and pheno-
types, whilst their parents appear normal. Research into the underlying genetic
architecture of these diseases has shown that particularly in families with high
autozygosity (parents are related), the disorder can often be the result of recessive
inheritance of rare variants (homozygous for the deleterious variant) (Martin et al.,
2017b). More often though, developmental disorders with genetic causes are due to
de novo variants in dominant or recessive developmental disorder genes, particularly
when there is no inbreeding in the family (Martin et al., 2017b). As these variants
are on their own sufficient enough to cause severe phenotypes, they are likely to be
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located in the protein-coding region of the genome, disturbing protein structure
or function (MacArthur and Tyler-Smith, 2010; Garcia-Alonso et al., 2014). A
high proportion of de novo variants observed in developmental disorders is also
a reflection of the reduced reproductive capacity of the patients. Chromosomal
abnormalities can also span monogenic disease genes, resulting in developmental
disorders, though in these cases identifying the causal gene(s) has been difficult
(Moreno-De-Luca et al., 2015; Bergbaum and Ogilvie, 2016).
There are currently 1,767 genes associated with developmental disorders (Firth
et al., 2009) (downloaded 30th August 2018), of which 32% are monoallelic and 61%
biallelic (including overlapping genes). In order to find causal rare variants, and to
assess whether they were inherited or occurred de novo, it is particularly helpful to
look at exome sequence data for trios (Wright et al., 2015). This is because exome
sequencing is still relatively cheap compared to whole genome sequencing (Sazonovs
and Barrett, 2018), and due to the severity of the phenotypes it is expected that
the causal variant is within the protein-coding region of the genome (Wright et al.,
2015). The benefit of the trio design is to help identify the pattern of inheritance,
which greatly helps to inform families on the recurrence risk of the disorder.
Many neurodevelopmental disorders shared phenotypic symptoms, including re-
duced cognitive function, seizures, autism and schizophrenia. Studying chromosomal
abnormalities has shed some light to which genes could be causal for such diverse
symptoms. By assessing the symptoms of e.g. patients with differential length
deletions spanning the same region, it is possible to refine likely causal genes within
that region (Theisen and Shaffer, 2010). With the availability of WES and WGS,
there is now evidence that variants in the protein-coding regions of genes are also
associated with different neurodevelopmental and neuropsychiatric disorders (Zhu
et al., 2014). For example, a study by Singh et al. (2017) found that rare variants in
genes associated with neurodevelopmental disorders were enriched in schizophrenia
patients with intellectual disability. These studies point towards overlap between
genes associated with different disorders of the brain.
These previous studies have sensibly focused on identifying rare genetic variants,
since such rare and severe disorders seem likely to be caused by highly deleterious
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variants that would rapidly be removed from the population. However, (as detailed
in section 1.3.4) the idea that common variant background could modify severe
disorder outcomes or expressivity is not new in the field. In order to detect common
variant effects contributing to these disorders, a genome-wide analysis would need
to be done on a large number of patients, ideally in a large batch using the same
genotyping chip in order to avoid biases from combining numerous small datasets.
There now exists a dataset in which such a scan is possible, namely the Deciphering
Developmental Disorders (DDD) Study (Wright et al., 2015).
This DDD study aims to find a genetic diagnosis for patients suffering from
previously genetically undiagnosed developmental disorders. In 2011 to 2015, the
study recruited ∼14,000 patients with neurodevelopmental disorders, congenital,
growth or behavioral abnormalities, and dysmorphic features. Recruitment was
done in the UK and Ireland through 24 genetics services. Each patient was assessed
by a clinical geneticist, who deemed that the likely cause for the disorder was
genetic (monogenic). Most patients had undergone previous genetic testing, but
all had remained genetically undiagnosed at the time of recruitment. Phenotypic
data were recorded for the majority of DDD patients, and some individuals had
growth measurements and prenatal information as well.
In order to find genetic diagnoses for families, the DDD Study is exome sequencing
all individuals recruited to the study, including parents whenever possible. This
trio design has so far been successful in unravelling new developmental disorder
associated genes (Deciphering Developmental Disorders Study, 2017), aiding new
diagnoses to be made. Importantly, clinically relevant variants are curated by
the clinical geneticists who recruited the families. When a diagnosis is found, the
information is then fed back to the families who receive genetic counselling.
Exome sequencing of DDD trios has unveiled plenty of information about the
genetic architecture of previously undiagnosed developmental disorders (Short
et al., 2018; Lord et al., 2018; Martin et al., 2017b). The most recent published
analysis of de novo mutations in the first ∼4,000 trios estimated that ∼40% of the
cohort have causal protein-coding de novos, but these have not all been identified
yet due to lack of power (Deciphering Developmental Disorders Study, 2017). In
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addition, the DDD Study has for the first time shown evidence that de novo
mutations in non-coding elements of fetal brain-expressed genes also contribute
to the disease burden in the cohort (Short et al., 2018). De novos in canonical
splice site regions have also been shown to contribute to disease in the cohort (Lord
et al., 2018). Finally, it has also been estimated that from the European subset
of DDD patients, 3.6% carry diagnostic autosomal recessive variants, whereas in
patients with Pakistani ancestry this fraction is much higher at 31% due to elevated
autozygosity. It is important to bear in mind though, that since the patients
recruited to the Study have already undergone clinical assessment and usually
genetic testing before recruitment, the cohort is depleted for clinically recognisable
genetic disorders (Deciphering Developmental Disorders Study, 2017).
Importantly for the work presented in this thesis, the majority of DDD patients were
also genotyped on a DNA chip. This means that DDD represents the largest cohort
of genotyped patients with rare, undiagnosed developmental disorders. This dataset
allows us to test whether common genetic variants contribute to heterogeneous, rare
developmental disorders, or whether the genetic contribution to these disorders is
solely attributable to rare variants. In addition, since we have data available on the
rare variants for these individuals, we can ask whether there is a difference between
the polygenic background of patients with and without rare diagnostic variants
in the exome. In Chapters 2 and 3, I explore the common variant architecture of
specifically neurodevelopmental disorders, using data from the DDD Study.
2.2.2 Polygenic scores in genetic studies
In this chapter, I describe two main analyses. The first is to conduct a GWAS using
data from the DDD Study. The second analysis uses polygenic scores, which are an
important tool for leveraging genome-wide data in the complex trait field. Polygenic
scores can be used to quantify polygenic effects in a given cohort by utilising pre-
existing information from other GWAS (International Schizophrenia Consortium
et al., 2009). A polygenic score for an individual is the sum of tiny predicted effects
from thousands (or millions) of variants discovered in an independent study of
a given phenotype given the individual’s genotype. The genetic effect estimates
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for the variants are typically obtained from GWAS. The polygenic scores are
constructed by taking the β (effect) for the effect allele at a single variant, and
multiplying this by the individual’s allele count at that locus (0, 1 or 2 for variants
with two possible alleles). The same procedure is repeated at each variant of
interest, and these are then summed to give one polygenic score for each study
participant (Polygenic score = Σβ1x1+β2x2+ ... +βixi), (Figure 2.1).
Figure 2.1: Illustrative figure of how polygenic scores are calculated in three study individuals,
who have each been genotyped for two variants. Variant effect sizes or betas (β) from a GWAS
are multiplied by the effect allele count in each individual (red = known effect allele). All effects
are summed over for each individual to create a risk score for that individual.
Polygenic scores can enable us to compare the distribution of polygenic burden of
a specified set of variants for a given trait, between two or more groups (Figure
2.2). As an example, a study by Talmud et al. (2013) used a polygenic score
for higher low density lipoprotein C, to assess polygenic risk for high cholesterol
in individuals diagnosed with familial hypercholesterolemia, with and without a
confirmed diagnostic variant. They found that individuals with an unexplained case
of the familial disease had elevated polygenic scores compared to those with a known
variant. However, affected carriers of diagnostic variants also had significantly
higher polygenic scores than controls with normal cholesterol levels. In this study,
the authors used a polygenic score constructed from 12 SNPs which had previously
been associated with higher cholesterol in blood. It is more common practice now
to also include variants which are not all necessarily associated with the trait at
genome-wide significance (International Schizophrenia Consortium et al., 2009).
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Typically in this approach, variants are selected to be added to the score set if they
pass a certain P-value threshold. The variants are also thinned so that only one
variant from each independent locus is included in the score. Some studies then
construct multiple polygenic scores using different thresholds, and report results
from all of these. Others choose to use a cutoff that has previously been shown to
explain the most variance for the phenotype in an independent cohort. Methods
also exist to include all variants, but these will have to account for decreased
accuracy when estimating the effect sizes for low frequence variants in a GWAS
(Vilhja´lmsson et al., 2015). By when adding more variants to a polygenic score, it
is likely that more of the effects that truly contribute to trait h2 are also included.
However, the drawback to this is that it can add noise or bias to the scores.
Figure 2.2: In this illustration, the distribution of polygenic scores in cases (red) is shifted to the
right (higher risk) from the control distribution (in blue). The cases have on average a slightly
elevated polygenic risk compared to the controls for the trait or disease in question. The tails of
the distributions may also give important information about differences in polygenic burden in
two groups.
2.3 Contributions and publication note
Genotyping of DDD samples was done by the Sanger Institute genotyping facility.
Daniel Rice wrote custom scripts that allowed for efficient computation of polygenic
scores. Hilary Martin contributed to the supervision of this work. The work
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described in this chapter was completed under the supervision of Jeffrey Barrett,
and was published in Niemi et al. (2018).
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2.4 Methods
2.4.1 Datasets and quality control
In order to measure polygenic effects on neurodevelopmental disorders in the DDD
Study, I performed a GWAS. As controls for this study, I used individuals recruited
as part of the UK Household Longitudinal Study, who are not suffering from early
childhood onset, severe neurodevelopmental disorders. In this section I will describe
the cohorts I used, the genotype data, and the selection of samples and variants
for GWAS.
Deciphering Developmental Disorders
Recruitment and phenotyping of DDD patients is described in detail in Wright
et al. (2015) and Deciphering Developmental Disorders Study (2015). Families
gave informed consent for participation. Briefly, the DDD study recruited patients
with a previously undiagnosed developmental disorder, in the UK and Ireland.
Recruitment was done by senior clinical geneticists who had assessed that each
patient’s disorder was sufficiently early-onset and severe that it was likely monogenic.
Patient phenotypes were systematically recorded by clinical geneticists using Human
Phenotype Ontology (HPO) terms in a central database, DECIPHER (Firth et al.,
2009). Most patients are recruited at a young age, with the mean decimal age
at assessment being 7.7 years, but, 6% of patients were recruited as adults over
the age of 18 years. The DDD Study genotyped 11,304 patients on the Illumina
HumanCoreExome. In addition, a cohort of 930 full trios, with the addition of
some parent-proband duos and proband singletons were genotyped on the Illumina
HumanOmniExpress chip. Genotyping was carried out by the Wellcome Trust
Sanger Institute genotyping facility. All data were on GRCh37, and detailed
information of genotyping chips is shown in Table 2.1.
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Table 2.1: Quality control for UK cohorts.
Quality control steps -
DDD and UKHLS data
DDD trios DDD
probands
(1)
DDD
probands
(2)
UKHLS con-
trols
DNA chip NA HumanOmni-
Express 12v1
BeadChip
Human Core-
Exome 24v1.0
BeadChip
InfiniumCore-
Exome
24v1.1 A
Beadchip
Human
CoreExome-
12v1-0 B
BeadChip
Pre QC
samples NA 930 3,000 8,304 10,484
variants NA 811,844 547,644 551,839 538,403
Post sample
and variant
QC
samples samples that passed
QC
911 2,832 7,724 10,391
variants variants that passed
QC and had
MAF≥0.5%
587,655 246,506 246,506 246,506
Post
imputation,
neurodevelop-
mental GBR
subset
samples samples with non-GBR
ancestry or without a
neurodevelopmental
phenotype excluded,
one individual from
related pairs removed
(excl. trios)
728 1,966 5,021 9,270
variants imputed variants fil-
tered for INFO≥0.9
4,934,465 4,134,438 4,134,438 4,134,438
UK Household Longitudinal Study
We obtained data from the UK Household Longitudinal Study (UKHLS) to use
as controls for our discovery GWAS (University of Essex Institute for Social and
Economic Research, 2018). The UKHLS cohort consists of a continuation of the
British Household Panel Survey (BHPS) and additional ongoing recruitment of
individuals living in the UK. Individuals were recruited to the study based on their
postcode, with the aim to capture a representative population of the people living
in the UK, and to collect extensive longitudinal data on these individuals. Study
participation was incentivised with a monetary reward for every questionnaire
completed. A registered-nurse visit was offered to UKHLS and BHPS participants
during waves 2 and 3, spanning years 2010-2012 (University of Essex Institute for
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Social and Economic Research, 2014). All those aged 16 and above were invited
to take part. Upon consent, blood samples were taken during the nurse visit, and
these were used for genotyping. Genotyping of 10,484 UKHLS samples was carried
out by the Wellcome Sanger Institute on the Illumina HumanCoreExome chip. All
data were on GRCh37, and detailed information of genotyping chips is shown in
Table 2.1.
All participants in the nurse visit were asked about their general health, but they
were not excluded from giving a blood sample based on disease status other than
blood borne disease e.g. HIV, as long as they were healthy enough to undergo nurse
interview and assessment (University of Essex Institute for Social and Economic
Research, 2014). Since the study participants who were invited to give a blood
sample were at least 16 years of age at the time of sampling, the UKHLS cohort
mean age was higher than that of DDD. However, due to the fact that individuals
were not deliberately excluded on the basis any diseases or traits, the expectation
is that the distributions of alleles associated with these traits are relatively close to
the population distributions. This also means that the UKHLS may include some
individuals who have a diagnosis for complex diseases, e.g. nonpsychiatric diseases
such as inflammatory bowel disease, diabetes type 1 and 2, etc. Therefore, since
neither the UKHLS nor DDD ascertains participants based on the presence of any
of these diseases (or who would develop them), we would expect the distribution of
risk alleles for these non-neurodevelopmental complex diseases to be similar within
the DDD and UKHLS cohorts. Therefore the difference in age or potential presence
of individuals with complex diseases in the UKHLS is not a concern for our GWAS.
Quality control of datasets
Sample and variant quality control is essential to remove biases that may arise
from e.g. ascertainment or the genotyping process, which may lead to spurious
variant-phenotype associations in a GWAS. I performed variant and sample quality
control for each dataset separately, adapting the protocol suggested by Anderson
et al. (2010). I received all data in PLINK format as hard-called genotypes. Specific
steps that I took are summarised in Table 2.2. Briefly, I removed variants that were
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missing in ≥3% of samples, and samples that had ≥3% of their genotypes called as
missing by the genotyping algorithm. I also assessed the proportion of heterozygous
genotypes per individual, and removed samples that had high heterozygosity to
control for admixture or low heterozygosity which implies consanguinity of the
parents (±3 standard deviations from the mean). I then removed one of each pair
of sample duplicates, which I defined on the basis of two samples sharing alleles
identical by descent ≥0.98. The HumanCoreExome chip contains a high proportion
of rare variants with minor allele frequency (MAF) ≤0.005 (45% of variants), which
are likely to be enriched for genotyping errors. In order to minimise potential biases
resulting from this, I removed rare variants before imputation for these dataset.
As an additional quality control step in the DDD trios data, I removed families
that had an elevated numbers of Mendelian errors.
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Table 2.2: Sample and variant quality control parameters.
Sample quality control
Reported sex inconsistent with data
Sample genotype missingness ≥3%
±3 standard deviations from mean heterozygosity (control for inbreeding and admixture)
Sample duplicates (alleles identical by descent ≥98)%
High number of mendel errors in trio >2000
Variant quality control
Variant genotype missingness ≥3%
Chromosome and position duplicates
Position other than chromosomes 1-22
Hardy Weinberg Equilibrium test P<1 ×10−5
Strand information unavailable for SNP
Alleles discordant between case and control datasets
Alleles and frequency in Europeans discordant with HRC v1.1
Differential missingness between cases and controls P<1 ×10−20
Post-imputation
Variants INFO ≤0.90
Samples non-GBR ancestry
Relatives in discovery GWAS (proportion of alleles identical by descent >0.12), sample with
higher missingness removed
Selecting samples with European ancestry
Variation between populations is typically correlated with geographical location
(Campbell et al., 2005; Novembre et al., 2008). Therefore comparing the allele
frequencies between two randomly selected cohorts would result in associations
that have nothing to do with the intended trait measured but instead are different
due to systematic differences in the population structure between these groups.
Therefore case-control GWAS typically attempt to maximise homogeneity between
individuals with respect to their genetic ancestry before analysis. Although genetic
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ancestry tends to be more homogeneous among samples collected in the same
geographical region or country, neither the DDD nor the UKHLS recruited their
study participants using information about their genetic ancestry (more discussion
below), and so the expectation was that these included individuals from different
ancestral populations. I therefore checked the genetic ancestry of individuals before
conducting the GWAS.
I defined sample genetic ancestry based on a projection principal component (PCA)
analysis using PLINK with 1000 Genomes Phase 3 populations (1000G). For this
analysis, I used only variants with a minor allele frequency (MAF) of ≥0.10 to
reduce bias from rare alleles, and variants that were not in linkage disequilibrium
with each other. A principal component analysis tries to fit a statistical model,
where independent components explain variance in the data. The first principal
components also typically correlate with ancestry and geographic location, and
therefore selecting samples based on their clustering on PC1 and PC2 axes is often
used for determining population ancestry groups (Novembre et al., 2008). Datasets
such as the 1000 Genomes panel include individuals from a number of different
geographical and ancestral groups, and therefore these are often used as reference
panels for determining ancestry of new datasets. In my projection PCA, I used
the 1000G samples to determine the genetic distance between individuals within
1000G (Figure 2.3a), and then projected my DDD and UKHLS samples on top
of these, in order to assess where they lie in relation to the 1000G samples. The
largest cluster of DDD and UKHLS samples that overlay with the 1000G samples
had Great Britain ancestry. As illustrated by the PCA plots in Figure 2.3 b and
c, the genetic ancestry of DDD patients and parents was quite diverse. Because
the DDD Study recruited patients with the aim of exome sequencing trios, and
within-trio analyses are immune to population structure, recruitment of individuals
with heterogeneous ancestries was not a concern for the Study. The PCA may also
reflect an enrichment of South Asian ancestry in the DDD, since consanguinity
increases the risk of developmental disorders (Martin et al., 2017b).
When doing case-control GWAS, it is also customary to only include individuals who
are not related more closely than second-degree relatives. Otherwise it is possible
for genotypes found within these families to become over-represented relative to
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the population allele frequency (Anderson et al., 2010). Increasing the sample size
for GWAS can increase power to detect association, so some GWAS software such
as BOLT-LMM (see section 2.4.3) build a relationship matrix from the genotypes
of individuals. This should in theory make the analysis immune to population
structure. In this Chapter, I use BOLT-LMM to conduct my discovery GWAS,
however, in practice I saw that removing relatives from the analysis strengthened our
downstream findings. I therefore identified pairs of related individuals equivalent to
second-degree relatives or closer (alleles identical by descent >0.12, using PLINK)
from the case-control cohorts, and removed the individual who had a higher variant
missingness rate out of the two. I also checked that individuals in the discovery
case-control DDD and UKHLS cohorts were not related to individuals who were
included in the DDD trios (alleles identical by descent >0.12).
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Figure 2.3: a, Reference samples (N=2,504) from 1000 Genomes Phase 3, colored by the five
super populations, used for a projection PCA of UK cohorts (DDD and UKHLS). b, All DDD
cases (discovery N=11,304 and trios N=930) from projection PCA with 1000 Genomes. Case
samples with European ancestry are plotted in red and non-Europeans in grey. c, All UKHLS
controls (N=10,396) from projection PCA with 1000 Genomes. Control samples with European
ancestry are plotted in blue and non-Europeans in grey. All cases and controls coloured in grey
(panels b and c) were excluded from analysis due to non-European ancestry.
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Phasing and imputation
Genotyping chips capture only part of the known common variation in the genome,
but it is possible to fill in the gaps, or to ’impute’, the missing variants by inferring
them from the surrounding markers (Marchini and Howie, 2010). The sample is
compared to a panel of reference haplotypes, which allows for the best guess of the
missing genotypes in the target sample. This process of inference from surrounding
markers is made more efficient by first phasing, i.e. constructing haplotypes from
the genotyped markers. Imputation is often done for GWAS samples to boost the
coverage of the genome for association testing, and to increase overlap between
datasets genotyped on different chips. In the context of this study, imputation
allowed me to include more variants shared between the DDD cases and healthy
controls, boosting coverage, as well as between the discovery and replication cohorts.
Stringent quality control before imputation is key to avoiding amplification of biases
that may arise from subtle differences between batches of data, arising from e.g.
differences in missingness or genotyping error in the original genotype-calling.
After sample and variant quality control, I phased and imputed the discovery GWAS
cohorts (DDD singletons and UKHLS), genotyped on the HumanCoreExome back-
bone, together using variants that intersected between the different versions of the
chip (Table 2.1). I then phased and imputed trios that were genotyped on the
HumanOmniExpress in a second batch, due to the small number of overlapping
variants with HumanCoreExome chips. I used the Sanger Institute Imputation
Service (McCarthy et al., 2016) to carry out phasing and imputation, using Eagle2
(v2.0.5) (Loh et al., 2016) and PBWT (Durbin, 2014) software respectively. For
imputation, I selected the Haplotype Reference Consortium as the reference geno-
type panel (release 1.1, chr1-22, X) (McCarthy et al., 2016). After imputation I
removed variants that had a missingness of >0.05 or an INFO score <0.9.
Phenotype data in DDD Study
In a case-control GWAS of a heritable trait, the phenotype for which cases are
recruited to the study is usually well defined. However, the DDD cohort comprises
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of patients with thousands of different phenotypes, likely with numerous different
genetic contributors. I therefore first tried to increase power for association testing
by refining the phenotype which we wanted to test. We decided to take the approach
of selecting patients with at least one phenotype HPO term that indicated an
abnormality of the central nervous system. The HPO tree begins with the root term
phenotypic abnormality, and descends into organ system level, and further down to
more specific phenotypic terms, as illustrated in Figure 2.4. I first manually studied
the HPO term tree in order to define which groups of terms were associated with the
central nervous system. I then ran a HPO text search for patients who had at least
one of the following HPO terms or daughter terms of abnormality of the nervous
system morphology (HP:0012639) or the following physiological sub-abnormalities:
abnormal metabolic brain imaging by MRS (HP:0012705), abnormal brain positron
emission tomography (HP:0012657), abnormal synaptic transmission (HP:0012535),
abnormal nervous system electrophysiology (HP:0001311), behavioural abnormality
(HP:0000708), seizures (HP:0001250), encephalopathy (HP:001298), abnormal-
ity of higher mental function (HP:0011446), neurodevelopmental abnormality
(HP:0012759). The neurodevelopmental patient subset included both individuals
who have, since recruitment to the DDD study, been found to carry diagnostic
mutations in protein-coding genes (Wright et al., 2015; Deciphering Developmental
Disorders Study, 2017; Martin et al., 2017b; Short et al., 2018), and individuals
for whom no likely diagnostic rare variant has yet been found. The definition for
the main phenotype in this study is therefore neurodevelopmental disorder risk,
which is the risk of having a previously undiagnosed developmental disorder, being
recruited to the DDD study, and having at least one neurodevelopmental HPO
(Figure 2.5).
In addition to HPOs, some DDD patients had clinical growth measurements for
height (78% of unrelated patients with European ancestry), birth weight (93%) and
head circumference (87%). These measurements had been standardised by the DDD
Study to reflect departure (standard deviations) from the age and sex-adjusted
population means. I pulled these adjusted metrics from the DDD Study internal
phenotype database, which is acquired from DECIPHER database.
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Figure 2.4: Illustration of the HPO tree. The term ”phenotypic abnormality” descends down to
abnormalities of different organ systems, and further down to more specific phenotypic terms.
Figure 2.5: Summary of the DDD study samples.
2.4.2 Counting affected organ systems
We wanted to determine how many distinct organ systems were affected in each
patient who was in included in the final sample (Figure 2.5). This was complicated
by the fact that many HPOs fell under more than one organ system category. For
example, microcephaly, which is a common term in the cohort, falls under ”nervous
system”, ”head or neck” and ”skeletal system”. In order to assign each HPO into
only one organ system, I used a ranked organ system approach. To do this, I
first ranked organ systems based on the number of raw counts of individuals with
at least one term under that system (Table 2.3) in the full DDD cohort. After
ranking organ systems, I then looked for individuals with at least one HPO under
the system ranked most commonly affected (in this case the nervous system), and
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assigned these individuals an organ system count of 1. I then removed these HPOs
from the patients’ lists, before continuing to identify individuals with at least one
HPO in the organ system ranked second most prevalently affected (in this case head
or neck). I continued to count organs and remove HPOs until we had assigned all
individuals a count of organs systems affected out of 19 non-overlapping systems.
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Table 2.3: Proportions of DD patients who have at least one HPO term belonging to a particular
organ system category. The HPO tree descends down from ”phenotypic abnormality”, to different
organ systems, down to specific terms describing particular phenotypes. Each HPO term used by
clinicians to describe patients was traced up the tree to the organ system level. However, some
HPOs may belong to more than one organ system category. For example, microcephaly will be
counted under ”nervous system”, ”head or neck” and ”skeletal system” in the HPO tree, whilst
global developmental delay will only appear under ”nervous system”.
Rank Organ system % All DDD pa-
tients (N=13,558)
% Neurodevelop-
mental subset of
unrelated DDD
patients, GBR an-
cestry (N=6,987)
1 Nervous system 87 100
2 Head or neck 68.9 71.2
3 Skeletal system 61.7 61.8
4 Limbs 35.1 35.3
5 Eye 34.9 35.3
6 Integument 31.2 31.9
7 Ear 20.1 19.7
8 Digestive system 20 19.1
9 Musculature 19.9 18.7
10 Cardiovascular system 15.1 13.5
11 Genitourinary system 12.4 11.4
12 Respiratory system 8.1 7.3
13 Connective tissue 7.4 6.3
14 Immune system 6.8 6.5
15 Endocrine system 4.1 4.1
16 Metabolism homeostasis 4.1 4
17 Breast 3.7 3.7
18 Blood and blood forming tissues 2.1 2.1
19 Voice 1.1 1.1
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2.4.3 Genome-wide association study
To conduct the GWAS of neurodevelopmental disorder risk, I used BOLT-linear
mixed models (BOLT-LMM) (Loh et al., 2015b). The method first builds a genetic
relationship matrix (GRM) using a set of ∼500,000 thinned variants. Although our
study phenotype is a dichotomous trait, the data is suitable for using BOLT-LMM,
because it fulfils recommendations by the authors of the software: the discovery
GWAS sample size is large, the MAF threshold we use is high (≥0.05), and cases
and controls are well balanced (0.43 fraction of case) (BOLT-LMM v2.3.2 User
Manual 2018; Loh et al., 2018). Using this method should control for cryptic
relatedness and any remaining ancestry bias more accurately than e.g. adding
ancestry PCs as covariates in a logistic regression for association testing. For the
GWAS described in this thesis, I included sex as a covariate in the model.
I report a genomic inflation factor for the GWAS. Genomic control (λGC) quantifies
the deviation of observed chi2 test statistics from the expected null-distribution
in a genome-wide association study. It is defined as a ratio median(observed
chi2)/median(expected chi2) (Devlin and Roeder, 1999). Inflation of lambda (from
λGC=1) indicates either true polygenic signal, or biases such as population structure
in the data. Often the observed test statistics are visualised against the expected
values in a quantile-quantile plot which can give an idea as to whether the data
are behaving appropriately. Traditionally in GWA studies, λGC has been used to
correct for confounding, as it is expected that SNP effects on all chromosomes
are affected by the same bias (e.g. from population stratification), and therefore
the test statistic is divided by λGC. In this thesis, however, I do not use genomic
control on the test statistics, because BOLT-LMM should in theory handle potential
non-polygenic biases.
2.4.4 SNP heritability using LD score regression
To estimate SNP heritability for discovery neurodevelopmental disorder GWAS, I
used Linkage Disequilibrium score regression (LDSC) (Bulik-Sullivan et al., 2015a),
as the method is able to distinguish between confounding and polygenic effects.
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One of the key benefits of using this method is that individuals’ genotype-level
data are not needed. Instead, the method uses summary statistics as input, which
also greatly reduces processing and analysis time.
The principle of LDSC lies in the assumption that variants that tag (are in high
LD with) more variants are also more likely tag a causal variant for a given
phenotype. For this reason, those variants will have on average stronger association
test statistics when there are real polygenic effects. However, confounding (e.g.
population stratification) does not cause inflation in test statistics in proportion to
LD. Specifically, the method involves regressing the association χ2 test statistic at
each SNP against the average linkage disequilibrium (LD) in that region, which
reflects the extent to which that variant tags other variants (the LD score). The
LD score for each SNP can be estimated from reference panels such as the 1000
Genomes European cohort. Best practice is to use scores derived from a population
with matching ancestry to the cohort studied. The intercept from this regression
can be transformed into an estimation of the proportion of phenotypic variation
explained by effects other than polygenic, such as population substructure. The SNP
heritability estimate is achieved by rescaling the slope of the LD score regression.
If genomic control is required in a GWAS, the LD score intercept can be used as
an effective alternative to the more conservative λGC, which does not distinguish
between inflation from true polygenic signal and bias (Bulik-Sullivan et al., 2015a).
However, in the absence of major inflation of test statistics and the fact that
correction can downward bias LDSC estimates, I did not apply any genomic control
to variant effects (betas) in work described in this thesis.
I used the LD score website LD Hub (Zheng et al., 2017), to estimate SNP
heritability from the discovery GWAS neurodevelopmental disorder risk summary
statistics (BOLT-LMM output). As recommended by the authors (Zheng et al.,
2017), I removed the major histocompatibility complex (MHC) region (chromosome
6, 26-34MB) from the GWAS results before analysis due to its complex LD structure.
LDSC default output is SNP heritability (h2) on the observed scale, however h2 on
the liability scale can be obtained by specifying the ratio of cases to controls in
the study and the estimated population prevalence of the trait. In our scenario
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though, estimating true population prevalence of neurodevelopmental disorders
such as those included in my discovery GWAS is difficult due to several factors,
including: (1) DDD participants included in the discovery GWAS were selected
from a cohort of undiagnosed disorder patients specifically for neurodevelopmental
abnormalities defined by HPO terminology; therefore any neurodevelopmental
disorder patient whose condition was diagnosed through NHS clinical genetics
clinics would not have been recruited to the DDD Study. (2) In addition, the
DDD cohort consists of heterogeneous etiologies, including but not restricted to
de novo coding mutations (Deciphering Developmental Disorders Study, 2017),
bi-allelic inherited mutations (Martin et al., 2017b), de novo non-coding mutations
(Short et al., 2018), and unexplained cases. I report SNP heritability assuming a
prevalence of 1% in the population. By varying the prevalence between 0.2% and
2%, the SNP heritability estimate remained approximately within the 95% CI of
the reported SNP heritability.
2.4.5 Polygenic scores
The formula I used for calculating polygenic scores took into consideration the
β (effect size) of each known effect allele, and their allele counts in the target
individual (Polygenic score = Σβ1x1+β2x2+ ... +βixi). To select which variants to
include in polygenic scores calculated from summary statistics for our developmental
disorder risk discovery GWAS, I started by identifying which variants existed in
both the discovery GWAS and the imputed data for DDD trios (replication set).
This is because I could only use variants for which we know the effect (β) on
neurodevelopmental disorder risk, to calculate the polygenic scores for this trait
in the target trios. All variants that I selected had a MAF≥0.05 in both the
discovery GWAS and probands from the European trios, and had been directly
genotyped or imputed with high confidence (INFO≥0.9) in both datasets. To find
independent variants to include in the scores, I pruned the remaining intersecting
variants in the trios data using PLINK, which takes the top variant and removes
variants within 500kb and that have r2≥0.1 with the top variant. PLINK then
repeats the process until no SNP has a P-value below a pre-defined threshold. To
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obtain this threshold, I did ten rounds of simulations where I first repeated the
neurodevelopmental disorder risk GWAS having removed a random subset of 20%
of cases and controls. I then calculated a neurodevelopmental disorder (NDD) risk
polygenic score in the leave-out subset, and performed a logistic regression with 10
ancestry principal components to assess association of case-control status with the
score. I tried different P-value thresholds which were P<0.005, P<0.01, P<0.05,
P<0.1, P<0.5, P<1. I then chose a P-value threshold which resulted in a score
that was most strongly associated with case/control status. The threshold P<1
performed best in ten independent permutations. As a note, there is currently
no uniform protocol for how to define a P-value cutoff for polygenic scores. Some
studies choose to use an a priori P-value cutoff that explains the most variance in a
replication cohort as we have done, others report results for a range of thresholds,
and some report only the analysis which post hoc resulted in the most significant
results. After calculating the scores for each study individual using the predefined
threshold of P<1, I normalised the proband scores and parental scores to have a
mean of 0 and variance of 1.
2.4.6 Polygenic transmission disequilibrium test
I used the polygenic transmission disequilibrium test (pTDT) method (Weiner
et al., 2017) to replicate neurodevelopmental disorder risk using trios data. The
method compares the means of two polygenic score distributions: one comprising of
scores of the probands, and the other of the average scores of parent-pairs. The test
is equivalent to a paired, one-sample t-test, and assesses whether the mean of the
score distribution in probands deviates from the mean of parent-pair score average,
which is the expected score when there is random transmission. For pTDT analysis
of neurodevelopmental disorder risk in trios, I report a one-sided P-value because
our expectation was that the direction of transmission would be accumulation of
risk alleles in affected children.
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2.5 Results
2.5.1 Discovery GWAS for neurodevelopmental disorder
risk
After removing relatives and non-European ancestry in the DDD Study, 86% of
the remaining patients had at least one abnormality affecting the central nervous
system. This left 6,987 unrelated DDD patients for our discovery GWAS. Some
of the most common phenotypic abnormalities in this neurodevelopmental subset
included global developmental delay, intellectual disability, cognitive impairment or
learning disabilities (in 86% of the neurodevelopmental subset) and autism spectrum
disorders in (16%), among others. Some of the more clinically relevant phenotypes
(Wright et al., 2015) observed in the full DDD cohort and neurodevelopmental
subset are shown in Figure 2.6 a. In addition to the neurodevelopmental phenotype,
88% of these patients’ disorder included an abnormality affecting at least one other
distinct organ system (Figure 2.6 b).
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Figure 2.6: Patients recruited to the DDD study have diverse phenotypes. a. Examples of
specific phenotypes affecting different organ systems, observed in the full DDD cohort and the
neurodevelopmental subset of patients. These phenotypes were determined to be clinically relevant
for developmental disorders in a previous publication (Wright et al. 2015). b. Distribution of the
number of distinct organ systems affected in the set of 6,987 patients with neurodevelopmental
abnormalities (Methods).
I carried out the GWAS in 6,987 DDD cases with neurodevelopmental disorders
and 9,270 ancestry-matched controls in ∼4,1M genetic variants on chr 1-22, with a
MAF≥0.05, genotyped on or imputed from the HumanCoreExome chip. No single
variant reached genome-wide significance for association (p< 5× 10−8) (Figure 2.7
a), which was unsurprising given then phenotypic heterogeneity between patients.
In fact, the heterogeneity among cases would have led us to be suspicious had
there been any significant hits, as these would likely have arisen due to genotyping
error or bias rather than real signal. Despite no significant hits in the GWAS, the
quantile-quantile plot of observed P-values versus expected (under assumption of
no association), were modestly inflated (λGC=1.097) across the genome (Figure
2.7 b). This inflation could either originate from residual bias due to e.g. cryptic
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relatedness or hidden ancestry, or be evidence of a real polygenic contribution from
common variants to neurodevelopmental disorder risk.
Figure 2.7: Discovery GWAS of neurodevelopmental disorder risk. a. Manhattan plot of
neurodevelopmental disorder discovery GWAS, with 6,987 DDD cases and 9,270 ancestry-matched
UKHLS controls (both European ancestry), using 4,134,438 variants MAF≥5% chr1-22. P-values
were from a two-tailed chi squared distribution. Red line = threshold for genome-wide significance
(P=5 ×10−8). b. Quantile-quantile plot of neurodevelopmental disorder discovery GWAS. Red
line = expected values under the null.
2.5.2 Estimating SNP heritability
To investigate whether the inflation in test statistics in the discovery GWAS was
due to confounding or real polygenic effects, a natural progression of analyses was
to look for evidence of SNP heritability. When put into context with the traditional
view that developmental disorders are monogenic conditions, and therefore the
patients’ phenotype is explained solely by rare variants or environmental factors,
we would expect the SNP heritability for neurodevelopmental disorder risk not to
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significantly depart from zero. However, the LDSC analysis showed that common
variant (MAF≥0.05) heritability was 0.077 (SE=0.021, 95% confidence interval
(CI): [0.036, 0.118]), when assuming an overall 1% population prevalence of severe
neurodevelopmental disorders (observed scale h2=0.138, SE=0.037, 95%CI: [0.066,
0.211]).
Strikingly, this is similar to what has been reported for major depressive disorder
(MDD) (h2=0.089, SE=0.004, assuming lifetime population risk of 15%) (Wray et al.,
2018) and autism spectrum disorders (h2=0.118, SE=0.01, population prevalence
1.2%) (Grove et al., 2017). Both these studies were carried out with much larger
numbers of cases than our study with 130,664 MDD cases and 18,381 autism cases.
However, our h2 estimate was substantially lower than what has been recently
reported for some other neuropsychiatric traits such as schizophrenia (h2=0.244,
SE=0.007, population prevalence 1%) (Pardin˜as et al., 2018) and attention deficit
hyperactivity disorder (ADHD) (h2=0.216, SE=0.014, population prevalence 5%)
(Demontis et al., 2017). The significant SNP h2 finding for neurodevelopmental
disorders (NDDs) directly contradict the monogenic view for these disorders, and
warrants further analysis into understanding how common variants are playing a
modifying role in disease liability and how they affect the presentation of clinical
symptoms. I return to this in Chapter 3. Additionally, LDSC determined that
66% (SE=11.5%) of the variance observed in the GWAS were due to true polygenic
effects. This is lower than what has been reported for other traits by studies that
used the same software, but those traits are known to be polygenic and therefore
likely also have a cleaner phenotype that they are measuring.
2.5.3 Replication in DDD trios
Having shown that a significant contribution to neurodevelopmental disorder risk
in our discovery case-control cohort comes from common genetic variants, I then
sought to replicate the findings in an independent dataset. For this, I used data
for trios who were also recruited as part of the DDD Study, but who not related to
the individuals in the discovery GWAS. This cohort of around one thousand trios
had been genotyped on a significantly denser chip (Illumina HumanOmniExpress)
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than the larger DDD singletons cohort used for the discovery GWAS (Illumina
HumanCoreExome). These two chips had an overlap of only ∼100,000 common
variants. Imputation from such a small number of shared variants would have
likely have resulted in poor quality data, and I therefore treated the trios data
separately. I initially attempted to increase power for the GWAS discovery phase
by meta-analysing association results from the trios with the discovery GWAS (I
describe these analyses in more detail in section 2.5.4). However, due to issues
with the data quality and sample size of the trios dataset, I eventually employed
an independent replication approach, instead of adding them to the GWAS.
In order to replicate my finding of a contribution of common variation to neurode-
velopmental disorder risk, I wanted to assess whether the effect alleles (and thus
their conferred risk) from the discovery neurodevelopmental disorder GWAS were
over-transmitted from parents to the affected DDD children. For this approach, I
used the polygenic transmission disequilibrium test (pTDT), developed by Weiner
et al. (2017). Specifically for our purpose, the benefits of this method included the
fact that if any effects in the discovery GWAS were driven by residual bias instead
of real differences between cases and controls with respect to NDD risk, we would
not expect to see these same effects over-transmitting in a family-based design.
This residual bias was not a concern for h2 estimation using LDSC in the discovery
GWAS, but polygenic scores, even when controlling for population structure, are
more susceptible to this type of error. In addition, by using a test only within the
trios, this eliminates genotyping chip biases.
Having constructed the polygenic risk scores using 71,356 variants, I performed the
pTDT for neurodevelopmental disorder risk in 728 European ancestry trios from
the DDD Study. I found that parents were over-transmitting neurodevelopmental
disorder risk-increasing alleles to the affected child (P=0.0035, one-tailed t-test),
replicating the finding of significant polygenic contribution to severe neurodevelop-
mental disorders.
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2.5.4 Pitfalls and lessons learnt from the DDD GWAS
Discovery GWAS
Initially when carrying out the discovery GWAS, I had included in the analyses
another control dataset, a Dupuytren’s contracture cohort (EGAS00001001206)
(Ng et al., 2017). These 4,201 individuals suffered from Dupuytren’s disease,
which is a common, heritable, late-onset connective tissue disease that causes
contracture of digits. The cohort was collected as part of the British Society for
Surgery of the Hand Genetics of Dupuytren’s Disease consortium, and samples
were genotyped on the Illumina HumanCoreExome chip. We initially reasoned
that these individuals would represent a random sample of the population with
respect to their distribution of risk alleles for complex traits and diseases other
than Dupuytren’s hand contracture phenotype, so this cohort could be used as
extra controls for our neurodevelopmental disorder risk study.
I therefore initially carried out a developmental disorder GWAS (before the de-
cision to refine the phenotype to neurodevelopmental disorders) combining the
Dupuytren’s cohort with controls from the UKHLS. Quite surprisingly, this analysis
showed some near genome-wide significant loci. Upon further inspection, I realised
these loci were among the significant loci from the Dupuytren’s phenotype GWAS
(Ng et al., 2017). This served as a lesson to us that including a cohort, even if
as controls, that had been ascertained for a specific phenotype not related to the
one we were interested in, could introduce biases into our results. Even though in
the event that there had been significant loci associated with neurodevelopment in
our GWAS, the downstream analyses paths that we wanted to take would have
been affected: e.g. when looking for genetic overlap between neurodevelopmental
disorder risk and other published traits (Chapter 3), we would have run into
problems trying to decipher whether the correlations would were driven by genetic
architecture of neurodevelopmental disorders or an unrelated complex trait for
which the controls had been ascertained. In order to avoid any more less obvious
biases that could have arisen from the ascertainment of the Dupuytren’s cohort, we
decided to exclude the cohort from the neurodevelopmental disorder GWAS. This
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analysis served as a cautionary tale about the how sample ascertainment can induce
spurious genetic correlations, an important lesson that I return to in Chapter 3.5.6.
Trios data
As mentioned above, I initially attempted to utilize the trios data for boosting
the discovery GWAS instead of using them for independent replication, before
eventually opting for the pTDT method and independent replication. Here, I
describe that analysis and discuss some lessons learnt from this.
I attempted to use 911 probands from the trios set, combined with healthy controls,
to perform a GWAS and meta-analyse with the larger discovery GWAS. Because I
was not able to find suitable controls genotyped on the HumanOmniExpress chip,
I instead used 4,612 controls from the Wellcome Trust Case Control Consortium 2
(WTCCC2) project. These individuals had been genotyped on a combination of
Illumina 1.2M and Affymetrix500 chips.
In this smaller GWAS using DDD probands (from the trios dataset) and WTCCC2
controls, I found that, despite extensive data quality control, multiple variants
were associated with NDD risk at genome-wide significance. It seemed highly likely
that these were spurious due to the fact that the better-powered larger GWAS had
not detected any significant associations. The cause for some of these associations
turned out to be genotyping error, and I subsequently removed these variants.
However, many associations were not obviously due to error. The most likely
explanation was that these were a result of chip biases. Due to the unreliability of
the results, we decided to explore other options for using the extra DDD samples.
Eventually, we opted for using the pTDT method and polygenic scores constructed
from neurodevelopmental disorder discovery GWAS summary statistics to test for
over-transmission of these effect alleles in the independent trios.
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2.6 Discussion
In this chapter I have shown that there is a significant contribution from common
genetic variants to severe, rare neurodevelopmental disorders. The SNP heritability
of these disorders is 7.7% on the liability scale, when assuming a population
prevalence of 1%. I also show that alleles increasing risk for these NDDs are
over-transmitted from parents to affected children in an independent cohort of
DDD Study trios. Patients were ascertained to participate in the DDD Study to
be exome sequenced because the clinical geneticists who assessed them believed
that their disorder was likely monogenic. Therefore this study represents one of
the first GWAS of a large scale heterogeneous cohort of disorders that match the
phenotypic profile of monogenic disease. The SNP heritability estimate for NDDs
is similar to what has been estimated e.g. for major depressive disorder (Wray
et al., 2018) and autism spectrum disorder (Grove et al., 2017).
One of the limitations of my work on neurodevelopmental disorder risk in this
thesis, is that I have not included variants with MAF<0.05. The decision for a
MAF cutoff at 0.05 was taken for two main reasons. Firstly, the purpose of the
study was to assess whether truly common variants contribute to developmental
disorders, as has been shown for other related brain disorders such as autism (Grove
et al., 2017) and schizophrenia (Loh et al., 2015a). In addition, including only
variants with a higher MAF, particularly when cases and controls are genotyped
on the same chip, reduces the number of false positives. Ultimately, the finding of
significant SNP heritability in the common variant range is important for shaping
our understanding of the genetic architecture of neurodevelopmental disorders, since
specifically rare variants have previously thought to be the sole genetic contributors
to these disorders.
Although assessing the lower frequency MAF ranges, e.g. MAF=0.005-0.05, was out
of scope of this project, we can expect there to be at least some SNP heritability to
be discovered there. Martin Kelemen, a PhD student in our group, performed some
investigative analyses into this lower frequency variant space. His analyses using
methods other than LDSC suggested that potentially much more SNP heritability
can be found, particularly in the MAF=0.0001-0.005 range. Though at these very
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low minor allele frequencies, analyses are easily prone to bias. However, a good
example of a report of a large contribution to a trait from low frequency variants
comes from a recently published paper on intelligence. Intelligence is a trait that is
likely under purifying selection, and therefore variants with large effect sizes are
removed from the population. Most of the SNP heritability for intelligence had
previously been explained by common variants with smaller effect sizes. Hill et al.
(2018), however, showed that including imputed variants down to MAF=0.001-
0.01 almost doubled the variance explained. This brought their h2 estimate to
around 0.50, which is in the range of heritability estimates from family studies of
intelligence (though the confidence intervals for this estimate were wide). Analyses
looking more deeply into including low frequency variants for neurodevelopmental
disorders would be something that can be considered in the future. However, this
would require careful consideration of potential caveats relating to estimating SNP
heritability attributable to low frequency variants. These include reports that
even subtle population stratification between cases and controls can lead to biased
estimates when dealing with lower frequency variants (Bhatia et al., 2016). Delving
into even lower MAF ranges, other members of the DDD Study team are currently
exploring an oligogenic model using inherited low frequency variants, that may
individually have moderate effects on the phenotypes we observe in the cohort
A critical caveat of our study, which could downward bias our discovery GWAS
h2 estimate, is that the analysis was performed on a very sparse genotyping
chip. This can lead to incomplete tagging of common variants, therefore affecting
h2. Additionally, I applied a stringent imputation quality cutoff before analysis.
Another general consideration for SNP heritability analyses in case-control studies
is that SNP heritability can be underestimated if the controls are not screened
for the disease (Peyrot et al., 2016). This is because affected individuals may be
included as controls. However, in the case of NDD risk, this is unlikely, since
individuals who participated in the UK Household Longitudinal Study (i.e. my
GWAS controls) were likely not suffering from neurodevelopmental disorders of
the severity that the DDD patients have. However, since I do not have data on
rare variants from the controls it is possible that some individuals may be carriers
of deleterious variants in neurodevelopmental disorder genes, but the individual
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is on the milder spectrum of cognitive or neurodevelopmental phenotypes. These
individuals could potentially end up in a population survey study, however this
would likely be a small proportion of the cohort.
In this chapter I have also discussed how sample size and selecting for a cleaner
phenotype among all cases can increase power for association, and consequently for
estimating h2. Finding additional cohorts similar to the DDD Study to boost our
sample size would be challenging. There are several datasets that have been collected
for traits such as intellectual disability, e.g. the Northern Finland Intellectual
Disability study (Kurki et al., 2018) and a cohort in Nijmegen, Netherlands.
However, sample ascertainment is a needs to be considered when combining datasets,
as the particular phenotypes and genetic architectures between DDD Study and
other cohorts may be somewhat different. Although a large proportion of DDD
patients (∼70%) suffer from intellectual disability or developmental delay, the
majority are also affected in organ systems other than the nervous system. Therefore
the genetic architecture of this cohort may be different to e.g. a cohort ascertained
for non-syndromic intellectual disability. Intellectual disability as a trait also
has a phenotypic range from mild to profound intellectual disability, and it is
thought the extremes of phenotype have somewhat different genetic underpinnings
(Reichenberg et al., 2016). Despite these notions, combining the DDD Study with
other intellectual disability cohorts would likely boost power for association testing.
Another limitation of the work presented in this thesis is the exclusion of chromo-
some X from the GWAS. There is a known enrichment of developmental disorder
associated genes on chromosome X, with almost over 20% of known monoallelic
developmental disorder genes being found on this chromosome (Firth et al., 2009).
The decision to drop chromosome X from the analyses came in two parts. Firstly,
including it in a GWAS would require additional quality control steps and using
a different model for association, to account for the the fact that females have
two copies and males only one. The pseudoautosomal regions would need to be
removed or treated separately. At the time, we BOLT-LMM did allow for including
chromosome X in the data, however it did not (from my understanding) treat it in
a different way to autosomes. The BOLT-LMM team have recently released a soft-
ware update, which now allows for more specialist treatment of the chromosome X.
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Therefore including chromosome X using BOLT-LMM, or applying other software
e.g. PLINK logistic regression models, would be worth looking into in the future.
Secondly, downstream analyses from the GWAS mainly require autosome data only,
as LDSC estimates h2 from only autosomes. Polygenic scores for example also rely
on published GWAS, which typically exclude the X. In Chapter 3, I also describe
analyses which utilise data from other published GWAS, and these typically once
again use data from autosomes only.
In this Chapter, I have also discussed different caveats of GWAS data in trios.
We had data for a small cohort of DDD families, which we wanted to utilise to
our best ability. Having attempted replication GWAS in a small cohort through
both case-control GWAS and family-based GWAS (TDT), I proceeded with the
polygenic transmission disequilibrium test, which uses polygenic scores instead
of genotypes for the test of transmission. Whilst the more conventional way to
utilise the data would have been to meta-analyse with the larger discovery GWAS,
the challenges that arose during this process were good examples of the types of
considerations that need to be made when planning a GWAS study. Had the trios
been genotyped on the same HumanCoreExome chip, which is also cheaper than
the HumanOmniExpress chip, it would have been easier to meta-analyse TDT
results with the NDD discovery GWAS. Had this been the case, we would not
necessarily have considered using the pTDT method. In hindsight, pTDT was
perhaps an even more useful tool for us, as it provided the opportunity to perform
replication, whilst a meta-analysis would not have resulted in a large increase in
power for association, with an addition of only ∼700 cases to the GWAS. These
exploratory analyses show a good example of how GWAS data can be used in
multitude of ways.
Finally, an obvious limitation of the analyses presented here, and also in the follow-
ing chapters, is that they focus on individuals of European ancestry. Populations
not only differ in LD structure, but also the causal variants may be different.
Therefore, we cannot make generalisations about the genetic architecture of neu-
rodevelopmental disorders in populations with other ancestries from our results.
Although the DDD cohort includes other ancestries, particularly South Asian
ancestry, we were not able to find suitable controls for these cohorts, and we did
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not have genotype data for many trios of non-European ancestry. This a general
issue in the field, and since most published GWAS to date are in Europeans only,
the downstream analyses in Chapter 3 would not have been possible to carry out
in non-European DDD patients. Hopefully in the future many more studies on
non-Europeans will be carried out.

Chapter 3
Investigating shared genetic
architecture and polygenic
substructure in severe
neurodevelopmental disorders
3.1 Chapter overview
In this chapter, I aim to further understand the observed common variant effects
contributing to risk of rare severe neurodevelopmental disorders. I first attempt to
partition the overall SNP heritability for these disorders into categories of variants
that have specific functional roles, or which are within regions of the genome that
are expressed in different tissues. By doing this I hope to learn about the biology
underlying the signal I found. After this, I compare the neurodevelopmental
disorder GWAS results to other published GWAS for a variety of traits. I do
this to look for genetic overlap, to learn more about shared underlying biology
between our GWAS and other traits. Finally, I employ polygenic scores to look
for differences between patient groups within the DDD cohort. These analyses
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may tell us whether the polygenic burden is concentrated in patients with specific
phenotypes or molecular aetiologies to their disease.
3.2 Background
In Chapter 2, I showed that there is a significant contribution from common genetic
variants to severe rare neurodevelopmental disorders. A typical GWAS study would
focus downstream analyses on deciphering which variants in the discovered trait-
associated regions are more likely to be causal for the association, and honing in on
which genes and biological pathways are affecting the trait. The aim of this process
is usually to understand the basic biology of the trait, and to hopefully find potential
new candidate drug targets for treatment of diseases. With our neurodevelopmental
disorder (NDD) risk GWAS, however, I was not able to go down the path of finding
candidate causal variants. This is because we had no genome-wide significant
variant associations with the phenotype. Instead, in this chapter I explore different
avenues to learn more about polygenic effects contributing to NDD risk. Much of
this involves utilising information from other already published work in the field.
One of these possibilities is to partition the SNP heritability for NDD risk. This
analysis is to find out whether variants expressed in specific tissues are enriched
for common variant effects in our GWAS, or whether particular functional element
classes are disproportionately responsible for any of this polygenic burden. In
addition, by comparing NDD risk to common variant architectures of other GWAS’d
traits, we can potentially gain insight into whether the SNP heritability for NDD
risk is capturing effects previously associated with brain or neurodevelopment.
Finally, utilising the phenotypic data available for the DDD cohort, we can ask
the question whether the polygenic effects we are observing contribute more to
particular patient groups, or whether these are distributed equally among all
patients.
One way to investigate these questions is to use polygenic scores. DDD patients
and UKHLS controls have been ascertained for whether or not they have a se-
vere neurodevelopmental disorder phenotype. We can then ask whether they are
3.2. Background 61
significantly different from each other with respect to their allele frequencies for
variants associated with previously published GWAS looking at other traits. If
they are different, this would be an indication that NDD risk shares effect alleles
with the trait in question. This type of approach to look for genetic overlap
between traits using polygenic scores was first used by International Schizophrenia
Consortium et al. (2009). In this study, the authors showed that patients with
bipolar disorder had elevated schizophrenia polygenic scores compared to healthy
controls, which indicated shared biology between the two diseases. Importantly,
the study also showed that polygenic scores for schizophrenia predicted the disease
in an independent cohort, but the prediction was better when applying a higher
P-value cutoff and including more variants in the scores.
Nonetheless, polygenic scores still have some caveats. In the field there are no
set rules for how to construct polygenic scores, and there are multiple parameters
that can be tweaked when deciding which variants to include. This can cause
issues when attempting to replicate results and when looking for genetic overlap
between diseases and traits, as different studies will use different approaches to
defining which variants to use. Often there are multiple published GWAS for the
same trait, so the decision on which data to use to construct scores is also an
important one. One may choose to use the GWAS with the largest sample size,
or potentially a GWAS with a more homogeneous measured phenotype. Another
caveat is that polygenic scores can only be reliably constructed in a target population
with the same genetic ancestry as the original GWAS. This is because the allele
frequencies between populations are different, and subsequently polygenic scores do
not necessarily follow an expected normal distribution in a target population with
different ancestry (Weiner et al., 2017). Additionally, a polygenic score derived
in one population may not capture risk in a second population because linkage
disequilibrium patterns differ between them. This means the causal variants may
not be tagged in the second population (and indeed, there may be different causal
variants). Polygenic scores also typically explain a small proportion of variance
in the phenotype. The predictive power of a polygenic score relies heavily on the
sample size of the discovery GWAS, and the SNP heritability of both the discovery
and target trait. Even if the discovery GWAS is well powered and has high h2, an
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analysis may be underpowered if the h2 of the target cohort is small, the sample
size is small, or the individuals are heterogeneous with respect to their common
phenotype.
A more traditional approach to looking for genetic overlap between traits was
to utilise family studies, particularly twin studies (Plomin et al., 2008). These
genetic correlation approaches involve estimating genetic correlation by comparing
cross-twin cross-trait correlations between monozygotic and dizygotic twins. If the
traits were more correlated in MZ twins than DZ twins, this was an indication
of shared genetic influences between the traits. For example, a study comparing
correlations of brain volume and intelligence (IQ) using ∼100 twin pairs, estimated
the genetic correlation of these traits to be 0.23-0.30 (Leeuwen et al., 2009).
More recent approaches utilising molecular genetic data have also been developed
to look for overall genome-wide shared patterns of genetic effects between pairs
of traits. These methods typically use information on hundreds of thousands of
variants obtained from GWAS results. One of these methods, termed GCTA, has
been quite widely used in studies of genetic correlation. However the downside
of this method is that it requires genotype-level data from both studies assessed,
which may not always be available. In addition, because the model first builds a
relationship matrix for each pair of individuals using the genotype data, the runtime
can become substantial when sample sizes increase. A more recent method, which
has become very popular for genetic correlation analysis, is bivariate LDSC (Bulik-
Sullivan et al., 2015b). This method only requires summary-level data from GWAS,
removing issues to do with data sharing, since an individual’s genotype cannot be
determined from this summary format. This greatly reduces the processing and
analysis time, making it easy to perform numerous pairwise analyses. Bivariate
LDSC also accounts for sample overlap between studies. To facilitate genetic
correlation analyses in the field, the authors have built a web tool named LD Hub
(Zheng et al., 2017). Here, a researcher can easily perform heritability analysis
on their data and genetic correlation with other traits of interest. The downside
of LDSC is that it requires sample sizes in the thousands, and therefore smaller
studies tend to use alternative methods such as GCTA.
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Bivariate LD score regression method (Bulik-Sullivan et al., 2015b) derives from
the univariate LD score regression which is used for SNP heritability analysis
(introduced in Chapter 2.4.4). Bivariate LDSC relies on the assumption that for
a single SNP, the product of z scores from the two GWAS will, on average, be
higher if the traits are genetically correlated than if they are not. This product is
then regressed against the LD score (amount of genetic variation tagged) for that
SNP. The genetic correlation (rg) between the two GWAS can then be estimated
as a function of the slope of this regression. The advantage of this method over
polygenic scores is that as long as each GWAS used has individually controlled
for population stratification bias, the resulting rg analysis should be unaffected by
confounders; the method accounts for genetic distance between individuals, whereas
polygenic scores may be more biased by e.g. cryptic relatedness. Polygenic score
analyses usually include covariates in attempt to correct for stratification.
Bivariate LDSC has greatly advanced our understanding of shared genetic architec-
ture between traits. A landmark paper published in 2015 by authors of the bivariate
LDSC method (Bulik-Sullivan et al., 2015b), described results from 276 genetic
correlations between 24 different traits using summary statistics from published
GWAS. At the time, the studies included in their analyses represented the largest
available datasets for the traits, including Rietveld et al. paper on educational
attainment which with ∼126k samples had only found three genome-wide significant
loci (Rietveld et al., 2013). In comparison, the currently largest study on the trait
found 1,271 independent SNPs (Lee et al., 2018). Some other GWAS included
in the Bulik-Sullivan et. al paper had no significant loci associated with them.
However, using LDSC bivariate analysis, the authors showed that significant overlap
of common variant effects could be detected between traits even in the absence
of significant loci in the GWAS, illustrating the power of leveraging genome-wide
data in these analyses. This paper found shared genetic architecture between traits
that had been suspected to have shared causes based on previous epidemiological
studies, but also highlighted some unexpected correlations such as the positive
genetic correlation between schizophrenia and anorexia. In addition, the study
found examples where trait pairs that had been expected to be genetically linked
turned out not to be. Since then, more studies have analysed the genetic overlap
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between common cognitive, neuropsychiatric (e.g. schizophrenia, bipolar disorder),
neurodevelopmental (e.g. autism) and neurological traits (e.g. Alzheimer’s and
Parkinson’s) (Anttila et al., 2017; Okbay et al., 2016).
Whilst genetic correlation analysis is a powerful tool for investigating the overall
shared genetic effects between traits, it does not provide information on the internal
genetic architecture of a study. In the case of our neurodevelopmental disorder
GWAS, we cannot make conclusions about whether the DDD cohort as a whole are
all contributing to SNP heritability and shared genetic effects with other traits. To
do this, we need to employ other methods such as polygenic risk scores, to assess
the burden of genetic variation between subsets of patients determined utilising the
phenotypic data we have of the patients. One huge advantage of the DDD Study
over many other cohorts for severe neurodevelopmental defects is that the patients
have detailed phenotypic data that have been systematically recorded using HPO
terms. This essentially reduces heterogeneity between different clinicians’ use of
terminology, and increases our chances of capturing all individuals with a specific
abnormality when text mining the data. In addition, many of patients phenotype
record also includes different measurements of growth, and information on when
they reached developmental milestones such as age they first walked or talked.
Additionally, some records include a free text note written by the clinician, which
sometimes includes more detail about e.g. severity of the phenotypic abnormality
which may not have been logged with the HPO terms. In the context of this thesis,
I can leverage these data to understand more about whether effects from common
variants are more important in particular patient groups who are phenotypically
more similar to each other.
3.3 Contributions and publication note
Elizabeth Radford provided data on developmental milestones in the general pop-
ulation. Wendy Jones provided useful conversations about the clinical genetics
assessment of developmental delay. The Australian data were collected by Sui Yu,
Jozef Gecz Nicholas Martin, and the raw data were prepared by Kerrie McAloney
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and Scott Gordon. Hilary Martin performed the quality control and imputa-
tion of Australian datasets, helped generate PCA plots for these, performed the
AVENGEME power calculation in Australians, and contributed to supervising this
work. The work described in this chapter were completed under the supervision of
Jeffrey Barrett, and the key findings were published in Niemi et al. (2018).
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3.4 Methods
3.4.1 Partitioned heritability
I used partitioned LDSC (Finucane et al., 2015) software to look for neurodevelop-
mental disorder (NDD) SNP heritability enrichment using the baseline model LD
scores and regression weights available online. The method captures the proportion
of variation in the phenotype that is explained by a pre-defined subset of variants
in the genome. If a category of variants are enriched for heritability for that trait,
then SNPs that are in high LD with variants in that category will have increased
χ2 test statistics compared to if the SNPs were in high LD with a category that
is not enriched for heritability (Finucane et al., 2015). For cell type groups and
functional categories I set the significance threshold to P<0.005 (0.05/10 tests)
and P< 9.2× 10−4 (0.05/54 tests), respectively.
The method also allows for partitioned heritability analysis of custom regions of
interest in the genome. For NDD risk, I was particularly interested in two custom
sets of variants. The first set of variants were those within the boundaries of
genes that are known to cause developmental disorders, namely the Developmental
Disorders Genotype-Phenotype Database (DDG2P) genes. These are a set of 2,044
genes that have been curated by clinicians in the DDD Study, and confirmed or
presumed probably causal for developmental disorders (Firth et al., 2009). The
second group of genes of interest were the highly constrained genes (Lek et al., 2016).
These are genes where loss-of-function mutations are depleted from the expected
numbers in a large exome sequence database of relatively healthy individuals in
the ExAC consortium. To more accurately estimate the expected observations
of rare variants in genes, this model incorporates information about the gene’s
length and the sequence-context based mutation rates under minimal selection.
The authors (Lek et al., 2016) describe this metric as a probability for being loss-of-
function intolerant (pLI). I analysed the partitioned heritability in the set of 3,230
genes with high evidence (pLI≥0.9) for selective constraint. Selecting for high pLI
scores captures most of the severe haploinsufficiency genes that are known to cause
human disease (Lek et al., 2016), out of those that are sufficiently large to estimate
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constraint for. For partitioned heritability in variants within DDG2P genes, I
added 35kb upstream and 10kb downstream of the gene boundaries, following the
example of Grove et al. (2017). I then annotated each variant used in the LDSC
baseline model according to whether it was within any of the DDG2P boundaries
or not. I then calculated new LD scores for variants using LDSC, and ran the
partitioned heritability analysis following instructions on github (Finucane et al.,
2015). I repeated the same steps for a list of highly constrained genes (pLI≥0.9).
3.4.2 Genetic correlation
For the traits that were available through LD Hub, I used the online server, and
for others I downloaded the LDSC software from github and ran the analyses on
the command line. The 19 traits tested included cognitive performance, education,
psychiatric traits and diseases, anthropometric traits and non-brain related traits
and diseases. I set the significance threshold to p<0.0026 (0.05/19 tests).
3.4.3 Australian replication cohort
Datasets and patient phenotypes
To replicate findings from the genetic correlation analyses, we collaborated with a
group from Australia, who provided us data for Australian cases with neurodevel-
opmental disorders and ancestry-matched population controls. The majority of the
patients (>95%) were under 18 years old when recruited. They were originally geno-
typed as part of routine clinical care to ascertain pathogenic copy number variants;
50-60% were recruited through clinical genetics units, and the rest through neurolo-
gists, neonatologists, paediatricians and cardiologists. Our Australian collaborators
reviewed information on the request forms, and found that the majority of patients
had developmental delay/intellectual disability and malformations involving at
least one organ (e.g. brain, heart, and kidney). 15-20% were recruited as neonates
with multiple malformations involving brain, heart and/or other organs, and were
too young to be diagnosed with developmental delay/intellectual disability. The
68 Chapter 3. Genetic correlation and polygenic substructure in severe NDDs
population-matched controls came from the Brisbane Longitudinal Twin Study
(Queensland Institute of Medical Research, (Wright and Martin, 2004; Mina-Vargas
et al., 2017)).
Quality control and imputation
Both case and control data were on GRCh37, and detailed information of genotyping
chips is shown in Table 3.1. Sample and variant quality control was performed
following steps described in (Chapter 2.4.1). Patients without a neurodevelopmental
phenotype were removed prior to data quality control, therefore all cases quoted in
the table have the relevant phenotype (compared to DDD cohort quality control
steps in Table 2.1). Rare variants MAF≤0.005 were removed before phasing and
imputation. The samples were then phased and imputed in a single batch, using
SNPs that intersected between the CytoSNP-850K chip (cases) and the Illumina
610K chip (controls). The Sanger Institute Imputation Service (McCarthy et al.,
2016) was used to carry out phasing and imputation, using the same software
Eagle2 (v2.0.5)(Loh et al., 2016) and PBWT (Durbin, 2014), and the Haplotype
Reference Consortium as the reference panel (release 1.1, chr1-22, X)(McCarthy
et al., 2016) as I had used for DDD and UKHLS (Chapter 2). Samples of European
ancestry were then selected by defining a cluster around the 1000 Genomes Great
British (GBR) Phase 3 samples in a projection PCA (Figure 3.1).
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Table 3.1: Quality control for Australian datasets.
Quality control steps - Aus-
tralian data
Australian ID
cases
Australian
(BLTS) con-
trols
DNA chip NA CytoSNP-
850K
Illumina
610K
Pre QC
Samples NA 2,283 4,274
Variants NA 854,413 526,217
Post sample and
variant QC
Samples samples that passed QC;
one individual from related
pairs and non-GBR sam-
ples removed
1,270 1,688
Variants variants that passed QC
and had MAF≥0.5%; inter-
section of CytoSNP-850K
and Illumina 610K SNPs
282,595 282,595
Post imputation,
neurodevelopmen-
tal GBR
subset
Samples NA 1,270 1,688
Variants imputed variants filtered
for INFO≥0.9
4,636,561 4,636,561
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Figure 3.1: Ancestry principal components analysis of Australian cohorts. a. Reference samples
from 1000 Genomes Phase 3, colored by the five super populations, used for a projection PCA of
Australian cohorts (cases and controls). b. All Australian cases (N=2,283) from projection PCA
with 1000 Genomes. Case samples with European ancestry are plotted in red and non-Europeans
in grey. c. All Australian controls (N=4,274) from projection PCA with 1000 Genomes. Control
samples with European ancestry are plotted in blue and non-Europeans in grey. All cases and
controls coloured in grey (panels b and c) were excluded from analysis due to non-European
ancestry.
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Polygenic scores in Australians
The principle behind constructing polygenic scores is described in chapter 2.4.5. I
used P<1 threshold for choosing SNPs for NDD risk scores in Australian analyses.
I also constructed scores for seven published GWAS (educational attainment (Lee
et al., 2018), intelligence (Sniekers et al., 2017), schizophrenia (Pardin˜as et al.,
2018), autism (Grove et al., 2017), intracranial volume (Adams et al., 2016),
height (Wood et al., 2014) and birth weight (Horikoshi et al., 2016)). Some of
these traits were correlated with NDD risk (educational attainment, intelligence,
schizophrenia), whilst e.g. autism is prevalent in NDD patients, and intracranial
volume is correlated with head circumference that is often abnormally small or large
in DDD patients (micro- or macrocephaly, see Figure 2.6). Again, for all traits, I
included only variants that had a MAF≥0.05 and that were directly genotyped or
imputed with high confidence (INFO≥0.9) in the Australian sample. As P-value
thresholds for published GWAS, I used the threshold that had been found to
explain the most variation in the most recent available published studies for the
trait (educational attainment P<1 (Okbay et al., 2016), intelligence(Sniekers et al.,
2017), schizophrenia P<0.05(Pardin˜as et al., 2018) and autism P<0.1 (Weiner
et al., 2017)). Note that for educational attainment and autism, the paper cited
for the P-value threshold is different than that of the summary statistics used for
the trait because at the time of analysis we had obtained the summary statistics
through personal communication without access to the manuscript associated with
the data as these were yet unpublished. For traits which we had phenotype data
for in the DDD, I used thresholds that explained the most variation in DDD cases
using linear regression and R-squared: P<1 for intracranial volume, P<0.01 for
birth weight and P<0.005 for height. Thresholds and the number of SNPs used for
each score are shown in Tables 3.2. All scores were normalised to a mean of 0 and
variance of 1.
The schizophrenia PGC-CLOZUK study (Pardin˜as et al., 2018) included some
controls from the Brisbane Longitudinal Twin Study that I would be using as
controls. If I constructed polygenic scores from these summary statistics this would
result biased score differences between the Australian cases and controls. Through
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Table 3.2: Summary of polygenic score parameters in Australian cohorts.
Polygenic score parameters
Polygenic score r2 for SNP
pruning
P-value thresh-
old for SNP
pruning
Number of
SNPs in score
Educational attainment 0.1 1 92,092
Height 0.1 0.005 9,809
Intelligence 0.1 0.05 21,551
Schizophrenia (QIMR removed) 0.1 0.05 23,878
Intracranial volume 0.1 1 90,928
Autism 0.1 0.1 26,846
Birth weight 0.1 0.01 6,828
Developmental disorder risk (dis-
covery GWAS)
0.1 1 67,001
personal communication, Antonio Pardias reran the schizophrenia GWAS having
removed the Brisbane Longitudinal Twin Study from PGC-CLOZUK data, and I
used these summary statistics instead of the published ones.
To test for differences in scores between cases and controls, I used R (version 1.90b3)
to perform logistic a regression, including the first ten principal components from
the ancestry PCA as covariates to control for potential population stratification.
We used AVENGEME (Palla and Dudbridge, 2015) to calculate power to find
significant association, assuming that the SNP heritability was the same (h2=0.077)
in both the Australian and British cohorts, and that the genetic correlation between
them was 1.
3.4.4 Subsetting the DDD Study patients
By diagnostic variant
We wanted to investigate whether DDD patients with diagnostic rare variants were
different from individuals with no diagnostic variants, with respect to their polygenic
burden. Identification of clinically relevant rare variants from the exome data was
performed by the DDD exome analysis team. This process was based on the clinical
filtering procedure described in (Wright et al., 2015), which focuses on identifying
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rare, damaging variants in a set of genes known to cause developmental disorders
(https://www.ebi.ac.uk/gene2phenotype/), that fit an appropriate inheritance mode.
Briefly, variants that pass clinical filtering are uploaded to DECIPHER (Firth et al.,
2009), where the patients’ clinicians classify them as definitely pathogenic, likely
pathogenic, uncertain, likely benign or benign. This process of clinical classification
is necessarily dynamic as new disorders are identified and patients manifest new
phenotypes.
Our diagnosed set of 1,127 patients fulfilled one of these criteria: a) they were
amongst the diagnosed set in a recent reanalysis of the first 1,133 trios (Wright
et al., 2018b), or b) had at least one variant (or pair of compound heterozygous
variants) rated as definitely pathogenic or likely pathogenic by a clinician, or c)
had at least one variant (or pair of compound heterozygous variants) in a class
with a high positive predictive value that passed clinical filtering but had not yet
been rated by clinicians. De novo or compound heterozygous loss-of-function (LoF)
variants were considered to have high positive predictive value, since of the ones
that had been rated by clinicians, 100% of compound heterozygous LoFs and 94.%
of de novo LoFs had been classed as definitely or likely pathogenic. My undiagnosed
set consists of 2,479 patients who had no variants that passed the clinical filtering,
or in whom the variants that had passed clinical filtering had all been rated as
likely benign or benign by clinicians, or who were amongst the undiagnosed set
in the first 1,133 trios that have previously been extensively clinically reviewed
(Wright et al., 2015). Note here, that my diagnosed versus undiagnosed analysis
shown excludes 3,375 patients who had one or more variants that passed clinical
filtering in a class with a relatively low positive predictive value, but who have not
yet been rated by clinicians.
By severity of intellectual disability or developmental delay
I defined patients as having mild intellectual disability or delay if their HPO phe-
notypes included borderline, mild or moderate intellectual disability (HP:0006889,
HP:0001256, HP:0002342) and/or mild or moderate global developmental delay
(HP:0011342, HP:0011343). Patients were included in the severe ID or delay set
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if they had severe or profound intellectual disability (HP:0010864, HP:0002187)
and/or severe or profound global developmental delay (HP:0011344, HP:0012736).
I excluded patients with ID or global developmental delay of undefined severity.
A comparison of polygenic scores between all three categories of severity (mild,
moderate, severe) would have been possible, but my concern was that the power
for this analysis was too low due to small sample numbers. Instead, we decided to
group mild and moderate DD/ID patients together as mild.
3.4.5 Polygenic scores in DDD patients
I constructed polygenic scores for educational attainment (Lee et al., 2018), intelli-
gence (Sniekers et al., 2017), schizophrenia (Pardin˜as et al., 2018), autism (Grove
et al., 2017), intracranial volume (Adams et al., 2016), height (Wood et al., 2014)
and birth weight (Horikoshi et al., 2016) in the 6,987 DDD patients (Table 3.3),
the same way as described for the Australian cases and controls. I then performed
a linear or logistic regression in R of the phenotype against each polygenic score,
including 10 PCs from the ancestry PCA as covariates, with threshold P<0.007 for
significance (P<0.05/7 correcting for seven polygenic scores).
Table 3.3: Summary of parameters used to construct polygenic scores for DDD patients cohort
(European ancestry, N=6,987).
Polygenic score r2 for SNP
pruning
P-value thresh-
old for SNP
pruning
Number of
SNPs in score
Educational attainment 0.1 1 79,296
Intelligence 0.1 0.05 19,387
Schizophrenia 0.1 0.05 21,321
Autism 0.1 0.1 23,648
Intracranial volume 0.1 1 76,788
Birth weight 0.1 0.01 6,212
Height 0.1 0.005 9,019
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3.4.6 Power for detecting differences in polygenic scores
I assessed power to detect differences in scores between diagnosed and undiagnosed
patients, by testing the hypothesis that diagnosed patients were effectively a random
sample of population controls with respect to their polygenic profiles. To test this,
I randomly sampled 1,127 controls (i.e. the same number as we had diagnosed
patients) and compared the polygenic scores between them and the undiagnosed
patients (N=2,479) using logistic regression. I repeated this 10,000 times and
determined the proportion of iterations where there was a significant difference
P<0.007 (P<0.05/7 correcting for seven polygenic scores) as proxy for power. For
educational attainment, this was 99.1% of iterations, 93.6% for schizophrenia,
61.2% for intelligence, 34.8% for height, 2.2% for autism, 0.75% for birth weight
and 0.08% for intracranial volume.
3.5 Results
3.5.1 Partitioning neurodevelopmental disorder SNP heri-
tability
In Chapter 2, I described an overall 0.077 (95% CI : [0.036, 0.118]) contribution
to NDD risk coming from common genetic variants in the discovery case-control
GWAS, calculated using LDSC. As a first approach to tease apart this common
variant burden, I used an an extension of the LDSC method by Finucane et al.
(2015), termed stratified LDSC. This method can be used to further break down
trait SNP heritability into functional genomic categories (e.g. conserved regions,
enhancers or histone marks, etc.) or cell type groups (e.g. central nervous system,
liver or cardiac, etc.) that are enriched for the heritability observed.
The partitioned LD score regression results showed that SNP heritability for neu-
rodevelopmental disorders was nominally significantly enriched in cells of the central
nervous system (P=0.025) (Table Appendix A), and in mammalian constrained
regions (Lindblad-Toh et al., 2011) (P=0.009) (Appendix A), consistent with sim-
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ilar analyses for other neuropsychiatric and cognitive traits. Neither the highly
constrained genes (pLI≥ 0.9) nor the DDG2P genes showed significant enrichment
or depletion of h2.
Although significantly greater than zero, the h2 for NDD risk is still relatively
low and the study has a small sample size compared to other neuropsychiatric
disease studies where specific enrichment has been detected (Grove et al., 2017;
Pardin˜as et al., 2018). The nominally significant finding of CNS variant enrichment
in the partitioned heritability analysis supports CNS involvement, but it does not
give us much more information about the potential mechanisms behind NDD risk.
Similarly, enrichment in mammalian constrained regions would be plausible if real,
as we know that genes that are highly conserved are more likely to also be important
for normal development. It would be interesting to see whether the heritability
enrichment results became stronger if we could increase our power by obtaining
more samples, or if further refinement of the NDD phenotype could increase the h2
estimate and subsequently power for partitioned heritability analysis.
3.5.2 Shared genetic architecture with other traits
To further investigate the genetic architecture of NDD risk, I next looked for
overall genetic overlap of common variant effects on this trait with other published
GWAS. Due to the increasing amount of evidence for polygenic effect sharing
between neuropsychiatric and cognitive phenotypes, we were particularly interested
in knowing whether severe neurodevelopmental disorder risk shared effects with
common cognitive and neuropsychiatric traits. We decided to investigate genetic
correlation (rg) with autism, which is a neurodevelopmental disorder, educational
attainment, which is a proxy phenotype for cognitive performance, and schizophre-
nia, which, at the start of this project, had one of the largest neuropsychiatric
GWAS available. In addition, we were interested in intelligence, which became
available later on as this project progressed. In addition, we also decided on a
list of good-quality available non-neurodevelopmental GWAS for different types of
traits to check for genetic correlation against. Due to the fact that both the DDD
patients and UKHLS controls had not been ascertained for the presence or absence
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of any complex diseases or traits, our expectation was that the allele frequencies for
traits unrelated to neurodevelopment would likely not differ between DDD patients
and UKHLS controls (as described in section 2.4.1). Therefore, I would not expect
to find that polygenic effects in the NDD discovery GWAS overlapping with those
found in GWAS on these traits. These kind of traits can therefore be regarded
as negative control GWAS, shown in green in Figure 3.2. An example of such a
trait is Crohn’s disease which has a later onset in life and does not involve the
brain. If we found no evidence for genetic overlap of such traits with NDD risk, this
would be an indicator that there are no subtle ascertainment differences between
the cases and controls that are affecting the genetic architecture of NDD risk we
detect. Other traits that we were interested in included anthropometric traits such
as height and birth weight, because developmental disorders often include growth,
skeletal system and muscular abnormalities, as illustrated in Figure 2.6.
I carried out genetic correlation of the neurodevelopmental disorder risk discovery
GWAS against nineteen published traits, using bivariate LD score regression (Bulik-
Sullivan et al., 2015b). NDD risk was significantly negatively correlated with genetic
predisposition to higher educational attainment (rg=-0.49, SE=0.08, P=5.3×10−10)
and intelligence (as measured by Spearman’s g; see Chapter 4) (rg=-0.44, SE=0.10,
P=2.2×10−5), and positively correlated with genetic risk of schizophrenia (rg=0.28,
SE=0.07, P=2.7 × 10−5) (Figure 3.2 and Table 3.4). Interestingly, educational
attainment and schizophrenia have both been are linked to neurodevelopment
(Owen et al., 2011; Noble et al., 2015), however they do not share effects with each
other (see discussion below). Although genetic correlation analysis is a powerful
way to find genetically related traits, we cannot extrapolate more about which
particular effects may be the ones shared between NDD and these traits. None
of the anthropometric traits, nor the negative control traits, were significantly
genetically correlated with our NDD GWAS after accounting for multiple testing.
These results, together with the findings from the partitioned heritability analysis
in section 3.5.1, suggest that thousands of common variants have individually small
effects on brain development or function, which in turn influences neuropsychiatric
disease risk, cognitive traits, and risk for severe neurodevelopmental disorders.
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Figure 3.2: Genetic correlations between neurodevelopmental disorder risk (6,987 cases and
9,270 controls) against nineteen other traits. Cognitive or psychiatric (purple), anthropometric
(orange) and negative control traits (green) with SNP heritability (h2) displayed for the trait.
SNP heritability for dichotomous traits is displayed on the liability scale. Genetic correlation
was calculated using bivariate LD score correlation, with the bars representing 95% confidence
intervals (using standard error) before correction for multiple testing. Uncorrected P-values are
only shown if they pass Bonferroni correction for 19 traits. Sample sizes for 19 other GWAS are
shown in Table 3.4.
Educational attainment is used as a proxy trait for cognitive performance (Rietveld
et al., 2014), but it is also a trait that can easily be influenced by other factors than
cognitive performance. Therefore, general intelligence, which is measured through
cognitive tests, would arguably be a more robust measure of cognitive performance,
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Table 3.4: Results from genetic correlation analyses with discovery neurodevelopmental disorder
GWAS. Population prevalence for categorical traits was used to calculate trait 2 SNP heritability
on the liability scale.
Trait 2 rg between
developmen-
tal disorder
risk and
trait 2
Standard
error
(SE)
95% con-
fidence
interval
(SE, lower
bound)
95% con-
fidence
interval
(SE, upper
bound)
P-value h2 for
trait 2
(liability
scale)
SE for
h2
Population
preva-
lence
Years of schooling -0.491 0.079 -0.336 -0.645 5.31×10−10 0.112 0.004
Intelligence (Spear-
man’s g)
-0.441 0.104 -0.237 -0.645 2.15× 10−5 0.203 0.013
Schizophrenia 0.279 0.066 0.148 0.409 2.71× 10−5 0.242 0.008 0.010
ADHD 0.727 0.292 0.155 1.299 0.013 0.071 0.031
Major depressive disor-
der
0.389 0.177 0.042 0.736 0.028 0.087 0.017 0.150
Childhood IQ -0.252 0.153 0.048 -0.553 0.100 0.279 0.051
Autism spectrum disor-
der
-0.078 0.103 0.123 -0.28 0.445 0.118 0.010 0.012
Bipolar disorder 0.033 0.105 -0.172 0.238 0.751 0.250 0.023 0.010
Height -0.176 0.07 -0.038 -0.314 0.012 0.336 0.021
Body mass index 0.174 0.071 0.035 0.312 0.015 0.189 0.010
Child birth length -0.291 0.155 0.013 -0.595 0.061 0.165 0.027
Intracranial volume -0.319 0.218 0.107 -0.746 0.142 0.167 0.053
Birth weight -0.133 0.098 0.059 -0.326 0.174 0.095 0.008
Alzheimer’s disease 0.424 0.259 -0.083 0.932 0.101 0.068 0.013 0.050
Coronary artery dis-
ease
0.077 0.091 -0.101 0.254 0.396 0.070 0.005 0.050
Lumbar Spine bone
mineral density
0.101 0.132 -0.158 0.36 0.447 0.116 0.018
Parkinson’s disease 0.093 0.136 -0.173 0.359 0.494 0.167 0.050 0.002
Type 2 Diabetes 0.071 0.122 -0.168 0.309 0.562 0.120 0.012 0.080
Crohn’s disease -0.024 0.096 0.164 -0.211 0.804 0.252 0.027 0.003
and therefore a preferable trait for using in polygenic analyses also in this thesis.
However, it is difficult to obtain both intelligence test results and genotype data for
large (ideally ancestrally homogeneous) cohorts, whereas it is easier to obtain data
on how many years of schooling study individuals obtained. Therefore the sample
sizes for educational attainment GWAS are vastly larger (now 1.1M (Lee et al.,
2018)) than cognitive GWAS, and as long as this trait correlates well genetically
with intelligence, it can be used as a proxy. It is therefore not surprising that NDD
risk rg analysis results with these traits are very similar. However, for downstream
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analyses, it may be that educational attainment polygenic scores are more powerful
for detecting significant differences between groups of individuals, as the GWAS is
much larger than the GWAS for intelligence.
3.5.3 Replication of genetic overlap findings in Australians
Having shown that there is significant polygenic contribution to neurodevelopmental
disorder risk which has shared genetic effects with other brain-related phenotypes,
the next question was whether these findings were specific to the DDD Study,
or would they replicate in other similar cohorts. If the results replicated in a
completely independent cohort which had been ascertained for similarly severe
neurodevelopmental disorders, this would strengthen our findings of polygenic
contribution to developmental disorders.
For this attempt at replication, we obtained data for 1,270 South Australian
patients who with neurodevelopmental disorders, and 1,688 population-matched
controls. However, the small cohort size for the Australians meant that I was not
able to do direct genetic discovery or subsequently genetic correlation analysis,
as this requires >5,000 samples (as stated in LDSC github). Instead, I tested
whether there was a difference in common variant polygenic scores between cases
and controls for a number of traits that I had found to be significantly correlated
with NDD risk (Chapter 3.4.3). A significant difference in scores would signify
replication of the rg findings in this smaller cohort. To do this, I calculated
polygenic scores using summary statistics from our discovery NDD GWAS, and
the publicly available GWAS, including educational attainment (Lee et al., 2018)
and intelligence (Sniekers et al., 2017).
The results showed that Australian neurodevelopmental disorder patients had
lower polygenic scores for educational attainment and intelligence compared to
controls (P=1.4 × 10−8 and P=7.6 × 10−4 respectively) (Table 3.5). I initially
observed suspiciously significantly increased in polygenic scores for schizophrenia
(P=1.2× 10−36) in the Australian cases. However, this turned out to be due to the
fact that some of the Australian controls were included in the schizophrenia GWAS
(Pardin˜as et al., 2018). We obtained new summary statistics from the authors, in
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Table 3.5: Summary of polygenic score results in Australian cohorts.
Results*
Polygenic score Beta Standard
error
P-value
Educational attainment -0.216 0.038 1.4× 10−8
Height -0.155 0.040 8.8× 10−5
Intelligence -0.126 0.038 7.6× 10−4
Schizophrenia (QIMR removed) 0.092 0.038 0.014
Intracranial volume -0.078 0.038 0.041
Autism 0.070 0.038 0.063
Birth weight -0.062 0.038 0.098
Developmental disorder risk (dis-
covery GWAS)
-0.047 0.038 0.212
which the Australian controls had been removed from the GWAS, and I repeated
the analysis. Here, Australian cases had nominally significantly higher scores for
schizophrenia (P=0.014).
For neurodevelopmental disorder risk, I did not see a significant difference between
cases and controls for the scores constructed from our discovery GWAS. We therefore
wondered if we had enough power to detect a significant association (at P<0.05)
between our polygenic score for neurodevelopmental disorders and case/control
status in the Australian dataset. This analysis showed that we should have had
95% power to detect a difference if the two cohorts had identical phenotypes.
This suggests that differential phenotypic ascertainment between the British and
Australian cohorts diluted our ability to quantify their shared genetics.
The fact that the NDD-risk polygenic score were not significantly different between
cases and controls, despite the fact that we have shown that NDD and intelligence
are negatively genetically correlated, likely reflects low power to estimate variant
effects in our NDD GWAS. Out-of-sample polygenic score prediction is affected
both by the discovery sample size, and the total amount of heritability that can
be predicted. Our neurodevelopmental disorder risk GWAS found significant but
still relatively low heritability (0.077). In comparison, the educational attainment
GWAS had a huge sample size of 1.1M, so polygenic scores using these SNP effects
will be much better powered despite the trait also having a relatively low SNP
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heritability (0.11). If we compare this to an early GWAS study of educational
attainment in 9,538 Australian individuals, a similar size to our study, they also
failed to explain any significant variation (r2<0.0023, P≥0.14) in an independent
target cohort of 968 individuals (Martin et al., 2011a)
Interestingly, the Australian patients also had lower scores for height than controls
(P=8.8× 10−5) (Table 3.5). Even though NDD risk GWAS was not significantly
genetically correlated with height after multiple testing correction, the direction
of effect was in the same direction as in this analysis. A possible explanation
for this finding is residual population structure differences between Australian
cases and controls: height is well known to correlate with latitude within Europe
(Novembre et al., 2008), and the cases are recruited from Adelaide, where there
is more Mediterranean (Greek, Italian) ancestry, and controls were recruited in
Brisbane, which has more Irish ancestry. It is possible that height scores could
differ for this reason if the PC covariates were not sufficient to control for this. This
result is, however, potentially interesting, since developmental disorder patients
often have growth abnormalities associated with their condition.
3.5.4 Polygenic substructure in DDD patients
Having replicated the NDD risk discovery GWAS results in an independent Aus-
tralian cohort, I returned to the DDD Study data to answer more specific questions
about the distribution of polygenic risk among patients with heterogeneous pheno-
types. The DDD cohort is one of the largest severe neurodevelopmental disorder
cohorts in the world, and furthermore, the deep phenotyping of patients by clinical
geneticists adds a whole new layer of valuable information for studying the genetic
architecture of these diseases. Specifically, this phenotypic information, coupled
with the data from exome sequencing of DDD trios, allows us to explore whether
polygenic burden is more enriched in certain patient subgroups than others. Some
of the key questions we were interested in answering included: (1) Are patients who
had a diagnostic variant through the exome sequencing project any different from
patients for whom we have not identified a likely severe pathogenic mutation? (2)
Do common variant effects correlate with severity of the developmental disorder?
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(3) Are specific phenotypes correlated with differences in polygenic risk? Here, I
investigate these questions using polygenic scores.
Comparing patients with and without diagnostic rare variants
We hypothesized that the so far genetically undiagnosed DDD patients would be
contributing to NDD polygenic risk, because in other complex neuropsychiatric
traits individuals without causal mutations have overall higher polygenic risk for
the trait than healthy controls (International Schizophrenia Consortium et al.,
2009). In contrast, for the DDD patients who had a rare diagnostic variant, we
thought the polygenic contribution in these individuals could be slightly different.
As an example from another trait, a study on hypercholesterolemia (Talmud et al.,
2013) found that carriers of familial mutations causing the disease also had an
elevated polygenic risk for the disease compared to healthy controls. However, their
polygenic risk was lower than in patients with disease but no familial mutation. It
would therefore seem plausible a hypothesis, that some of the polygenic burden in
the DDD cohort was also carried by individuals with diagnostic variants. However,
since the neurodevelopmental disorders in DDD patients are so severe, we thought it
could also be that the these individuals did not carry elevated polygenic liability to
neurodevelopmental disorders, since the single diagnostic variant in a developmental
disorder gene could be enough to cause disease. In order to find out whether the
polygenic burden discovered in Chapter 2 was more different in patients without
diagnostic variants, I compared polygenic scores between patients with and without
diagnostic variants.
From the cohort of 6,987 European ancestry and unrelated DDD patients who I
used for NDD discovery GWAS, all had undergone exome sequencing as part of the
DDD Study. From these patients, 1,127 have so far been found to carry de novo or
inherited candidate diagnostic variants. In addition, 2,479 patients had no variants
that passed the clinical filtering. From this analysis, I excluded 3,375 patients who
had variants that were not likely to be diagnostic, but which had not been rated
by clinicians.
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Table 3.6: Polygenic score analysis comapring DDD patients who have a genetic diagnosis
(N=1,127) to those who are genetically undiagnosed (N=2,479). Diagnosed cases were labelled as
1 in the logistic regression.
Polygenic score Estimate Std.Error P
Educational attainment 0.080 0.037 0.028
Intelligence 0.063 0.036 0.080
Schizophrenia 0.017 0.036 0.644
Autism -0.077 0.036 0.032
Intracranial volume 0.005 0.036 0.891
Birth weight 0.002 0.036 0.966
Height 0.001 0.036 0.971
The analysis comparing polygenic scores showed that diagnosed patients were
not significantly different from undiagnosed patients with respect to any of the
polygenic scores tested, after correcting for multiple testing (Table 3.6). Since
the sample sizes for this analysis were quite low, this analysis was potentially
underpowered. I tested our power to detect a significant difference in polygenic
scores between these groups. These power analyses showed that diagnosed patients
were not as different from undiagnosed patients as population controls were, at
least for educational attainment and schizophrenia (Methods). This suggests that
both common and rare variants are contributing in many neurodevelopmental
disorder patients. As the DDD project continues to identify new diagnoses, we
anticipate that the increase in power by adding more patients to the diagnosed or
undiagnosed group may show that monogenic and polygenic contributions are not
purely additive.
In the meantime, in attempt to increase the power for detecting differences between
diagnosed and undiagnosed patients, I tried using different criteria to add samples
or to refine the set of individuals included. I then performed the logistic regression
between diagnosed and undiagnosed patients based on new criteria:
– Including uncertain cases in the undiagnosed set (low predictive value for the
variant(s) and not rated by clinicians)
3.5. Results 85
– Restricting the undiagnosed set to only definitely undiagnosed (note here the
difference to the main analysis is that this excluded the likely benign variants
who are probably undiagnosed)
– Restricting diagnosed set to those who have a de novo loss-of-function variant
or large deletion in a gene with pLI>0.99 or pLI>0.999
None of these new criteria showed significant differences in any of the polygenic
scores tested between the two patient groups. This indicated that the finding of
common variants contributing to both diagnosed and undiagnosed patients with
severe neurodevelopmental disorders is quite robust (at these sample sizes) to
changes in how we define the diagnosed and undiagnosed patient groups.
Comparing patients with mild or severe developmental delay/intellec-
tual disability
The detailed phenotype information annotated for DDD patients also allowed
me to look into the impact of common genetic variation to the severity of global
developmental delay and intellectual disability. Intellectual disability (HP:0001249)
is a neurodevelopmental disorder where individuals suffer from deficits in intellectual
and adaptive functioning, that begin during the developmental period (American
Psychiatric Association, 2013). Intellectual functioning is typically measured with
psychometric testing, where scores more than two standard deviations below the
mean are regarded as intellectual disability. The severity of the condition is usually
determined by the level of adaptive functioning. Global developmental delay is used
to describe delay in reaching a number of intellectual performance developmental
milestones when children are typically under the age of five, and therefore they are
too young to be assessed using tests for intellectual disability (American Psychiatric
Association, 2013). Within the cohort of 6,987 European ancestry (unrelated)
DDD patients, 69% had global developmental delay and/or intellectual disability
(DD/ID). Of these, 13.3% had mild DD/ID, 26.2% had moderate and 18.9% had
severe DD/ID; the remaining 41.6% had DD/ID of unspecified severity.
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Table 3.7: Polygenic score analyses comparing DDD patients with mild/moderate (N=1,902) or
severe (N=911) developmental delay or intellectual disability. Severe cases were labelled as 1 in
the logistic regression.
Polygenic score Estimate Std.Error P
Educatinal attainment 0.116 0.040 0.004
Intelligence 0.089 0.040 0.028
Schizophrenia 0.078 0.041 0.054
Autism 0.001 0.041 0.974
Intracranial volume 0.010 0.040 0.800
Birth weight -0.045 0.040 0.260
Height -0.057 0.041 0.161
I wanted to assess whether the severity of developmental delay or intellectual dis-
ability was associated with any polygenic scores I had constructed for these patients.
The results showed that severe DD/ID patients (N=911) were significantly enriched
for educational attainment increasing alleles compared to mild or moderate cases
(N=1,902) (P=0.004, variance explained Nagelkerke’s R2=0.008), after correcting
for multiple testing (Table 3.7). Whilst this finding might seem initially counter-
intuitive, it is consistent with epidemiological studies (Reichenberg et al., 2016)
which found that the siblings of patients with severe intellectual disability showed a
normal distribution of intelligence quotient (IQ), whereas siblings of patients with
milder intellectual disability had lower IQ than average. This implied that mild
intellectual disability represents the tail-end of the distribution of polygenic effects
on intelligence and severe intellectual disability has a different etiology. At the
time of writing this thesis, another study was published on bioRxiv (Kurki et al.,
2018) which found individuals with intellectual disability in a Northern Finnish
cohort had lower polygenic scores for educational attainment and intelligence, and
higher scores for schizophrenia than matched controls. In addition, the authors
found no significant difference between patients with and without diagnostic exome
mutations in genes known to cause developmental disorders. These findings are
in line with our observations, but the authors did not see a significant difference
between mild and more severe forms of ID (though their sample sizes were smaller
than ours).
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Adding patients to developmental delay categories based on develop-
mental milestones
In an attempt to increase power for the severity of DD/ID analysis, I tried different
ways of moving patients from the DD/ID of unspecified severity category, who were
excluded from the analysis above, to either mild or severe categories. In order to
do this, I used phenotype data on the age when the child developed their first five
words and the age when they first walked (Figure 3.3). If the child reached the
milestone at the age of less than +4SD from the mean, I assigned them to have
mild delay. Children who reached the milestone by +8SD from the mean were
assigned to have severe delay. For the analysis, I also removed patients who at the
time of assessment were younger than +4SD the population mean age of reaching
the milestone, as we cannot distinguish whether these patients are severely delayed
or not.
Re-categorising patients with unspecified severity DD/ID based on their milestones
added a further 168 patients to mild category and 657 to severe category (total
2,070 mild and 1,568 severe). But the result was the same as in the original analysis
despite the increase in sample size, as only educational attainment polygenic score
was significantly associated with severity of delay (higher in the severe group,
P=0.008).
I also attempted an analysis, whereby I re-categorised all patients from the previous
analyses based solely on their recorded milestones. Here, anyone with DD/ID HPO
regardless of the specific category who reached walking or talking milestone at age
<4SD was labelled as mild, and >8SD as severe delay. For walking alone, the mild
category contained 1,902 patients and the severe category 1,798. For talking alone,
mild category had 1,023 patients and severe 2,966. I found no significant association
between the delay of speech or walking and the polygenic scores. Finally, I asked
whether individuals who were either mildly delayed or severely delayed in both
talking and walking had different polygenic scores (mild N=586, severe N=1,424),
but again there was no association. From these analyses, we can conclude that
face-to-face clinical assessment is more effective in distinguishing patients with
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Figure 3.3: Histogram of the age that DDD patients with developmental delay or intellectual
disability reached developmental milestones. The patients are coloured by severity of DD/ID.
There is a long right hand tail of individuals from each of the categories, however, since mild
DD/ID was plotted first and severe last, the tail appears green as the numbers in the severe
category were highest. The population mean, +2SD, +4SD and +8SD from the mean are
displayed as red lines.
differential genetic aetiologies with respect to their developmental delay, than is
categorising patients by their developmental milestones.
3.5.5 Investigating phenotypic expressivity in DDD patients
A final question that I was able to investigate with the DDD cohort genotype
and phenotype data was whether individual presentation of symptoms within the
cohort was affected by common genetic variants for that trait. I identified four
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phenotypes measured in our neurodevelopmental disorder cohort, which are often
described as part of the symptoms or syndrome of patients in the DDD, and for
which published GWAS were available. These were autistic behaviour (16% of
cohort, HP:0000729), birth weight, height, and head circumference. On average,
the 6,987 neurodevelopmental DDD patients I studied had a head circumference
1.20 SD smaller, they were 0.72 SD shorter than, and weighed 0.15 SD less than
the age and sex-adjusted population average.
Using common variant polygenic scores for the four phenotypes described above,
I tested for association between the phenotype and relevant score in our cohort,
including 10 ancestry PCs as covariates. In all four traits, there was significant
association with the score (Table 3.8), demonstrating that common variation
contributes to the phenotypic expression of these traits in our study. Although
this type of trait ∼ polygenic score association seems unsurprising to those in the
complex trait field, in clinical genetics where these traits are typically considered
to form part of the patient’s profile of symptoms, the finding may have significance
in understanding variable phenotypes among patients. Whilst these results do not
directly answer whether common variants play a role in variable penetrance of
specific severe neurodevelopmental disorders, the indication is that this could be
the case. In order to investigate this we would need larger cohorts of individuals
with rare variants in the same genes with deep phenotype data.
Table 3.8: Association between measured traits and the relevant polygenic score in 6,987 DDD
patients (European ancestry). Linear or logistic regression of measured traits in the DDD Study
against the respective polygenic score, including ten ancestry principal components as covariates.
P-values are two-sided, from t-distribution (linear) and z-score distribution (logistic). Autistic
cases were labelled as 1 in the logistic regression (Naegelkerke’s R2 reported).
Measured trait Polygenic score Estimate Std.Error P R2
Height Height 0.408 0.033 1.2× 10−35 0.033
Birth weight Birth weight 0.187 0.017 2.5× 10−28 0.020
Head circumference Intracranial volume 0.132 0.031 1.8× 10−5 0.004
Autistic behaviour Autism 0.120 0.033 2.5× 10−4 0.006
To better understand how well our polygenic scores were explaining variance in
these phenotypes, I compared some of these to phenotype predictions performed
in the original studies. The autism GWAS (Grove et al., 2017) showed that with
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five target-training samples within their cohorts, the mean variance in the trait
explained was 2.5% (Naegelkerke’s R2). As comparison, the autism polygenic
score in DDD patients explains 0.6% of variance in whether the patient shows
autistic behaviour or not. For height, although the polygenic scores explained 3%
of the variance in height in DDD patients, this is substantially lower than what the
original GWAS study reported for a test set of individuals, which was close to 30%.
What this perhaps indicates is that whilst polygenic effects are still influencing the
phenotypic expressivity of height in severe neurodevelopmental disorders, other
genetic and non-genetic factors potentially have a relatively larger contribution to
height in this patient group than in the general population.
3.5.6 Challenges in interpreting genetic correlation
Control ascertainment in NDD risk GWAS and effects on rg
Whilst the analyses of genetic overlap between NDD risk and other common traits
and diseases yielded very interesting results, I also came across some results that
required careful consideration over potential differences in sample ascertainment
between studies. In this section, I will discuss some of these observations and
the implications that sample ascertainment might have on studies, particularly
those looking for shared genetic effects between cohorts ascertained for the same
phenotype and between different traits.
The strongest findings from bivariate LDSC of NDD risk with 19 other traits was a
negative genetic correlation with educational attainment and intelligence. Although
intuitively this finding makes sense in the context of NDD patients being severely
cognitively affected, we need to consider the possibility of sample ascertainment
affecting the rg results. It is, for example, possible that individuals who are more
highly educated and cognitively better functioning are more likely to consent to
participate in studies, particularly as controls. In context with our findings from the
rg analysis, the question then was whether the effect was driven by real depletion
of educational attainment and intelligence increasing alleles in DDD patients, or
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by enrichment of educational attainment- and intelligence-increasing alleles in the
controls.
The concern over sample ascertainment initially arose during the NDD discovery
GWAS phase. I had at the time included another control cohort in the analysis,
from Born in Bradford study (BiB). This longitudinal study recruited expectant
mothers at the Bradford Royal Infirmary, between 2007 and 2010 (Raynor and Born
in Bradford Collaborative Group, 2008), with the aim to study both genetic and
environmental factors affecting the wellbeing and health of families. The genetic
data collected for the study included mothers who were genotyped on a version of
the Illumina HumanCoreExome chip. Out of these 3,033 had European ancestry
and I included them as controls in my study, along with UKHLS.
After I had performed an initial NDD GWAS, I also checked the genetic concordance
between the two control cohorts by performing a GWAS of BiB mothers (as cases)
against UKHLS (controls). The findings, summarised in Table 3.9, were surprising.
First of all, the SNP heritability estimate for BiB vs. UKHLS was greater at
h2=0.141 (SE=0.043) than our NDD GWAS (h2=0.043, SE=0.020) even with
a smaller sample size. This was alarming, so I carried out a rg analysis with
educational attainment (Lee et al., 2018), which showed that there was a more
significant negative genetic correlation between BiB and UKHLS than between
DDD and UKHLS with respect to genetic factors influencing educational attainment
(Table 3.9). I then carried out a GWAS comparing DDD (as cases) to BiB (controls),
and found that there was no significant SNP heritability or genetic correlation,
although the direction of effect was that BiB were even more depleted for educational
attainment increasing alleles than DDD were. Other education and cognitive traits
showed the same trend for these rg analyses. To test whether the lack of significant
differences between DDD and BiB was due to decreased sample size, I performed
three simulation GWAS in which I randomly sampled 3,033 non-overlapping sets
of UKHLS and used these as controls against DDD. These analyses demonstrated
that the DDD vs. BiB was likely underpowered, but also that there is potentially
less of a difference between DDD and BiB than DDD and UKHLS with respect to
common variants.
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Table 3.9: Results from LDSC SNP heritability analysis for GWAS on different cohort pairs.
Genetic correlation of the GWAS with educational attainment. Liability scale conversion was
done assuming a population prevalence of 1% for developmental disorders. Note, compared to
our final discovery NDD GWAS, the GWAS used in these analyses included relatives, which I
later removed to reduce noise in the analysis.
SNP heritability rg with Years of Education (2018)
Cases Controls h2 (liability
scale)
SE h2 Prop.
polygenic
effects
rg Standard
error
(rg)
P
DDD (N=7,274) UKHLS + BiB (N=13,087) 0.043 0.020 0.296 -0.489 0.124 8.3× 10−5
DDD (N=7,274) UKHLS (N=10,054) 0.068 0.023 0.395 -0.537 0.100 8.8× 10−8
DDD (N=7,274) BiB (N=3,033) 0.026 0.039 0.069 0.358 0.296 0.226
BiB (N=3,033) UKHLS (N=10,054) 0.141 0.043 0.275 -0.515 0.079 7.9× 10−11
The conclusion that could be drawn from these analyses was that mothers recruited
to BiB were more depleted for education-increasing alleles than DDD children
with rare severe neurodevelopmental disorders. This could perhaps be explained
by the fact that Bradford is one of the most deprived areas in the UK. Since
educational attainment correlates with socio-economic status (White, 1982), there
may be differences in the geographical distribution of these effect alleles even
within a country, that may result from a migration of more highly functioning
individuals from less affluent to more affluent places; a finding that is supported
by a recent preprint paper on UK Biobank data (Haworth et al., 2018). These
results highlight the importance of the choice of controls in GWAS, particularly
those on traits related to cognition, as their ascertainment can greatly affect the
resulting estimations of genetic effects. In the light of these findings, I dropped
the BiB mothers from the analysis, because I did not believe they were a good
representative population for the UK based on the information we had about the
socio-economic differences between Bradford and the rest of the UK.
UKHLS are a good (enough) representative sample of the UK popula-
tion with respect to educational attainment
Since one of our key results from the genetic correlation of NDD risk analysis was
the depletion of education and cognition involved alleles in the DDD, the question
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then remained, whether the UKHLS were representative of the UK population
in terms of the distribution of these alleles. In other words, if the UKHLS was
not a suitable comparison group, this could greatly impact the interpretation my
findings.
The UKHLS collects longitudinal data on its participants. These phenotypic data
included information about the highest level of educational qualification obtained.
Epidemiological studies looking at these data have argued that individuals in the
UKHLS who consented to their health data being recorded may be slightly biased
towards those who achieved secondary education (Cruise et al., 2015; Knies and
Burton, 2014). However, since the individuals who consented to giving blood for
DNA analysis were a subset of this group, we did not have information on whether
the subset was also biased with respect to their education. We therefore obtained
the educational attainment phenotype data on these UKHLS individuals, to see
whether they were skewed with regards to their educational attainment compared
to census and labour market data on the UK population (Table 3.10).
For all genotype participants in the UKHLS phenotype data, I extracted the highest
educational qualification they had achieved by 2012 (the year the nurse visits were
completed). The variable also took into consideration what the participant had
answered during previous data collections during the longitudinal study, so this
variable would always represent the highest qualification recorded at any point. I
then compared this data to the UK census 2011 data. Both datasets only included
responses from individuals who at the time were 16 years or older, though it
was likely the UKHLS age distribution would have been skewed to higher ages
compared to the census. The proportions of individuals who achieved a certain
level of qualification in all three datasets is summarised in table 3.10. It would
seem that the UKHLS is not particularly enriched for individuals who achieved
a degree, but there are larger differences in the lower categories. This may be
partly due to the fact that the census data categorises qualifications in a different
way, and partly due to real differences. When comparing the genotyped UKHLS
cohort to official labour market statistics from 2012, these match for the higher
categories of education, however the major caveat is that these are statistics for 16
to 64 year olds, whereas a substantial proportion of UKHLS will probably be over
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this maximum age. Data from census and labour market survey are displayed in
Appendix B.
Table 3.10: Comparing UKHLS to census and labour market data. UKHLS variable ”hiqual b”
from 2012 with available categories, UK census 2011 data for equivalent categories, and official
labour market statistics from 2012. Missing data for UKHLS was removed prior to calculation of
percentages.
UKHLS
2012 (%)
UK census
2011 (%)
Nomis statistics 2012
(ages 16-64) (%)
Degree/other higher degree 33.8 27.2 34.0
A-level 19.6 12.3 19.0
GCSE 21.2 15.3 18.7
Other qualification 11.2 22.5 18.4
No qualification 14.2 22.7 10.0
In attempt to convince ourselves that the NDD risk discovery GWAS had found true
polygenic effects that were driven by the patients, and not UKHLS controls, I tested
the unrealistic scenario whereby I removed from the controls all UKHLS individuals
who had achieved a degree qualification. I repeated the GWAS, and the SNP
heritability analysis still showed significant h2=0.059 (SE=0.025) common variant
heritability (assuming population prevalence 1%). The negative genetic correlation
with educational attainment (Lee et al., 2018) also remained significant rg=-0.22
(SE=0.075, P=0.0037), although it was attenuated. The positive genetic correlation
with schizophrenia rg=0.23 (SE=0.081, P=0.0048) also remained. Together, these
results imply that even if the UKHLS genotyped samples were slightly biased
towards individuals who had achieved secondary school education, after removing
a the top third of the whole cohort with respect to their educational attainment
(and reduced power to detect polygenic burden and genetic correlation due to the
reduced sample size) there is still significant polygenic burden associated with
neurodevelopmental disorder risk. It is worth noting here that the over-transmission
of NDD-risk alleles from parents to probands (Chapter 2.5.3) already provided
strong support for true polygenic contribution driven by the cases. The distribution
of educational attainment associated alleles in the UKHLS controls when having
removed a third of the cohort is highly likely not a realistic representation of the
population. But the point of this analysis was to show that the results from our
NDD GWAS are quite robust to this extreme subsetting.
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3.6 Discussion
In this chapter, I have shown that common variant effects that contribute to the risk
of severe, rare neurodevelopmental disorders in the DDD Study are shared with other
traits that involve brain function or development. Similar findings in an independent
cohort of Australian neurodevelopmental patients provides evidence for replicability
of the results, with a cautionary note that differential ancestry and ascertainment of
neurodevelopmental disorders may cause heterogeneity between cohorts. However,
when interpreting analyses assessing genetic overlap, an important consideration
is that any given results will be affected by sample size and ascertainment of the
original studies. As GWAS continue to grow in sample size, they gain more power
for association and heritability analyses. New reports on genetic correlations thus
continue to emerge, expanding our understanding of the genetic architecture of
various traits and diseases. But this also means that GWAS cohorts, and thus the
underlying genetic architectures, used for these analyses undergo changes over time.
The consecutive addition of more samples to existing datasets, and the analyses
of completely newly ascertained cohorts, can sometimes change the estimates of
genetic correlation between traits, or remove them completely. This brings attention
to some of the drawbacks of looking for genetic overlap between studies where
samples may have been ascertained in very different ways, and calls for more careful
consideration when interpreting genetic correlation results. In this chapter, I have
particularly discussed examples of how recruitment of study participants might
affect our understanding of subtle sharing of genetic effects between traits.
These results from our neurodevelopmental disorder GWAS and Australian cohorts
indicated that NDD patients are depleted for alleles that increase educational
attainment and intelligence, and enriched for those contributing to the risk of
schizophrenia, a neuropsychiatric disease. This is interesting in the light of published
literature on genetic overlap between different neuropsychiatric and cognitive traits
(Okbay et al., 2016; Pardin˜as et al., 2018; Brainstorm Consortium et al., 2018;
Grove et al., 2017), and particularly that of intellectual disability which found
essentially the same results (Kurki et al., 2018). In our study, the strong correlation
of NDD discovery GWAS with both educational attainment and schizophrenia,
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which do not share common variant effects with each other (Pardin˜as et al., 2018),
shows that NDD risk arises from a more complex combination of variant effects. We
also do not see a significant association between NDD discovery GWAS and bipolar
disorder, which is known to share polygenic effects with schizophrenia (International
Schizophrenia Consortium et al., 2009). Potential reasons for these include the fact
that the schizophrenia GWAS is just much better powered with a larger sample
size, or that NDD risk shares with schizophrenia specifically more of the effects
that are not shared with bipolar disorder. A recent study by Bansal et al. (2018)
found evidence that the polygenic relationship between educational attainment and
schizophrenia is not homogeneous across patients, indicating that both traits are
genetically heterogeneous. They suggest that some patients’ polygenic background
is more concordant with bipolar disorder and higher cognitive performance, and
others are more independent of these. The findings could explain part of the genetic
correlations of NDD risk with other traits that we observe, and some of the more
or less unexpected results.
The reported genetic correlation between educational attainment and schizophre-
nia on its own is interesting to us in the context of GWAS power and sample
ascertainment. Epidemiological studies have shown that individuals suffering from
schizophrenia have poorer educational attainment (Swanson et al., 1998) and cog-
nitive performance (Bowie and Harvey, 2006) even before the onset of disease.
But contrarily, an educational attainment GWAS from 2016 (Okbay et al., 2016)
described a small, but significant positive genetic correlation with the schizophrenia
GWAS from 2014. Both traits now have a newer, larger GWAS, but neither of these
studies report on genetic correlation between the traits (Lee et al., 2018; Pardin˜as
et al., 2018). Out of interest, I ran the rg analysis between these two studies from
2018. The results showed that there was no significant genetic correlation between
these studies (rg=0.009, SE=0.018, P=0.62). On the other hand, intelligence
(Sniekers et al., 2017) and schizophrenia (2018) show significant negative genetic
correlation rg=-0.226 (SE=0.0298, P=3.6× 10−5), which is in line with findings
from epidemiological studies. In this particular example, one of the many reasons
for why educational attainment is first correlated with schizophrenia but then not in
the newer studies could be differences in sample ascertainment between the studies
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on the same trait. Educational attainment is a quantitative trait and therefore
probably easier to measure in populations, whereas recruitment of patients with a
neuropsychiatric disease such as schizophrenia requires clinical recruitment. One
possibility therefore could be that the schizophrenia patients recruited to the 2014
study (Schizophrenia Working Group of the Psychiatric Genomics Consortium,
2014) could have represented a cohort of higher functioning patients, who were
able to consent to taking part in a research study. A bias such as this could in
turn result in the positive genetic correlation with higher educational attainment.
The 2018 schizophrenia study included the CLOZUK patient cohort, who were
recruited under the requirement that they were taking the oral antipsychotic drug
clozapine. There might thus be an argument to say that this sample may be less
biased towards sampling higher functioning patients. Although in this particular
example these notions are just speculation, the topic of recruitment bias in GWAS
cohorts is an important one which perhaps does not get as much attention in the
field as it should.
The interpretability of genetic correlation results is also affected by the SNP
heritability of the traits. As Wray et al. (2018) note, high rg with a trait is more
reliable when the SNP heritability for both traits is high. In the case of our discovery
NDD risk GWAS, h2 is still relatively low. Resulting from this, the magnitude
of rg with other traits that have a h
2 below ∼0.10 have very wide confidence
intervals, as with the example rg between NDD risk and ADHD, although this
overlap was not significant after multiple testing correction (Figure 3.2). It is
possible though that if we had more power for detecting shared effects, these other
neuropsychiatric or neurodevelopmental traits like ADHD and major depressive
disorder may pass the threshold for significant association. Both these traits have
been shown to be correlated with schizophrenia (Wray et al., 2018) and bipolar
disorder (Hulzen et al., 2017), and therefore a positive direction of correlation with
NDD risk was perhaps expected. It would potentially have been interesting to
include other neuropsychiatric and developmental polygenic scores in our analyses
(e.g. for bipolar disorder) but we wanted to select either well powered GWAS with
sample sizes in the tens of thousands, or GWAS that we had a measured phenotype
data for in the DDD cohort.
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The genetic correlation results did not show significant overlap of overall NDD risk
with autism spectrum disorder, and again there was no significant difference in
autism polygenic scores between Australian cases and controls. This is despite 16%
of the neurodevelopmental DDD patient subset showed autistic behaviour. Autism
is known to be associated with rare variants (Koch, 2014; O’Roak et al., 2014;
Iossifov et al., 2014), but also has a substantial contribution from common variants
with a common-SNP heritability of 0.09 (Grove et al., 2017). As the DDD cohort
is a mixture of patients with a range of phenotypes and severities, and with ∼30%
of the cohort genetically diagnosed, it would have seemed slightly implausible that
autism in each of these patients was explained solely by rare variants. Indeed,
when separating the DDD cohort into those who showed autistic behaviour and
those who did not, there was significant association between this behaviour and
increased autism polygenic scores. The same pattern was seen for birth weight,
height, and intracranial volume, all which are traits for which DDD children are on
average below the population mean. Together these results illustrate how despite
no overall genetic correlation with NDD risk, common variants that affect these
traits in the general population are also affecting phenotypic expressivity of the
trait in our neurodevelopmental cohort.
The negative result of no association between case/control status and NDD risk
polygenic score in the Australians is interesting, particularly since out-of-sample
prediction for e.g. schizophrenia has been successful at similar sample sizes (In-
ternational Schizophrenia Consortium et al., 2009). However, schizophrenia has
a much higher SNP heritability (h2=0.24 in the study I use for polygenic scores
(Pardin˜as et al., 2018)) than DDD (h2=0.077), and we know that predictive power
depends on the amount of heritability to be found. As a comparison, we can look
at how prediction using educational attainment scores with similar sample sizes
has performed in other studies. The current estimate for educational attainment
SNP heritability from the largest GWAS to date is h2=0.11 (Lee et al., 2018).
This GWAS was conducted using 1.1M samples, and we find significant association
in our Australian cohort. However, an earlier study by Martin et al. (2011b)
found that an educational attainment polygenic score constructed from a discovery
GWAS of N=9,538 Australian individuals failed to explain any significant variation
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(r2<0.0023, p≥0.14) in an independent cohort of 968 individuals. This illustrates
how the discovery GWAS sample size and SNP heritability of the trait can affect
the ability to detect association with polygenic scores. It is also likely that there is
more heterogeneity between our UK and Australian cohorts due to international
ascertainment differences, than there would be between two schizophrenia cohorts.
Schizophrenia is a clinically well characterised trait, although the specific combi-
nations of symptoms may be more heterogeneous than diseases such as Crohn’s
disease. Overall, our power analysis supports phenotypic heterogeneity due to
ascertainment differences between the NDD discovery cohort from the DDD Study
and the Australian cohorts. A final important notion from the polygenic score
analyses in Australians demonstrated, was that scores constructed from even large
meta-analyses of dichotomous traits are vulnerable to bias from sample overlap
with the target population, as we saw from the schizophrenia analysis.
An important finding from our study was that DDD patients with diagnostic rare
variants were not significantly different from patients without a genetic diagnosis.
This suggests that rare and common variants are both contributing to disease risk
in the DDD cohort. The study by Kurki et al. similarly found that individuals
with intellectual disability and likely causative rare variants were no different from
patients without a likely causal variant with respect to their polygenic scores for
educational attainment, intelligence and schizophrenia. Another study consistent
with these findings, by Weiner et al. (2017) similarly found no evidence for a
difference in polygenic risk scores between autism cases with a de novo diagnostic
mutation compared to those without. This suggests that both common and
rare variants are contributing in many neurodevelopmental disorder patients. If
common and rare variants are acting together in these patients with severe disorders,
a question that then arises is whether common variants could be affecting the
penetrance of disease in patients but also in the general population. This lead
us to wonder whether a polygenic profile skewed towards the opposite end of the
spectrum, i.e. enriched for cognitive performance increasing alleles and depleted
for neuropsychiatric disease alleles, could have a protective modifying effect on an
individual in the presence of rare, damaging variants. In Chapter 4, I explore these
questions in a cohort of seemingly healthy individuals from the general population.

Chapter 4
Do common variants protect
against rare, deleterious variants
in the general population?
4.1 Chapter overview
In this Chapter, I wanted to understand how rare and common variants affect
the cognitive scores (general intelligence) in a cohort of healthy individuals. I
test whether carriers of apparently deleterious rare variants were protected by
common variant polygenic scores, and whether there was an interaction between
rare variants and polygenic scores, as has been previously reported for a related
trait educational attainment (Ganna et al., 2016). These two questions are related
but not the same. I therefore first ask whether there is a difference in the overall
distribution of polygenic scores between rare variant carriers and those without,
and then look deeper into whether there is an interaction between the variant types.
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4.2 Background
In Chapters 2 and 3, I showed that neurodevelopmental disorder risk has a polygenic
component that overlaps with liability for complex neuropsychiatric phenotypes in
the population, and that common variants affect expressivity of specific phenotypes
in the DDD cohort. An interesting question which we did not directly touch upon
in the previous chapters was whether common variants also affect the penetrance
of rare variants in genes associated with developmental disorders.
Unpublished work in the DDD cohort by Kaitlin Samocha suggests that DDD
patients are enriched for rare LoFs and missense variants in known developmental
disorder genes and in genes depleted of such variation in the general population.
These are generally inherited from unaffected parents, implying that such variants
can be incompletely penetrant. We also know that patients with variants in the
same genes show different levels of severity of the disorder. Given the results from
Chapters 2 and 3, assessing whether common variants affect penetrance of rare
variants in genes associated with neurodevelopmental disorders would therefore
be interesting to us. However, there are several complicating factors to doing this
in the DDD cohort. First of all, as our probands are all affected, it is difficult
to assess penetrance of disease associated variants observed in the cohort since
it is likely that they are causal for the symptoms and therefore highly penetrant
on those individuals’ genetic background. Instead, assessing DDD patients would
probably tell us more about the expressivity of symptoms rather than penetrance.
In addition, patients may have multiple genetic aetiologies responsible for different
symptoms, which may or may not be masking the effects of other variants on
phenotypes of interest. For inherited candidate variants, we could utilise genetic
and phenotypic data from the parents or siblings where available, but often the
phenotypic information recorded for family members is not detailed and therefore it
may not be clear whether they are in fact somewhat affected or completely healthy.
At present, we have genotype data for only ∼1,000 pairs of parents, and therefore
assessing polygenic scores for parents is not feasible.
We have seen from previous studies of large sequenced cohorts, that even presumably
healthy individuals from the population carry damaging rare variants that would
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be expected to cause disease (MacArthur et al., 2012; Narasimhan et al., 2016).
We therefore wondered whether we could find rare deleterious variants in genes
associated with neurodevelopmental disorders or in other brain-expressed genes that
have been shown to be intolerant to deleterious mutations, in a healthy population
cohort. If we were to find individuals carrying these variants, we would then want to
investigate further why these individuals were not suffering from severe phenotypes.
Specifically, we would be interested in investigating whether common variants are
modifying these variants’ penetrance, by acting in a protective manner in healthy
individuals.
We therefore sought out a cohort of healthy individuals with genetic data available
on both common and rare variants, and with relevant phenotype data. The
UK-based INTERVAL cohort of ∼50,000 healthy blood donors had genotyped
all participants on a DNA chip, and also exome sequenced a smaller subset of
participants. Using this data meant that we could assess both common variants
and rare variants not captured by chip data. Conveniently for our purpose, the
participants in INTERVAL were also asked to complete tests that give an overall
measure of cognitive performance, or general intelligence. This general intelligence
score is a continuous measure, and would allow us to assess the impact of common
and rare variants on cognitive performance.
General intelligence is measure of overall intelligence or cognitive performance,
described first by Robert Spearman (1904). Spearman believed that there is a
single factor underlying different types of cognitive abilities. The single measure of
cognitive performance, general intelligence (or cognitive score g) has been shown
to explain a large proportion of variance in a variety of tests that can be used to
measure different cognitive abilities. The genetic factors contributing to general
intelligence have been extensively studied over decades. Intelligence is highly
heritable, and increases with age to H2 of ∼0.50-0.80 (Plomin and Deary, 2015).
The largest GWAS (using data from 78,000 individuals) so far have found that
common variants explain 20% of the variance in the trait (Sniekers et al., 2017),
although a recent study by Hill et al. (2018) showed that more heritability may be
found in lower frequency variants.
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Directly measuring cognitive scores requires participants to fully complete one or
more extensive questionnaires, which may not be possible in large cohorts recruited
for unrelated research purposes. For this reason, many studies indirectly measure
cognitive performance of participants by asking them about their educational
attainment. Educational attainment (or the number of years of schooling) in GWAS
has been used as a proxy phenotype for cognitive performance because the two
traits share common variant heritability (Okbay et al., 2016; Rietveld et al., 2014)
(genetic correlation between educational attainment (2016) and intelligence (2017)
rg=0.71, SE=0.02). Due to the high genetic correlation between the traits, it may
be expected that phenotypes associated with polygenic scores for intelligence will
also be associated with polygenic scores for educational attainment. The first study
showing that ultra rare variants in the general population also significantly affect
educational attainment was published in 2016 by Ganna et al. (2016). Therefore
one of the first questions we want to address is whether rare variants are in
fact associated with cognitive performance in INTERVAL, and then proceed to
investigate this further by looking for protective effects of polygenic scores and
testing whether common and rare variants ware intereacting with each other in
INTERVAL.
4.3 Contributions
Quality control of INTERVAL GWAS data was performed by Heather Elding and
Tao Jiang. Quality control of INTERVAL exome data was performed by Fernando
Riveros McKay Aguilera and Tarjinder Singh, and further filtering was performed
by Hilary Martin. Cognitive scores in INTERVAL were calculated by Hilary Martin,
following instructions and guidance provided by Steven Bell and Ian Deary. The
work described in this chapter was completed under the supervision of Hilary
Martin and Matthew Hurles.
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4.4 Methods
4.4.1 INTERVAL cohort
The INTERVAL study is a cohort of blood donors, recruited in 2012-2014 in the UK.
The study was run through collaboration between the Universities of Cambridge
and Oxford and the NHS Blood and Transplant Unit. The aim of the study was to
assess the impact of different blood donation intervals on the wellbeing of 25,000
men and 25,000 women. This dataset is uniquely useful for our purpose, because
the study collected three types of data on participants: GWAS chip data, sequence
data and phenotype data including cognitive tests. For us, this meant that we
could utilise data from individuals, for whom all three data were available, to assess
the contribution of genetic variants in a joint model. In our study we use exome
sequence data to find rare variants. INTERVAL has also performed whole-genome
sequencing on a larger cohort of INTERVAL participants, but at the time of this
thesis, these data were not ready for use.
4.4.2 Quality control of genotype data
Sample and variant quality control and imputation
Quality control (QC) and imputation of INTERVAL genotype chip data was
performed by Heather Elding and Tao Jiang, with details described in (Astle et al.,
2016). A total of 48,813 interval study participants were genotyped on the UK
Biobank Affymetrix Axiom chip which assays 820,967 variants. Duplicate and
non-European samples (from ancestry PCA with 1000G) were excluded before
we received the data. The QC’d genotyped dataset included 43,059 European
ancestry samples. The data were imputed using the Sanger Imputation Server (Loh
et al., 2016), using UK10K-1000G Phase III imputation as the reference panel and
SHAPEIT3 for imputation (Delaneau et al., 2011). All data were on GRCh37.
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Ancestry check of European samples
The INTERVAL European sample selection had been performed as part of the
study by Astle et al. (2016) before I received the data. I therefore wanted to check
how tightly the European INTERVAL samples clustered together on an ancestry
PCA, so I performed a new ancestry PCA of all the INTERVAL European samples
using the same 1000G Phase 3 samples that I had used previously in Chapters 2
and 3.
For the PCA, I used the same protocol as previously in Chapter (Section 2.4.1).
I ran the ancestry PCA in PLINK on directly genotyped variants, on 43,059
INTERVAL samples against 2,504 reference population samples from 1000G, using
73,444 variants (MAF>0.10) that overlapped between the two datasets. The PCA
plot (Figure 4.1) showed that, compared to our European sample selection in
Chapters 2 and 3, the Europeans selected by Elding and Jian were less tightly
clustered around the 1000G European samples. A zoomed-in plot of the the
INTERVAL samples (Figure 4.2) shows some substructure within the European
INTERVAL subset that they had selected.
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Figure 4.1: Ancestry principal components analysis of INTERVAL samples. a. Reference samples
(N=2,504) from 1000 Genomes Phase 3, coloured by the five super populations, used for a
projection PCA. b. European INTERVAL samples (N=43,059) that passed quality control (Astle
et al. 2016).
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Figure 4.2: A zoomed-in plot showing European INTERVAL samples (N=43,059) from the
ancestry PCA with 1000 Genomes.
Despite the apparent substructure, we decided to carry forward for further analysis
all the INTERVAL samples presumed European by Elding and Jian. This is
because we wanted to maximise the number of samples with all three types of data
(GWAS, exome and cognitive scores) for our first-pass analysis of effects of rare
and common variation on cognition. We reasoned that using ten ancestry principal
components as covariates in our analyses should correct for any effects resulting
from this substructure.
Removing relatives
To avoid bias in the planned analyses, I checked for relatedness in the INTERVAL
cohort. I performed a relatedness check with 83,434 directly genotyped variants
with MAF>0.10, using PLINK. I removed one individual from each pair of samples
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equivalent to second-degree relatives or closer (alleles identical by descent >0.12),
selecting the one who had the higher variant missingness rate. This resulted in a
genotyped dataset of 41,580 unrelated individuals.
4.4.3 Polygenic scores
After removing relatives from the data, I filtered the imputed genotypes by removing
variants with INFO<0.9, variants with MAF<0.05 and duplicate variants. I used
these filtered, imputed data to construct polygenic risk scores, using the method
described in Chapter 2.4.5 and Chapter 3.4.3. I constructed normalised polygenic
scores for all 41,580 unrelated INTERVAL samples, using variant effects from
our neurodevelopmental discovery GWAS, and GWAS on educational attainment,
intelligence, schizophrenia, autism, intracranial volume, birth weight and height
(parameters shown in Table 4.1). Our expectation was that that polygenic scores for
intelligence and educational attainment would be most relevant to cognitive scores
measuring general intelligence. Scores constructed from our neurodevelopmental
disorder discovery GWAS could potentially be relevant as well, however as seen in
Chapter 3 results in Australians, the GWAS is likely underpowered for these types
of analyses. Although we did not expect polygenic scores for anthropometric traits
to be associated with cognitive scores, these would still act as an additional check
that the data were not bringing up unexpected associations indicative of potential
biases.
Table 4.1: Parameters used for generating polygenic scores in INTERVAL cohort.
Polygenic score trait r2 for SNP pruning P-value threshold
for SNP pruning
Number of SNPs in
score
Neurodevelopmental disor-
der (discovery GWAS)
0.1 1 71,978
Educational attainment 0.1 1 122,400
Intelligence 0.1 0.05 24,955
Schizophrenia 0.1 0.05 28,084
Autism 0.1 0.1 30,949
Intracranial volume 0.1 1 110,859
Birth weight 0.1 0.01 8,793
Height 0.1 0.005 10,660
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Figure 4.3: Distribution of polygenic scores for eight traits in the INTERVAL unrelated European
cohort (N=41,580). Scores are normalised to a mean of 0 and variance of 1.
As shown in Figure 4.3, the polygenic scores were generally normally distributed
within the full INTERVAL European dataset (N=41,580). The outlier plot is the
one showing polygenic scores for height, which showed a heavy lower tail (bottom
right panel Figure 4.3). As it is known that the distribution of height increasing
alleles within Europe varies, particularly on the North-South axis (Novembre et
al., 2008), I decided to investigate whether the observed heavy tail was due to
population substructure within the INTERVAL cohort.
I first separated the individuals whose height scores were in the lowest 2% of the
cohort (Figure 4.4). I then re-plotted the ancestry PCA of INTERVAL samples,
but coloured those who fell into the lowest 2% in a different colour to the remaining
98%. From this plot, shown in Figure 4.5, it is evident that the 2% cluster together
separately from the majority of the cohort. This illustrates that the heavy lower
tail in height polygenic scores is accounted for by population substructure within
the European subset of INTERVAL samples. However, using ancestry principal
components as covariates in downstream analyses should in theory correct for bias
resulting from this stratification.
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Figure 4.4: Distribution of height polygenic scores in INTERVAL (N=41,580). The histogram
shows a heavy lower tail of height polygenic scores. The red vertical line is at the 2nd percentile,
which is equivalent to -2.8SD from the mean.
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Figure 4.5: Ancestry PCA plot of INTERVAL Europeans (N=41,580), coloured by polygenic
score for height. Interval samples with lowest 2% of polygenic score for height were coloured in
orange, and the remaining 98% in purple to investigate whether the long tail for height scores
was due to population substructure.
4.4.4 Quality control of exome data
We wanted to assess the contribution of rare loss-of-function (LoF) variants to
cognitive functioning in INTERVAL, because these variants are more likely to be
damaging and under purifying selection in the population. We also include in our
analyses missense variants that are predicted to have a damaging consequence, and
which lie within regions of a gene that are depleted of missense variants. High
constraint refers to the gene being depleted of deleterious variants in large cohorts
such as ExAC. These genes are likely haploinsufficient and deleterious variants in
these genes will be under purifying selection. The pLI metric (Lek et al., 2016)
is used to score genes for probability of loss-of-function intolerance. Variants in
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genes with a pLI score of >0.9 are considered highly constrained. Previous studies
have shown that deleterious rare variants in highly constrained genes are enriched
in individuals with neurodevelopmental disorders such as autism (Kosmicki et
al., 2017), schizophrenia (Genovese et al., 2016b), intellectual disability (Gilissen
et al., 2014; Singh et al., 2017) and severe childhood developmental disorders
(Deciphering Developmental Disorders Study, 2017; Singh et al., 2017). Many
neurodevelopmental or neuropsychiatric (Pardin˜as et al., 2018) associated genes
fall within the category of high pLI genes, but the majority of pLI>0.9 genes do
not yet have a disorder associated with them (Lek et al., 2016). We are therefore
interested in assessing variants in pLI>0.9 genes, and particularly variants that
have loss-of-function consequence on the the protein.
In total 4,502 individuals from the INTERVAL cohort were exome sequenced.
Illumina paired-end sequencing was performed at the Wellcome Sanger Institute
sequencing facility. Data were aligned and called by the Human Genetics Informatics
team at the Sanger Institute. All data were aligned to GRCh37. We were looking for
rare variants that are depleted in the population due to their damaging consequences.
This means that true damaging variants are very rare, and the a proportion of
apparent deleterious variants will be false positives. We therefore had to perform
quality control for the exome data. For the purposes of this project, we applied
further quality filtering on the data to find rare, loss-of-function (including small
insertion/deletions of up to 10 basepairs) or deleterious (see below) missense
variants in fetal brain-expressed genes. Genotypes were set to missing if they had
GQ<20 (genotype quality), DP<7 (depth) to decrease the probability of missing
a heterozygous call, and for heterozygous calls, a P-value from a binomial test of
allele balance < 0.001 to remove false heterozygous genotypes. We then restricted
to variants with MAF<0.001 to enrich for rare deleterious variants that are under
negative selection, and that reside in genes expressed in fetal brain based on
data from The Genotype-Tissue Expression (GTEx) project (GTEx Consortium,
2013). Finally, variants were restricted to those that had (1) loss-of-function
(LoF) consequence in all transcripts of a gene with pLI>0.9 (constraint score) to
increase the probability that the variants are deleterious and were annotated as high
confidence by LOFTEE (loftee), and are not in the last exon or intron; OR (2) were
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missense variants with CADD>30 (in top 0.1% of deleterious variants, Combined
Annotation Dependent Depletion) (Kircher et al., 2014) in (a) missense-constrained
regions or (b) in genes with overall missense constraint that did not split into
separate regions, and in a gene with pLI>0.9. These constrained genes and regions
were defined in Samocha et al. (2017). For both the gene-wide and region-based
analysis, we restricted to gene/regions with a ratio of observed to expected variation
<0.4, and and chi-squared p<0.001. These came to a total of 1,029 LoFs and 711
missense variants in the cohort of 1,906 individuals, breakdown of samples with
rare variants is shown in Table 4.2.
Table 4.2: Count of rare variants in INTERVAL individuals (total individuals N=1,906).
Number of variants per person
Variant class 0 1 2 3 4
Lof+missense pLI>0.9 1,491 365 43 6 1
LoF pLI>0.9 1,666 226 14 0 0
Missense pLI>0.9 1,702 192 9 3 0
4.4.5 Cognitive scores
As part of the INTERVAL study, participants were asked to complete sets of
cognitive tests, that could be used to calculate a general intelligence or cognitive
score (g). This testing was introduced part way through the study, meaning
that many individuals were never asked to complete the study. Therefore, the
missingness for test results is higher than simply from individuals opting out of
responding or not completing the full questionnaire.
The four tests included in the score were: a pairs test, which is a summary/total
score for a memory test completed by participants which was transformed due to
skewed positive tail, the fluid IQ test which is a problem solving test, the stroop
mrt test in which participants have to report the colour that the word is written in,
and the trails B which tests ability to join letters and numbers alternately. The four
cognitive measures were all taken at 24 months after the individual was enrolled in
the INTERVAL study. In total, there were 21,503 individuals who had complete
data for all four cognitive measures. The general cognitive score itself is calculated
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Figure 4.6: Distribution of cognitive scores in INTERVAL. a. Distribution of scores in all
individuals who completed all four tests (N=21,503). b. Distribution in the subset of individuals
who had data for polygenic scores, rare exome variants and cognitive scores (N=1,906).
by first performing a principal component analysis on the four test results. The
cognitive score is then taken as the first unrotated principal component from this
analysis, and it is positively correlated with fluid IQ and negatively correlated with
inverse-normalised pairs test, stroop MRT test and trails B duration test results.
Scores were normalised to a mean of zero and standard deviation of 1.
Figure 4.6 shows the distribution of these scores in all individuals who completed
the four tests, and in the subset of individuals who had genotype and exome
sequence data available. The distributions appear normal in the cohort and subset
with some outliers.
Cognitive functioning is known to decrease with age (Deary and Batty, 2007). I
therefore plotted the scores against the participants’ age in the genotyped subset
of 1,906 INTERVAL participants, and confirmed cognitive scores were negatively
correlated with age (Pearson correlation -0.49, P=6.7× 10−116) (Figure 4.7). I also
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Figure 4.7: Cognitive scores are negatively correlated with age in INTERVAL (N=1,906). Pearson
correlation -0.49, P=6.7× 10−116.
include age2 as a covariate in the downstream analyses, to account for a possible
non-linear relationship between age and cognition.
4.4.6 Power calculations
Power for detecting a difference in means
I carried out a power calculation to test our power to detect a significant difference
in polygenic scores between individuals with (N=415) and without (N=1,491) LoF
or missense variants. For the calculation I used software G*Power. Using this, I
estimated power as a function of sample size, given three different values for the
difference in polygenic score means. Since the polygenic scores were normalised, I
assumed a variance of 1 in both groups, and calculated power at a range of sample
sizes, assuming the same ratio of individuals with/without rare variants as we
observe in our cohort (ratio=0.28).
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Power for detecting an interaction
I carried out a power calculation to test what power we had to detect a significant
interaction term between common and rare variants in the regression on cognitive
scores in INTERVAL. To get an estimated effect size for an interaction term in
a model that includes all the other independent variables, I used the partial r2
for the interaction. Partial r2 estimates the proportion of residual variation in
the dependent variable explained by an independent variable, after the dependent
variable has been regressed on all other variables. Partial r2 essentially measures
the additional explanatory power of the remaining independent variable. Partial r2
can take any value between 0 and 1. I first estimated partial r2 for the polygenic
score, using the R function etasq(). I then used the software G*Power (v3.1) to
obtain the effect size (β) corresponding to the partial r2 and multiples of this.
4.5 Results
4.5.1 Assessing protective effect from common variants
To first confirm whether rare variants that we found were affecting the cognitive
performance of individuals in INTERVAL (N=1,906), I performed a logistic regres-
sion of cognitive scores on rare variant status, controlling for age, age2, sex and
ancestry principal components. I found that having a LoF or missense variant in
a brain-expressed pLI>0.9 gene (N=415 individuals with, N=1,491 without) was
nominally significantly associated with a -0.10 SD change in cognitive scores (95%
CI : [-0.007, -0.20], P=0.035). Similarly, having a LoF (N=240 individuals with,
N=1,666 without) was associated with a -0.17 SD change in cognitive scores (95%
CI : [-0.055, -0.29], P=0.004). Having confirmed that rare variants were affecting
cognitive scores in INTERVAL, I proceeded with investigating the interplay between
these rare variants and polygenic scores in the cohort.
Our hypothesis was that in a cohort such as INTERVAL, which consists of relatively
healthy and cognitively functioning adults, individuals with rare deleterious variants
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may be enriched for common variants that increase cognitive performance. In other
words, we suspected that common variants could be having a protective effect
against the effects of rare variants in this cohort. If the rare variants in individuals
are deleterious with respect to their cognitive performance, the negative shift due
to the rare variant is seemingly not sufficient to decrease the individual’s chance of
participating in the study. In other studies (e.g. UK Biobank) it has been noted
that individuals who participate in studies tend to be more highly educated than
average, implying that also their cognitive performance overall will be higher than
average. We therefore reasoned that it was possible common variant polygenic
scores were acting in a protective manner against the deleterious effects of rare
variants within INTERVAL.
To assess whether polygenic scores were protective in INTERVAL, I compared the
means of the distributions of polygenic scores for intelligence between individuals
with and without rare variants. These distributions are shown in Figure 4.8. I
performed a two-sample t-test, but neither the analysis comparing individuals
with LoF+missense (N=415 individuals) or LoF-only (N=240) to those with no
rare variants (N=1,491 and N=1,666 individuals, respectively) showed significant
difference between the two groups (P=0.06 and P=0.11 respectively, one-tailed test).
The trend in both analyses was that the mean of polygenic scores for individuals
with rare variants was higher than in the group with no variants.
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Figure 4.8: Distribution of intelligence polygenic scores in individuals with and without rare
variants. a. Density distribution of intelligence polygenic scores in individuals with LoF or
missense variants in pLI>0.9 genes (N=415) in purple, or without(N=1,491) in green, b, in
individuals with LoF variants in pLI>0.9 genes (N=240) in purple, or without(N=1,666) in green.
We therefore wondered whether our small sample size meant we did not have
enough power to detect a significant difference in the polygenic scores between
these groups. As an estimate (beta) of the difference between the group means,
I used the observed difference (beta=0.085). This showed the we had only 35%
power to detect a significant difference between the means if the true difference was
the observed mean. In this case, with the additional ∼6,000 samples from the WGS
dataset, we would have good power (almost 90%) to detect a significant difference.
I also tested our power to detect a difference in means, if the true difference was
larger or smaller than we observe with our current samples. Figure 4.9 shows the
power curves for these estimates. The larger difference estimate is the upper bound
of the 95% confidence interval (beta=0.19) where the true difference lies. At our
sample size, we had 80% power to detect a difference this large, so it is unlikely
that the true difference is of this magnitude. Because the lower bound of the 95%
confidence interval for the difference in means overlapped with zero, I took an
arbitrary lower value of beta=0.01, which constitutes a rather small difference in
standardised polygenic scores. It also appears that if the true difference in means
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was this small, we would have almost no power to detect a significant difference,
even at sample sizes in the hundreds of thousands.
Figure 4.9: Power to detect a significant difference in mean polygenic score between individuals
with and without a rare variant. The curves show our power to detect a significant difference
(P<0.05) between the mean intelligence polygenic score in individuals with and without LoF or
missense mutations in pLI>0.9 genes. The power is plotted as a function of sample size. In our
analysis, we observe a difference in means (beta) of 0.085 (blue line). The orange line depicts
our power to detect a significant difference if beta=0.19 (upper bound of 95% confidence interval
for difference in means). The green line depicts our power to detect a significant difference that
is no greater than beta=0.01. Long dashed line shows power at our current sample size 1,906
INTERVAL participants (with WES and cognitive data). Short dashed line shows power that we
could obtain after adding approximately 6000 more samples with WGS and cognitive data from
INTERVAL.
4.5.2 Joint contribution of rare and common variants to
cognitive functioning
We next wanted to assess what the actual measured effects of polygenic scores
and rare variants were on the cognitive performance of INTERVAL participants,
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and whether there was an interaction between these two types of genetic variation.
We were particularly interested in the latter question, which is whether the effect
of polygenic risk scores on cognitive ability are the same in people with a rare
deleterious variant as in people without. This type of an interaction effect between
rare and common variants has previously been described for rare and common
variant polygenic scores on educational attainment (Ganna et al., 2016).
We expected to find a significant positive association between a measure of general
intelligence (cognitive scores) in INTERVAL and polygenic scores for intelligence
and educational attainment as the two are genetically correlated. We also expected
that deleterious variants may have a negative effect on the cognitive scores, although
our sample size may be too small to detect this effect. Our main interest was
whether we would also find a significant interaction between polygenic scores and
rare variants on the cognitive scores. We were interested in seeing whether polygenic
scores explained less (or more) variance in cognitive scores in the presence of a rare
deleterious variant.
For our final dataset, we had 1,906 samples with polygenic scores, exome data
and cognitive scores. To test the effect of common and rare variants, and their
interaction on the cognitive scores in INTERVAL individuals, I performed a linear
regression using R. I regressed the cognitive scores against each polygenic score
(intelligence, educational attainment, schizophrenia, autism, intracranial volume,
birth weight and height), their exome variant status (at least one variant/no variant,
or a numerical count of the variants), the interaction of polygenic scores and rare
variants, age, age2, sex and ten ancestry principal components as covariates.
Cognitive score ∼ βprsprs +βvarvar+ βprsprs * βvarvar + βageage + βage2age2 +
βsexsex + βPC1PC1 + ... + βPC10PC10 + ε
Where prs = polygenic score, var = rare variant, ε = error. For rare variants, we
had done filtering on the exome data to include only variants expressed in fetal
brain and that had a pLI>0.9. As a first pass analysis, I chose variants that passed
similar variant filters as what they authors of Ganna et al. used in their study. This
first analysis included rare LoF and missense variants in pLI>0.9 genes, but we
had restricted to fetal brain-expressed genes earlier in our variant filtering pipeline.
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Out of 1,906 participants, 415 had at least one such variant, and 1,491 had none. I
fitted the regression model:
As perhaps expected, in each regression the variable age2 was negatively associated
with cognitive scores and explained the most variance in overall. When age2 is
included in the regression, the association between age and cognitive score (as
shown in Figure 4.7) becomes non-significant (and is in a positive direction). This
implies that age has a non-linear relationship with the cognitive score, and the
effect of age on the cognitive score is lesser in older participants.
As the polygenic score in this regression, I tested all eight polygenic scores to
find which ones were relevant for explaining variance in cognitive scores. Table
4.3 summarises the effect of each of these polygenic scores on the cognitive scores
in INTERVAL (N=1,906) in the joint regression model. Only intelligence and
educational attainment polygenic scores were significantly associated with cognitive
scores in the combined regression model, with individuals with a higher polygenic
score having higher cognitive scores. The effect sizes of these two polygenic scores
were very similar to each other, with 0.14 SD change in cognitive score for each
1 SD unit change in intelligence polygenic scores (P=7.8 × 10−10), and 0.14 SD
change in cognitive scores for each 1 SD change in educational attainment polygenic
scores (P=9.4× 10−11). I will therefore focus on analyses where I use these two
polygenic scores. To compare the effect of polygenic scores and other variables
such as rare variant status on the cognitive scores, I have plotted the effect sizes
of these in Figure 4.10 for the analyses using intelligence polygenic scores, and in
Figure 4.11 for analyses using the educational attainment polygenic scores.
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Table 4.3: Association of eight polygenic scores with cognitive scores in the combined regression
model. These results show association of each polygenic score with the cognitive score, in a
combined analysis with rare variant status (LoF or missense), an interaction term and other
covariates. The estimate describes a change in standardised cognitive scores for a 1 SD change in
polygenic score.
Polygenic score Estimate Std. error P
Neurodevelopmental disorder -0.047 0.023 0.042
Intelligence 0.139 0.022 7.8× 10−10
Educational attainment 0.143 0.022 9.4× 10−11
Schizophrenia -0.033 0.023 0.146
Autism 0.018 0.023 0.428
Intracranial volume 0.008 0.023 0.718
Birth weight -0.001 0.023 0.956
Height 0.011 0.023 0.669
In the analysis incorporating intelligence polygenic scores, in addition to the
significant association of the polygenic score with cognitive score, we also see a
significant effect of rare LoF or missense variants (Figure 4.10 a). Having one or
more LoF or missense variant decreased cognitive scores by -0.11 SD (P=0.018),
although the 95% confidence intervals for this estimate are wide. I also performed
a version of the regression analyses using the actual count of rare variants, and the
results of this analysis were very similar to the binary model using ≥1 or none.
There was no significant interaction between rare variants and polygenic scores in
this analysis (P=0.76).
I then tested whether refining criteria for rare variants would have an impact on
our results. I reran the regression analyses using only LoF variants (N=240 samples
with ≥1 variant, N=1,666 no variant) in pLI>0.9 genes. As shown in Figure 4.10 b,
the effect of rare LoF variants appeared to be stronger than in the LoF+missense
analysis, with an effect size equivalent to -0.19 SD change in the cognitive score
for individuals with at least one LoF (P=0.0013), but again with large confidence
intervals. As before, we did not detect a significant interaction between common
and rare variants on the cognitive scores (P=0.30).
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For comparison, the results from the regression analyses using polygenic scores for
educational attainment are shown in Figure 4.11. The results are very similar to
the regression using intelligence polygenic scores: the rare variants analysis shows
a similar trend to the previous analysis in that in the regression model, LoFs only
have larger effect on the cognitive score than LoFs+missense variants, and that
polygenic scores explain.
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Figure 4.10: Rare and common variants affect cognitive scores in INTERVAL (N=1,906) (intelli-
gence polygenic scores). Results from regression of cognitive scores on standardised polygenic
score for intelligence, age, age2, sex and 10 ancestry PCs (not shown) and a. deleterious LoF and
missense variants in pLI>0.9 fetal expressed genes. b. LoF variants only. Sex variable labelled
males=1, females=2. *Effect sizes were multiplied by -1 to allow for easier comparison to other
effects.
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Figure 4.11: Rare and common variants affect cognitive scores in INTERVAL (N=1,906) (educa-
tional attainment polygenic scores). Results from regression of cognitive scores on standardised
polygenic score for educational attainment, age, age2, sex and 10 ancestry PCs (not shown) and
a. deleterious LoF and missense variants in pLI>0.9 fetal expressed genes. b. LoF variants only.
Sex variable labelled males=1, females=2. *Effect sizes were multiplied by -1 to allow for easier
comparison to other effects.
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Assessing power to detect a significant interaction
In our regression analysis, we did not detect a significant interaction between rare
variants and the polygenic scores, unlike the (Ganna et al., 2016) study. One
potential reason for this is lack of power, since the Ganna study had over five times
as many samples we did in our study. We therefore wanted to assess our power to
detect a significant interaction in our study. We would like to get an estimate of
the relative magnitude of the interaction term effect and the polygenic score or rare
variants from the Ganna et al. study. However, the effect size of the interaction
was not reported in their analyses of educational attainment. This meant that we
did not have any prior for how large an effect size the interaction might have if our
data were comparable to the Ganna et al. study.
We therefore decided to test what power we had to detect an interaction at a range
of effect sizes (Figure 4.12). We reasoned that the effect of the interaction would be
no greater than that of the polygenic score alone, which had the strongest effect on
cognitive scores in our data. I then plotted a power curve for a sample size range,
assuming an effect size for the interaction that ranged from magnitude equivalent
to the polygenic score beta (beta prs), down to one 200th of the the beta prs. The
partial r2 from both regression analyses on LoF + missense and LoF only in brain
expressed pLI>0.9 genes was roughly the same (0.0241 and 0.0243 respectively), so
I thus used beta prs=0.025 as a starting point to to plot the power curves.
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Figure 4.12: Power for detecting a significant interaction effect. Our power to detect a significant
association for the interaction term between rare variants and the polygenic score in a regression
analysis on cognitive scores, based on partial r2 of the interaction term. The figure shows power
for a range of values for partial r2, with the maximum value being equal to partial r2 of the
intelligence polygenic score (beta prs=0.025). Long dashed line shows power at our current
sample size 1,906 INTERVAL participants (with WES and cognitive data). Short dashed line
shows power that we could obtain after adding approximately 6,000 more samples with WGS and
cognitiv e data from INTERVAL.
The power curves (Figure 4.12) show that we had good power in our analysis to
detect interaction effect sizes equivalent to the effect size of polygenic scores in
our regression model. We should also have ∼70% power to detect an effect size
down to one 10th of a the polygenic score effect. This suggests that if a significant
interaction existed in our cohort, the effect would likely be much smaller than that
of the polygenic score alone.
The INTERVAL project is currently sequencing 12,000 samples using whole genome
sequencing technology. Of these additional samples, approximately half will have
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cognitive data available, and all will have been genotyped on the same DNA chip
as the exome sequenced samples. The majority of WES and WGS samples do
not overlap, and WES and WGS cohorts are currently being jointly called. This
means that in the future we will be able to combine our current cohort of 1,906
with ∼6,000 additional samples. With these additional samples, we will have 60%
power to detect an interaction with an effect size down to ∼1/50 of the effect of
the polygenic scores.
4.6 Discussion
In this chapter, I set out to characterise the interplay between common and rare
deleterious variants in the healthy population. I specifically look at their effects on
cognitive ability, using data from healthy blood donors in the INTERVAL cohort. I
found that there is no significant difference in polygenic scores for intelligence and
educational attainment for individuals carrying deleterious rare variants in brain
expressed, highly constrained genes versus those without such variants. We plan
to reassess this with more samples in the near future. My second analysis found
that common and rare variants both contribute to explaining variance in cognitive
scores in INTERVAL. However, I did not observe an interaction effect between the
two types of variants, although again our power was limited at the samples sizes I
had. In addition, since we are looking at healthy individuals, it is likely that we
would observe less penetrant variants that do not have as strong effects on the
phenotype as would variants enriched in disease cohorts (Wright et al., 2018a).
When comparing to the results of our second analysis to the paper by Ganna et al,
I found similarities but also differences in our data. Similarly to Ganna et al., I
find a common variant and rare variant effect in our cohort. However, my analyses
did not replicate the interaction between common and rare variants. From the
power analysis, it seems evident that if there was an interaction that modified
the effect of polygenic scores in the presence of a rare variant in INTERVAL, the
effect would not be of the same magnitude as the effect of polygenic scores alone.
Ganna et al. did not describe the effect size of the interaction in their combined
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regression model. However, other studies that have found an interaction between
common and rare variants have reported a very small effect from the interaction.
For example, a paper by Barrett et al. (2009) studying type 1 diabetes, found that
individuals carrying high risk HLA genotypes had a decreased risk from other loci
associated with the disease compared to individuals who did not carry the HLA
genotypes. With the additional INTERVAL samples with WGS data soon to be
released, we should soon have better power to reassess the interaction between
common and rare variants.
A difference between our results and those reported by Ganna et al. include that
their paper found that the effect of common variants was approximately three
times as large as the effect of having a rare variant, whereas in our study we find
that the rare variant effect is almost as strong as 1SD change in polygenic scores
in the LoF+missense analysis, or even stronger than the polygenic score in the
LoF-only analysis. This difference may be the result of several factors, including
real differences in the ascertainment of the individuals in the two studies, or the
phenotypes measured (years of schooling versus general cognitive ability). For
polygenic scores, Ganna et al. used the same P-value threshold for pruning variants
for their educational attainment polygenic scores as we did for our score, but
we used a better powered, larger GWAS variant effects to construct the scores.
However, the genetic correlation between the two GWASs used is approximately
1 (analysis not shown), so therefore it is unlikely that there is a difference in
the polygenic architecture of the two GWAS which the scores were constructed
from. However, there are multiple differences in the rare variant filters we used.
These differences include restricting to fetal brain-expressed genes and using newer
annotation tools to filter LoFs and missense variants. In the near future, we plan
to replicate the filtering used by Ganna et al. for better comparison.
As mentioned above, a major difference in our analysis compared to Ganna et al.
was that we restricted our rare variants to those in fetal brain-expressed genes in
our the combined regression, whereas Ganna et al. did not. For the analysis testing
association between rare variants and educational attainment (Figure 2 in Ganna et
al.), the authors show that when LoF and missense variants are split into variants
in brain- and non-brain-expressed genes, the effect of LoFs is much stronger than
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the effect of missense variants in both sets of genes. The negative effect of LoFs in
brain-expressed genes was very close to the effect size of polygenic scores in their
combined regression, which is in effect what we see in our analysis of LoF variants
and polygenic scores. Variants in non-brain expressed pLI>0.9 genes, on the other
hand, did not have a significant effect on educational attainment. It therefore
seems likely that in their combined analysis, both not restricting to brain-expressed
genes and including missense mutations, the authors may have diluted the effects
of rare variants on educational attainment. In addition, their combined analysis
included rare CNVs, which we do not have data for. However, our future analyses
will include these data for INTERVAL, as CNV calling is currently underway.
Overall, these analyses show that even in a relatively small cohort, we can find
significant genetic modifiers of general cognitive performance in the INTERVAL
cohort. Further work will be required to carry out more extensive analyses into the
interplay between common and rare variants, and hopefully with a boost in sample
size we will be able to detect more subtle genetic effects. Expanding this analysis
framework to larger datasets such as the UK Biobank (who have 50,000 exomes
to be released), which has data on cognition but also educational attainment and
potentially other relevant phenotypes will be of great interest.

Chapter 5
Discussion and future directions
5.1 Common variants contribute to neurodevel-
opmental disorders
In chapters 2 and 3, I have described the largest GWAS to date of rare disorders
which had been presumed Mendelian. Studying these disorders using tools from
complex trait genetics field was challenging, particularly because our patient
cohort comprised of individuals with extremely heterogeneous phenotypes, and
therefore also likely different genetic aetiologies. Unsurprisingly (albeit initially
disappointingly), we did not see any individual common variant signals our GWAS.
However, when we looked closer we did find a significant overall contribution to the
risk of these disorders that was attributable to inherited common genetic variation.
This polygenic burden shared common variant effects with other neuropsychiatric
and cognitive traits, which implied that there may be shared underlying biology
between these disorders, and that some common variants on the one hand confer risk
to common disease and at the same time increase risk of rare neurodevelopmental
disorders.
One of the important aspects of our work was that the results were reproducible, as
both the overall risk (over-transmission in trios) and the genetic overlap with other
traits (polygenic scores in Australians) replicated in independent samples. These
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findings justify further work in the field, as they imply that leveraging data for
rare neurodevelopmental disorder patients from across the globe could be fruitful
in furthering our understanding of the genetic architecture of these disorders. In
addition, we found no significant differences in polygenic scores between DDD
patients who had a diagnostic rare variant and those who we had not yet identified
one for. This suggested that patients without a monogenic diagnosis may not be
solely responsible for the polygenic contribution to neurodevelopmental risk that
we observe.
5.2 Impact in the clinic
The findings from our study challenge the typical view in medical genetics that rare,
severe neurodevelopmental disorders are simply single-gene disorders. These findings
may encourage clinicians to consider the possibility of a polygenic contribution to a
patient’s disorder, or to particular phenotypes observed in the patient. In the future,
clinicians could be made aware of the possibility of common variants contributing
to disease, by providing them with informative polygenic scores. This could result
in clinicians reassessing and attempting to differentiate which phenotypes are more
likely to be associated with the monogenic disorder and which may be partially
explained by inherited common variants. As an example, if the patient’s short
stature was partially explained by a very low polygenic score for the trait, and
their parents were also short of stature, the indication could be that at least part
of the patient’s height phenotype was explained by common variants. To an extent,
clinicians are already evaluating the possibility of a common variant contribution
in clinic when they meet the parents of affected children in clinic. Clinicians will
often be able to notice unusual characteristics in the parents, particularly if they
are shared with the child. However, this is not always possible to do, and polygenic
scores would provide a way of assessing the common variant contribution even
when meeting the parents in person is not possible.
The incorporation of polygenic scores to a patients’ clinical data is something to
be considered carefully. Certainly for the DDD Study participants this would
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be possible, since information on polygenic scores could be incorporated into
DECIPHER database for clinicians to view. There are options to how the data
could be presented. For example, one might choose to report which quartile or decile
of the distribution of scores a patient lies within, with respect to the rest of the DDD
cohort. Another possibility would be to compare scores against a representative
reference population cohort, for scores relevant to neurodevelopmental disorders.
One would then generate polygenic scores for the reference individuals, and assess
where the patient lies with respect the reference distribution.
Availability of information about where a patient lies in the polygenic score dis-
tribution could be of interest for clinicians when they assess the genetic data for
the patient, particularly if there is evidence that the parents might be affected
to some extent, or if there are multiple affected siblings with different severities
of symptoms. However, it should be ensured that if such data were available for
clinicians to view, a clear explanation of the implications of the polygenic scores
would be required e.g. what is the expected distribution of IQ, or height, for people
in this decile of the distribution.
As a real life experiment for using polygenic scores together with other clinical data,
the DDD study is considering employing a clinician to have a closer look at specific
patients’ data, where the phenotype does not fully match the monogenic diagnosis.
This would involve first identifying such cases from the individuals for whom exome
sequencing has yielded a diagnostic variant in a developmental disorder associated
gene. If the patients’ abnormal phenotypes included any growth, cognitive or
neuropsychiatric symptoms that are known to be affected by common variants in
the general population, we could then supply polygenic scores for these traits for
that individual. The clinician could then assess whether any of the unexplained
symptoms could in part be explained by common variants acting in that individual.
This could serve as a pilot for incorporating polygenic scores into DECIPHER
for DDD clinicians to access for their patients. If incorporating polygenic scores
into clinical data proved feasible in practice, in the long run these could be used
to adjust recurrence risk estimates for families who are given genetic counselling.
Although it may be difficult to infer what the exact increase or decrease in risk
for families would be, particularly without the parental genotypes, it could still
136 Chapter 5. Discussion and future directions
be somewhat informative in cases where the scores are at the extreme ends of the
relevant distribution.
5.3 Expanding to other cohorts
As our study has demonstrated, different cohorts of neurodevelopmental disorder
patients will likely have different overall genetic burden due to differences in
ascertainment. However, there is likely some overlap between common variant
effects to be found in various cohorts of patients. One of the next logical steps
for future work in the field would be to expand these analyses to other cohorts
of neurodevelopmental disorder patients, and to perform a large meta-analysis
to better understand the underlying biology of the common variant component
to these disorders. Based on the results from our genetic correlation analyses
in DDD and polygenic scores in Australians, it seems likely that a substantial
proportion of the SNP heritability we found is shared with cognitive functioning
(intelligence) and related traits. We could therefore consider also including our
analyses to other cohorts of specifically intellectual disability cases on top of mixed
neurodevelopmental disorder patient cohorts.
The DDD Study is a rather unique cohort in the sense that the genotyping of
patients with rare disorders was done systematically in batches of ∼1,000 trios
and then a larger cohort consisting of the remainder of patients. This approach
greatly reduces biases and produces cleaner data for analysis. In addition, the
DNA chips used for DDD were regular genotyping chips that have been used in
other GWAS studies. For this reason, we were also able to find suitable controls for
our discovery GWAS of neurodevelopmental disorder risk. We have heard through
personal communication of other cohorts where intellectual disability cases or other
neurodevelopmental patients have been genotyped on a DNA chip. However, these
data were generated mainly to search for large CNVs for diagnostic purposes.
Therefore the DNA chips used were often older and the variants on these do not
overlap well with modern GWAS chips. In addition, we found that most of the
data consisted of singleton patients or patient-parent duos, and not complete trios,
5.4. Issues of differential ancestry 137
making it impossible to do trio analysis. Therefore, the main limiting issue in using
genotype data on patients from these older chips often is that no healthy controls
were genotyped using them. Using these samples in a large meta-analysis may
therefore prove challenging due to the biases introduced by genotyping cases and
controls on completely different chips, as well as from imputing data with only a
small number of overlapping variants between different datasets.
Another aspect to consider if embarking on an effort to create a large consortium
for studying common variant effects in rare, severe and heterogeneous disorders, is
how much such an effort would make an impact to the patients. The main purpose
of GWAS in human disease is finding significantly associated loci in order to hone
in on potential drug targets. With more patients, it is possible that we might
find genome-wide significant hits. It seems likely though that even if we were to
find such loci, many may be shared with risk for conditions such as intelligence,
educational attainment or schizophrenia, for which there are already well-powered
GWAS. In addition, severe childhood onset disorders tend to be largely incurable
conditions, where only the symptoms can be managed through drugs and therapies.
Efforts to finemap loci to find drug targets from association studies may not the
most effective approach for severe neurodevelopmental disorder treatment. If the
main goal for studying common variants in neurodevelopmental disorders was to
refine recurrence risks, an alternative approach could be to use polygenic scores for
other larger and better-power traits that share polygenic architecture with these
disorders (such as educational attainment or schizophrenia scores). Nevertheless,
if this type of approach could give some benefit to patients, such a path of work
could be considered.
5.4 Issues of differential ancestry
One major caveat of the work presented in this thesis is that it only considers
individuals with European ancestry. In our study, the genotyped DDD cohort
included a few thousand patients of non-European ancestry, but with the lack of
parental genotypes and suitable controls, we were unable to include these individuals
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in our discovery GWAS. For the downstream analyses using genetic correlation and
polygenic scores, we utilise summary statistics from previously published GWAS
which have also been performed mainly using individuals of European-ancestry.
This means that even if we had been able to include non-Europeans in our study,
we would still likely have been unable to use these samples in our downstream
analyses, at least using these methods. This is because the causal variants for
diseases and traits are not necessarily tagged by the same variants in different
populations due to differences in LD structure. It has previously been shown that
polygenic scores constructed using summary statistics from a single-population
do not translate well in other populations (Martin et al., 2017a; Weiner et al.,
2017). The authors of Martin et al. (2017a) also showed that scores generated
in a single population explained the most variance in a target population from
the same ancestral background as the original study. The study found that for
example, polygenic scores from a European GWAS predicted Europeans to be
taller than West Africans, despite the fact that West Africans are phenotypically
no shorter than Europeans. In order to better understand the genetic architecture
of neurodevelopmental disorders globally, we would need to consider how to better
design our studies to include more diverse populations.
5.5 Continuing the search for common variant
modifiers in health and disease
In Chapter 4, I described analyses of rare and common genetic variation in the
healthy blood donor cohort INTERVAL. We found that both common variant poly-
genic scores and rare deleterious variants (particularly LoFs) in highly constrained
genes affected the general intelligence scores in this cohort. Our sample size was
too small to conclusively say whether polygenic scores were acting in a protective
manner in individuals carrying these rare variants. However, our results suggest
that further analyses are warranted once the extra ∼6,000 samples (individuals
with cognitive data) from whole sequencing are ready.
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The question of penetrance in genes, specifically those associated with known
developmental disorders, is of great interest to the DDD analysis group. Current
work undertaken by Kaitlin Samocha has uncovered an enrichment in DDD patients
of inherited rare LoF and missense variants in known developmental disorder genes
and in highly constrained genes. This raises the question whether something in
the parental genotypes is protecting carrier parents from expressing the disease
phenotype. If we were able to generate genotype data for DDD parents (at least
those carrying inherited rare variants), we could then try to assess whether the
polygenic scores for parents are systematically more protective than those of their
affected children.
Another example of possible analyses taking on investigating variable penetrance
further, would be to assess whether common variants are contributing to the
phenotypes in DDD patients by affecting the expression of developmental disorder
genes. A recent paper by Castel et al. (2018) showed that in the general population,
deleterious variants were depleted on highly expressed haplotypes, decreasing their
penetrance. Conversely, in individuals with disease, these variants were more likely
to be on the more highly-expressed haplotype. To learn about haplotype expression
in the DDD, one could identify eQTLs for genes associated with developmental
disorders, and assess the expression of the haplotype that the diagnostic variants
recide on. For de novo variants, one could expect to find that patients with more
severe phenotypes have deleterious variants on the more highly expressed haplotype.
With inherited or recessive variants the picture may be more complicated, as the
unaffected parents carrying rare LoFs or deleterious missense mutations will have
their rare variant on the same haplotype as the patient. However, in these cases
one potential explanation could be to do with a shift in the relative expression of
the haplotype with versus without the deleterious rare variant between unaffected
parents and affected children. More analyses utilising data from the DDD could
potentially yield interesting information on mechanisms by which common variants
may (or may not) be playing a role in severe neurodevelopmental disorders and in
the healthy population.
On the whole, we previously knew that genetic contributors to rare severe neurode-
velopmental disorders included deleterious variants (inherited and de novo) within
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the protein-coding regions (Deciphering Developmental Disorders Study, 2017;
Martin et al., 2017b), in splice-site regions (Lord et al., 2018) and in regulatory
elements (Short et al., 2018) of genes associated with these disorders. Here, I have
described work that has uncovered a new contributor to our understanding of the
genetic architecture of these severe disorders.
Appendix A
Partitioned SNP heritability
Results from partitioned SNP heritability analy-
ses for discovery neurodevelopmental disorder risk
GWAS
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Table A.1: SNP heritability for discovery neurodevelopmental disorder risk GWAS, partitioned by
cell type groups. LDSC baseline model was used to estimate enrichment of neurodevelopmental
disorder discovery GWAS SNP heritability in cell type groups. Enrichment is defined as the
proportion of SNP heritability in the category divided by the proportion of SNPs in the category.
Results are ordered by coefficient z-score for cell type groups. P-values are uncorrected, two-sided
and from z-score distribution.
Cell type group Propor-
tion of
SNPs
Propor-
tion of
h2
Standard
error
(h2)
Enrich-
ment
Standard
error
(enrich-
ment)
P-value
(enrich-
ment)
Coefficient Standard
error (coef-
ficient)
z-score
(coeffi-
cient)
CNS 0.149 0.616 0.241 4.140 1.622 0.025 9.5× 10−8 4.4× 10−8 2.142
DDG2P 0.063 0.175 0.071 2.787 1.133 0.064 4.0× 10−8 2.5× 10−8 1.598
Cardiovascular 0.111 0.489 0.277 4.401 2.489 0.142 8.1× 10−8 8.1× 10−8 1.004
Other 0.203 0.740 0.324 3.652 1.600 0.068 6.1× 10−8 6.2× 10−8 0.997
GI 0.168 0.529 0.303 3.154 1.807 0.214 3.7× 10−8 5.9× 10−8 0.627
Connective or Bone 0.115 0.340 0.236 2.956 2.050 0.313 1.9× 10−8 5.7× 10−8 0.341
Kidney 0.043 0.140 0.183 3.288 4.284 0.592 2.9× 10−8 1.0× 10−7 0.290
Liver 0.072 0.202 0.186 2.804 2.579 0.477 1.6× 10−8 6.0× 10−8 0.268
Skeletal and Muscle 0.104 0.228 0.216 2.193 2.082 0.561 6.1× 10−9 7.3× 10−8 0.083
Immune 0.233 0.592 0.302 2.539 1.293 0.211 −6.3×10−9 5.6× 10−8 -0.114
pLI≥0.9 0.128 0.186 0.084 1.454 0.655 0.484 −2.1×10−9 1.9× 10−8 -0.109
Adrenal or pancreas 0.094 0.132 0.229 1.411 2.452 0.866 −4.2×10−8 7.1× 10−8 -0.595
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Table A.2: SNP heritability for discovery neurodevelopmental disorder risk GWAS, partitioned by
functional categories. LDSC baseline model was used to estimate enrichment of neurodevelopmen-
tal disorder discovery GWAS SNP heritability in overlapping functional categories. Enrichment is
defined as the proportion of SNP heritability in the category divided by the proportion of SNPs
in the category. Results are ordered by enrichment P value for functional categories. P-values
are uncorrected, two-sided and from z-score distribution. The LDSC model adds 500bp regions
around annotations and 100bp regions around ChIP-seq peaks to prevent upward bias in the
estimate from enrichment in nearby regions. Studies used for functional categories in the LDSC
baseline model are described in Finucane et al. (2015).
Functional category* Proportion
of SNPs
in the
category
Proportion
of h2 in the
category
Standard
error
(h2)
Ratio
(enrich-
ment)
Standard
error
(enrich-
ment)
P-value
(enrich-
ment)
Conserved LindbladToh 0.026 0.646 0.292 24.795 11.191 0.009
H3K4me1 Trynka 0.427 1.645 0.535 3.857 1.254 0.012
SuperEnhancer Hnisz.extend.500 0.172 0.459 0.144 2.672 0.841 0.030
DHS Trynka 0.168 1.706 0.811 10.167 4.833 0.035
DGF ENCODE.extend.500 0.542 1.369 0.435 2.528 0.803 0.044
DHS Trynka.extend.500 0.499 1.404 0.518 2.814 1.038 0.071
H3K4me3 peaks Trynka 0.042 -0.571 0.400 -13.661 9.564 0.095
SuperEnhancer Hnisz 0.168 0.399 0.150 2.371 0.893 0.101
PromoterFlanking Hoffman 0.008 0.259 0.177 30.785 20.953 0.120
Repressed Hoffman.extend.500 0.719 0.441 0.191 0.614 0.266 0.122
H3K4me3 Trynka.extend.500 0.255 0.701 0.321 2.743 1.255 0.142
DHS peaks Trynka 0.112 0.945 0.650 8.455 5.819 0.179
H3K4me1 Trynka.extend.500 0.609 0.989 0.268 1.623 0.440 0.183
TFBS ENCODE.extend.500 0.343 0.944 0.458 2.748 1.333 0.190
H3K27ac Hnisz 0.391 0.672 0.216 1.717 0.552 0.195
H3K27ac PGC2 0.269 0.750 0.404 2.784 1.499 0.200
Intron UCSC.extend.500 0.397 0.555 0.137 1.399 0.345 0.207
Intron UCSC 0.387 0.574 0.177 1.482 0.458 0.264
Enhancer Andersson 0.004 0.128 0.127 29.633 29.209 0.317
FetalDHS Trynka 0.085 0.553 0.498 6.519 5.872 0.345
CTCF Hoffman.extend.500 0.071 -0.180 0.286 -2.526 4.023 0.360
TSS Hoffman.extend.500 0.035 0.168 0.165 4.812 4.744 0.407
TSS Hoffman 0.018 0.177 0.196 9.696 10.756 0.407
H3K27ac Hnisz.extend.500 0.423 0.644 0.266 1.524 0.630 0.411
Coding UCSC.extend.500 0.065 -0.061 0.172 -0.948 2.663 0.462
Enhancer Hoffman.extend.500 0.154 0.383 0.328 2.490 2.130 0.480
TFBS ENCODE 0.132 0.479 0.49 3.615 3.702 0.482
Enhancer Andersson.extend.500 0.019 -0.077 0.144 -4.013 7.558 0.498
Transcribed Hoffman 0.345 0.121 0.363 0.350 1.051 0.551
Conserved LindbladToh.extend.500 0.333 0.163 0.303 0.489 0.910 0.560
Enhancer Hoffman 0.063 -0.137 0.349 -2.168 5.512 0.561
H3K27ac PGC2.extend.500 0.336 0.523 0.335 1.557 0.998 0.571
H3K9ac Trynka.extend.500 0.231 0.062 0.317 0.268 1.373 0.582
Promoter UCSC.extend.500 0.039 0.113 0.140 2.914 3.616 0.587
WeakEnhancer Hoffman.extend.500 0.089 0.244 0.290 2.740 3.261 0.591
Repressed Hoffman 0.461 0.253 0.452 0.547 0.980 0.635
CTCF Hoffman 0.024 -0.073 0.277 -3.044 11.626 0.727
UTR 3 UCSC 0.011 -0.031 0.121 -2.779 10.962 0.728
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Table A.3: SNP heritability for discovery neurodevelopmental disorder risk GWAS, partitioned
by functional categories (continued).
Functional category* Proportion
of SNPs
in the
category
Proportion
of h2 in the
category
Standard
error
(h2)
Ratio
(enrich-
ment)
Standard
error
(enrich-
ment)
P-value
(enrich-
ment)
H3K4me3 Trynka 0.133 0.011 0.361 0.086 2.706 0.737
H3K4me1 peaks Trynka 0.171 0.345 0.565 2.015 3.301 0.755
Transcribed Hoffman.extend.500 0.763 0.676 0.285 0.886 0.373 0.758
DGF ENCODE 0.138 0.336 0.668 2.443 4.856 0.766
FetalDHS Trynka.extend.500 0.285 0.425 0.490 1.491 1.719 0.776
WeakEnhancer Hoffman 0.021 0.091 0.268 4.333 12.687 0.792
H3K9ac Trynka 0.126 0.210 0.347 1.665 2.754 0.808
Promoter UCSC 0.031 0.075 0.190 2.420 6.097 0.814
UTR 3 UCSC.extend.500 0.027 0.057 0.134 2.126 4.981 0.822
PromoterFlanking Hoffman.extend.500 0.033 0.080 0.213 2.404 6.362 0.824
UTR 5 UCSC.extend.500 0.028 0.003 0.134 0.100 4.803 0.852
UTR 5 UCSC 0.005 -0.005 0.100 -1.005 18.434 0.914
Coding UCSC 0.015 0.029 0.164 1.982 11.209 0.930
H3K9ac peaks Trynka 0.039 0.018 0.327 0.462 8.440 0.949
Appendix B
Data on UK population highest
level of qualification achieved
UK census data 2011
Source: UK census 2011.
The highest level of qualification is derived from the question asking people to indicate
all types of qualifications held. People were also asked if they held foreign qualifications
and to indicate the closest equivalent.
There were 12 response options (plus ’no qualifications’) covering professional and
vocational qualifications, and a range of academic qualifications.
These are combined into five categories for the highest level of qualification, plus a category
for no qualifications and one for other qualifications (which includes vocational or work
related qualifications, and for foreign qualifications where an equivalent qualification was
not indicated):
No Qualifications: No academic or professional qualifications
Level 1 qualifications: 1-4 O Levels/CSE/GCSEs (any grades), Entry Level, Foundation
Diploma, NVQ level 1, Foundation GNVQ, Basic/Essential Skills
Level 2 qualifications: 5+ O Level (Passes)/CSEs (Grade 1)/GCSEs (Grades A*-C),
School Certificate, 1 A Level/ 2-3 AS Levels/VCEs, Intermediate/Higher Diploma, Welsh
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Baccalaureate Intermediate Diploma, NVQ level 2, Intermediate GNVQ, City and Guilds
Craft, BTEC First/General Diploma, RSA Diploma Apprenticeship
Level 3 qualifications: 2+ A Levels/VCEs, 4+ AS Levels, Higher School Certificate,
Progression/Advanced Diploma, Welsh Baccalaureate Advanced Diploma, NVQ Level 3;
Advanced GNVQ, City and Guilds Advanced Craft, ONC, OND, BTEC National, RSA
Advanced Diploma
Level 4+ qualifications: Degree (for example BA, BSc), Higher Degree (for example
MA, PhD, PGCE), NVQ Level 4-5, HNC, HND, RSA Higher Diploma, BTEC Higher
level, Foundation degree (NI), Professional qualifications (for example teaching, nursing,
accountancy)
Other qualifications: Vocational/Work-related Qualifications, Foreign Qualifications (Not
stated/ level unknown).
Table B.1: UK census data from 2011 on highest level of qualification achieved.
England and Wales
All categories Persons 45,496,780
No qualifications Percentage 22.7
Level 1 Percentage 13.3
Level 2 Percentage 15.3
Apprenticeship Percentage 3.6
Level 3 Percentage 12.3
Level 4 and above Percentage 27.2
Other qualifications Percentage 5.7
UK Labour Market statistics 2012
Source: Novis labour market statistics.
Qualifications data are only be available from the APS for calendar year periods, for
example, Jan to Dec 2005. The variables show the total number of people who are
qualified at a particular level and above, so data in this table are not additive. Separate
figures for each NVQ level are available in the full Annual Population Survey data set
(Query data).
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The trade apprenticeships are split 50/50 between NVQ level 2 and 3. This follows
ONS policy for presenting qualifications data in publications. Separate counts for
trade apprenticeships can be obtained from the full APS data set (Query data). No
Qualifications: No formal qualifications held. Other Qualifications: includes foreign
qualifications and some professional qualifications. NVQ 1 Equivalent: e.g. fewer than 5
GCSEs at grades A-C, foundation GNVQ, NVQ 1, intermediate 1 national qualification
(Scotland) or equivalent. NVQ 2 Equivalent: e.g. 5 or more GCSEs at grades A-
C, intermediate GNVQ, NVQ 2, intermediate 2 national qualification (Scotland) or
equivalent. NVQ 3 Equivalent: e.g. 2 or more A levels, advanced GNVQ, NVQ 3, 2 or
more higher or advanced higher national qualifications (Scotland) or equivalent. NVQ
4 Equivalent And Above: e.g. HND, Degree and Higher Degree level qualifications or
equivalent.
Notes: Level and % are for those aged 16-64. % is a proportion of resident population of
area aged 16-64.
Table B.2: UK labour market data from 2012 on highest level of qualification achieved.
UK (%)
NVQ4 and above 13,744,100 34
NVQ3 6,885,900 17.1
NVQ2 6,792,400 16.8
NVQ1 4,892,900 12.1
Other 2,545,800 6.3
Trade apprenticeship 1,476,600 3.7
No qualification 4,028,300 10
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